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‘When you are studying any matter, or considering any philosophy, ask yourself only what are the
facts. What is the truth that the facts bear out. Never let yourself be diverted either by what you
wish to believe, or by what you think would have beneficient social effects if it were believed; but
look only and solely at what are the facts.’
—Bertrand Russell. BBC interview on Face to Face (1959).

VSummary. In antibiotic therapy design, conventional wisdom holds that higher antibiotic
dosages always leads to the observation of fewer bacterial cells, resulting in a monotonic decay
in cell number as a function of increasing antibiotic dose; accordingly, throughout this thesis, we
will call this phenomenon a monotone dose-response profile. When we analysed the evolution
of antibiotic resistance mediated by the multi-drug efflux pump AcrAB-TolC in Escherichia coli
to study if such a monotone dose-response is maintained at all times, our analysis showed
that higher dosages can, in fact, lead to higher bacterial loads. This is because selection for
drug resistance is mediated by the duplication of the genes, AcrAB-TolC, that encode the
aforementioned efflux pump. As explained in detail below, our work highlights the idea that
Darwinian selection on additional copies of AcrAB-TolC is a non-linear function of antibiotic
dose and that the observed transition from monotone to non-monotone dose-response is a
consequence of AcrAB-TolC being strongly selected at very specific dosages. We term this
phenomenon an ‘evolutionary hotspot’.
Next, we extended the above experimental system to solid media to study how selection on
resistance mediated by AcrAB-TolC leads to a ‘spatio-genomic patterning’ effect that we call a
‘bullseye’. Using a bespoke culture device developed as part of this PhD, we show that spatial
selection on resistance also depends non-linearly on the distance of the cell from an antibiotic
source, and that the non-linearity can be multi-modal as a function of distance, and therefore
also of antibiotic dose. This result also contradicts the aforementioned principle that higher
antibiotic dosages necessarily lead to fewer bacterial cells.
Following on from this, we then studied the ability of microbial competitors for resources to
modulate the antibiotic sensitivity of a particular strain of E. coli, namely Tets, using a range of
multi-species experiments. We measured the sensitivity to antibiotics of Tets both with, and
without, one bacterial or fungal competitor. When that competitor was equally sensitive to the
antibiotic, we observed that Tets was less sensitive to it, in part due to an ‘antibiotic sinking’
effect carried out by the competitor strain. However, when the competitor was not sensitive to
the antibiotic, Tets was, accordingly, more sensitive than in the absence of competition. In this
latter case, the competitor seemed to reduce the growth of Tets by carbon theft as part of a
phenomenon known as ‘competitive suppression’. Moreover, this ecological effect is one that
synergises with the action of the antibiotic.
Finally, we turned to a study of an ecological trade-off motivated by ribosome-binding
antibiotics. So, by manipulating the content of ribosomal RNA in the E. coli cell, a large and
essential molecule that is bound by antibiotics such as tetracycline or erythromycin, we could
V I
subsequently manipulate what is known as a metabolic trade-off between growth rate and
growth yield. The latter is the number of cells produced per molecule of carbon found in the
extracellular environment of the bacterial population. Using glucose as carbon source we
therefore constructed an empirical fitness landscape that shows how the optimum number of
ribosomal rRNA operons depends on extracellular glucose concentration. Whilst this study
does not relate directly to the presence of an antibiotic, it does show that by altering the number
of operons in a manner that is known to affect antibiotic susceptibility, we can also mediate
important growth parameters like cell yield, aka efficiency, and growth rate.
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L I S T O F F I G U R E S
1.1 A) ‘Mutant Selection Window’ (MSW) model, adapted from REFERENCE 17.
The black bars represent bacterial density in number of cells or strains. The
selective gradient, as a function of antibiotic concentration, is represented
in red. Below or above this window there is no selection on resistance. B)
Sub-inhibitory selective window model. Growth rates of a sensitive (S, in
green) and a resistant populations (R, in red) as a function of antibiotic
dose. Assuming the existence of costs of resistance, here represented as the
difference in growth rate in the absence of antibiotic, the minimum selective
concentration (MSC) is defined as the concentration of antibiotic at which S
and R have identical growth rates, and thus selection on R begins. Note that
this selection takes places below the minimum inhibitory concentration of the
wild-type strain (MICs). Adapted from REFERENCE 19.. . . . . . . . . . . . . . . . . . . . . 3
2.1 A) The proposed transport mechanism and (b) estimated structure of the
multi-drug efflux pump AcrAB-TolC taken from REFERENCES 54 in the case
of A) and 52 in the case of B). The pump rests on a structure formed by
proteins AcrB and AcrZ in the inner membrane, opening out to the cytoplasm.
In the outer membrane lies TolC that forms a pore opened to the extracellular
environment. AcrA connects both in the periplasm, and forms a vestibule in
the periplasm with AcrB. The drug binding pocket is hidden in the vestibule.
The drug is captured and ejected to the environment powered by protons
(H+) from the periplasm. Note that further studies of this pump52 established
X X L I S T O F F I G U R E S
the cytoplasmic section of AcrB as a completely different component, AcrZ
that is also produced by the acr operon. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
2.2 Partial regulatory network of the operons mar and acr composed through
a reverse-literature research during this project (i.e. if acr is regulated by
rob, what regulates rob?). There are at least three main signals for the
acr operon. First is guanosine tetraphosphate (ppGpp), a small nucleotide
‘alarmone’ that acts as a global gene expression regulator in E. coli.57 This
signal is produced upon nutrient limitation and its accumulation leads to
the down-regulation of basic processes such as DNA replication, and the
up-regulation of processes such as glycolysis, oxidative stress and osmotic
stress response.57 Second is the response to oxidative stress specifically
mediated by the sox operon. This operon is able to sense reactive oxygen
species, known mutagenic byproducts of metabolism and activate a series of
downstream genes to remove such mutagenic byproducts.58 The third signal
depends on population density, or a quorum sensing mechanism, mediated
by sdiA. This gene is involved in the density-dependant regulation of cell
division.67 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
2.3 A comparative set of four dose-response profiles, using erythromycin, for
the strains of E. coli AG100, AG100-A, TB108, and eTB108 where optical
density data has been measured at 600nm (OD600) after 24h of growth. Note
that OD600 is shown on the y-axis whilst the concentration of erythromycin
is represented in a logarithmic scale on the x-axis. The IC99 and its 95%
confidence intervals, determined using n = 8, are shown for each strain on
top of the x-axis. Only three of these are visible as two of the strains have
overlapping confidence intervals for their IC99 values (eTB108 and AG100).. 12
2.4 A shematic showing the key parameters involved in the quantification of the
rate of adaptation with respect to any phenotype on the y-axis, here taken to
be the growth rate. The rate of adaptation is denoted α throughout the text. . 13
2.5 A) Variation in strength of selection on resistance as a function of the dose of
an antimicrobial: it has been postulated to have a linear form.26,27 Thus one
might anticipate a form whereby s(A) = σ · A for some coefficient σ. B) The
L I S T O F F I G U R E S X X I
rate of the sweep to fixation of an advantageous trait of interest, assuming a
constant selection coefficient s, see REFERENCE 23. This is a logistic curve
whose steepness, and therefore the rate of fixation, is positively correlated
with the value of s. From A) this rate of fixation is therefore also positively
correlated with the value of A, if dose is indeed positively correlated with the
selection coefficient. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
2.6 A prediction from the theoretical model defined in EQUATION 2.1. The con-
centration of antibiotic is represented on a logarithmic scale on the x-axis,
whereas the growth in terms of OD600 is represented as a linear scale on
the y-axis. This model predicts that the initial antimicrobial dose-response
profile is monotone in accordance with standard tests that are used to
quantify sensitivity to antibiotics in the lab. In time, following adaptation,
cells with a higher number of pumps grow better at higher concentrations
of antibiotic and they are selected through time, thus producing a non-
monotone dose-response profile, eventually. The parameters are as fol-
lows:74 V = 1139.6µg/OD600/h, Km = 0.53882µg/mL, κ = 0.2mL/µg, v =
3987.3µg/OD600/h, km = 19.681(dimensionless), g = 0.5(dimensionless),
d = 0/day , ϕ = 93.068mL/OD600/h, δ = 0.0025/gene,∆ = 18(dimensionless),
and c = 0.000315OD600/µg with initial conditions BIC = {0.01, 0, 0}. The
dashed line highlights the culture density in the absence of drug. . . . . . . . . . . . 18
2.7 A second prediction from the theoretical model defined in EQUATION 2.1
when the ability of products of the acr operon to pump antibiotic has been
removed from the model. The concentration of antibiotic is represented using
a logarithmic scale on the x-axis, whereas growth in terms of OD600 is
represented using a linear scale on the y -axis. The black line shows the total
population density. Due to the inability of the cells to increase their ability
to efflux the drug, and with the initial population lacking efflux pumps, the
dose-response profile remains monotone at all times. In such a case, the
IC90 shows little variation through time. Parameters as in FIG. 2.6 with only
one modification: δ = 0/gene. The dashed line highlights the culture density
in the absence of drug. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
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2.8 Experimental data on the growth of E. coli AG100 shown on the y-axis as
the mean of OD600 ± standard error (n = 8, black), as a function of the
concentration of erythromycin (Ery) on the x-axis. Data is plotted at the
moment of inoculation (t = 0h) each season (one day per season) and every
6h thereafter. The vertical dashed line represents the IC99 measured after
24h of growth. This IC99 is often said to be the lower boundary of the mutant
selection window (MSW), here represented in grey. In blue we represent
the best Hill fit to data. This clearly shows a transition from monotone to
non-monotone behaviour of the density data through time as the quality of
the blue line datafit deteriorates through time. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
2.9 Experimental data on the growth of E. coli AG100-A shown on the y-axis
as the mean of OD600 ± standard error (n = 8, black), as a function of the
concentration of erythromycin (Ery) on the x-axis. Data is plotted at the
moment of the inoculation (t = 0h) and every 6h thereafter. The vertical
dashed line represents the IC99 measured after 24h of growth. This IC99 is
often said to be the lower boundary of the mutant selection window (MSW),
here represented in grey. In blue we represent the best Hill fit to data ±
standard error (n = 8). (Note: we observed growth in the treatment containing
the highest concentration of erythromycin in 1 out of 8 replicates after day 5). 23
2.10The difference between optical density data for the strain AG100 (left), AG100-
A (right) and the best-fit monotone (Hill) profile (fitted with respect to OD600)
on the y-axis is plotted as a function of the concentration of erythromycin
on the x-axis (shown as ‘E’ in the subplots on the right). The area under
the curve of the difference between data and optimal datafit (AUCd ) is used
to monitor the deviation from monotonicity as a function of time and the
concentration of erythromycin (central plot). This shows maximal deviation is
achieved at an intermediate time point. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.11Experimental data on the growth of E. coli TB108 shown on the y-axis
as the mean of OD600 ± standard error (n = 8, black), as a function of
the concentration of erythromycin (Ery) on the x-axis. Data is plotted as
OD600 (top) and as normalised GFP (nGFP, bottom) plotted at the moment
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of the inoculation (t = 0h) and every 6h thereafter. The vertical dashed line
represents the IC99 measured after 24h of growth. In blue we show the best-fit
Hill function.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.12The difference between the optical density data for the strain TB108 and the
best-fit monotone (Hill) profile in OD600 (top) and normalised GFP (nGFP,
bottom) on the y-axis as a function of the concentration of erythromycin on
the x-axis (E, subplots in the right). The area under the curve of this difference
(AUCd ) is used to monitor the deviation from monotonicity as a function of
time and the concentration of erythromycin (central plot). . . . . . . . . . . . . . . . . . . 26
2.13Experimental data on the growth of E. coli eTB108 shown in the y-axis as
the mean of OD600 ± standard error (n = 8, black), as a function of the
concentration of erythromycin (Ery) on the x-axis. Data for OD600 (top) and
normalised GFP (nGFP, bottom) plotted at the moment of the inoculation (t
= 0h) and every 6h thereafter. The vertical dashed line represents the IC99
measured after 24h of growth. In blue we show the best-fit Hill function.. . . . . 27
2.14The difference between the optical density data for the strain eTB108 and
the best-fit monotone (Hill) profile in OD600 (top) and normalised GFP (nGFP,
bottom) on the y-axis as a function of the concentration of erythromycin on
the x-axis (E, subplots in the right). The area under the curve of this difference
(AUCd ) is used to monitor the deviation from monotonicity as a function of
time and the concentration of erythromycin (central plot). . . . . . . . . . . . . . . . . . . 28
2.15Top) A partial view of the regulation network of the acr operon (see p. 10
for details). Bottom) The expression profile of AcrB-sfGFP is shown as a
function of time over 24h at different concentrations of erythromycin for the
strain eTB108. A proxy for the relative abundance of AcrB-sfGFP per cell is
shown on the y-axis as a function of time (bottom). Different concentrations
of erythromycin are denoted by different colours. We note that the small
oscillations observed are seemingly produced by mechanical components of
the microplate reader and not by any oscillatory dynamic produced by the
above network (see FIG. S.13). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
2.16Erythromycin dose-response profiles for evolved E. coli AG100 measured
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every 24h. The growth measured as OD600 is shown on the y-axis as a
function of the concentration of erythromycin, represented on the x-axis.
For the subplots, the y-axis represent the point-to-point slope changes of
the dose-response profiles and significantly positive (green) or negative
(red) slopes are highlighted accordingly (α = 0.01). These numbers indicate
whether an increase or decrease in drug dose increases or decreases the
OD values. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
2.17Erythromycin dose-response profiles for E. coli eTB108 measured every 24h.
The growth measured as OD600 is represented on the y-axis as a function
of the concentration of erythromycin, represented on the x-axis. For the
subplots, the y-axis represent the point-to-point slope changes of the dose-
response profiles and significantly positive (green) or negative (red) slopes
are highlighted accordingly (α = 0.01).. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
2.18Erythromycin dose-response profiles for E. coli eTB108 measured every 24h.
The absolute abundance of AcrB measured as normalised GFP (nGFP) is
represented on the y -axis as a function of the concentration of erythromycin,
represented on the x-axis. For the subplots, the y -axis represent the point-to-
point slope changes of the dose-response profiles and significantly positive
(green) or negative (red) slopes are highlighted accordingly (α = 0.01). . . . . . 32
2.19Erythromycin dose-response profiles for E. coli eTB108 measured every 24h.
The relative abundance of AcrB per cell measured as normalised GFP (nGFP)
per OD600 is represented on the y-axis as a function of the concentration
of erythromycin, represented on the x-axis. For the subplots, the y-axis
represent the point-to-point slope changes of the dose-response profiles
and significantly positive (green) or negative (red) slopes are highlighted
accordingly (α = 0.01). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
2.20Erythromycin dose-response profiles for E. coli TB108 measured every 24h.
The absolute abundance of AcrB measured as normalised GFP (nGFP) is
represented on the y -axis as a function of the concentration of erythromycin,
represented on the x-axis. For the subplots, the y -axis represent the point-to-
point slope changes of the dose-response profiles and significantly positive
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(green) or negative (red) slopes are highlighted accordingly (α = 0.01). . . . . . 33
2.21Erythromycin dose-response profiles for E. coli AG100-A measured every
24h. The growth measured as OD600 is represented on the y-axis as a
function of the concentration of erythromycin, shown on the x-axis. For the
subplots, the y-axis represent the point-to-point slope changes of the dose-
response profiles and significantly positive (green) or negative (red) slopes
are highlighted accordingly (α = 0.01).. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.22Erythromycin dose-response profiles for E. coli TB108 measured every 24h.
The growth measured as OD600 is represented in the y-axis as a function
of the concentration of erythromycin, represented in the x-axis. For the
subplots, the y-axis represent the point-to-point slope changes of the dose-
response profiles and significantly positive (green) or negative (red) slopes
are highlighted accordingly (α = 0.01).. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
2.23Selection statistics for E. coli AG100 as a function of the concentration of
erythromycin: rate of adaptation per replicate based on rAUC (αAUC , left).
Darker greys represent lower rates of adaptation, eight replicates shown,
whereas brighter greys represent higher rates. Mean rate of adaptation as
a function of the concentration of erythromycin (right). The numbers shown
correspond to the p-values of an unpaired t-test (α = 0.05). The error bars
represent the standard error of the mean (n = 8), and the grey area represents
the mutant selection window (MSW). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.24Selection statistics for E. coli AG100-A as a function of the concentration
of erythromycin: rate of adaptation per replicate based on rAUC (αAUC , left).
Darker greys represent lower rates of adaptation, eight replicates shown,
whereas brighter greys represent higher rates. Mean rate of adaptation as
a function of the concentration of erythromycin (right). The numbers shown
correspond to the p-values of an unpaired t-test (α = 0.05). The error bars
represent the standard error of the mean (n = 8), and the grey area represents
the mutant selection window (MSW). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.25Selection statistics for E. coli TB108 as a function of the concentration of
erythromycin: A,C,E) rate of adaptation per replicate based on rAUC (αAUC).
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Data for A) OD600, C) absolute abundance of AcrB-sfGFP as normalised
GFP (nGFP), E) relative abundance of AcrB-sfGFP as normalised GFP per
OD units. Darker greys represent lower rates of adaptation, eight replicates
shown, whereas brighter greys represent higher rates. B,D,F) Mean rate of
adaptation as a function of the concentration of erythromycin (right column).
The numbers shown correspond to the p-values for an unpaired t-test (α =
0.05). The errorbars represent the standard error of the mean (n = 8), and
the grey area represents the mutant selection window (MSW). . . . . . . . . . . . . . 36
2.26Selection statistics for E. coli eTB108 as a function of the concentration of
erythromycin: A,C,E) rate of adaptation per replicate based on rAUC (αAUC).
Data for A) OD600, C) absolute abundance of AcrB-sfGFP as normalised
GFP (nGFP), E) relative abundance of AcrB-sfGFP as normalised GFP per
OD units. Darker greys represent lower rates of adaptation, eight replicates
shown, whereas brighter greys represent higher rates. B,D,F) Mean rate of
adaptation as a function of the concentration of erythromycin (right column).
The numbers shown correspond to the p-values for an unpaired t-test (α =
0.05). The errorbars represent the standard error of the mean (n = 8), and
the grey area represents the mutant selection window (MSW) . . . . . . . . . . . . . . 37
2.27Estimation of the number of AcrB proteins per cell for populations the strains
E. coli TB108 (top) and eTB108 (bottom) as time changes. The two main
plots in the left-hand column represent the relative normalised GFP per OD600
in each population (y-axis, shown are means ± standard error, n = 8) as a
function of time (x-axis) and the different concentrations of erythromycin have
different colours. The subplots in the right-hand columns show sweep rates
per replicate as a function of erythromycin (Ery) whereby lighter squares
have higher values (8 replicates shown). The rate of sweep (ψ) is measured
using AUC as implemented in EQUATION 2.4 (bottom), and the maximum rate
of change in the time-series dataset for nGFP ·OD−1600 (y) for robustness as
max
0h≤t≤168h
dy
dt (top). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
2.28A) Genomic data for E. coli AG100. Coverage of the acr operon, relative to
the genome background, as a function of the concentration of erythromycin
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and time (x-axis, mean ± s.e.m, n = 3). B) Rate of sweep as the increase in
acr copies per day as a function of the concentration of erythromycin on the
y -axis, of the acr operon based on the genomic data.. . . . . . . . . . . . . . . . . . . . . . 40
2.29A) Estimation of the number of AcrB proteins per cell for populations the
strains E. coli as time changes. The main plot in the left-hand column repre-
sents the relative normalised GFP per OD600 (y-axis, shown are means ±
standard error, n = 8) as a function of time (x-axis) and the different concen-
trations of erythromycin have different colours. The subplots in the right-hand
columns show sweep rates per replicate as a function of erythromycin (Ery)
whereby lighter squares have higher values (8 replicates shown). The rate of
sweep (ψ) is measured using both AUC (bottom), and finite difference approx-
imations (top) for robustness. B) Rate of sweep, measured as the increase in
acr copies per day as a function of the concentration of erythromycin on the
y -axis, of the acr operon based on the genomic data.. . . . . . . . . . . . . . . . . . . . . . 41
3.1 Dose-response profiles for C. albicans showing the change in growth rate
as a function of the concentration of fluconazole in the absence (dark grey,
n = 2), and in the presence (light grey, n = 3) of the fluconazole-resistant
competitor C. glabrata. Growth rate in the absence of fluconazole is plotted on
the y-axis. The vertical dotted lines represent the concentration at which 90%
of the growth measured in the absence of fluconazole condition is inhibited,
coloured accordingly (IC90 = 1.821 and 1.811 µg/mL in monoculture, IC90 =
1.563, 1.823, and 0.978 µg/mL in coculture). Data provided by Emily Cook,
University of Exeter. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
3.2 Dose-response profiles for E. coli Wcl showing the change in growth rate
as a function of the concentration of tetracycline in the absence (dark grey),
and in the presence (light grey) of the competitor S. typhimurium, where the
latter is sensitive to this antibiotic. Growth rate in the absence of tetracycline
is plotted on the y-axis. The vertical dotted lines represent the concentration
at which 90% of the growth measured in the absence of tetracycline is
inhibited, coloured accordingly: IC90 = 0.245 ± 0.004 µg/mL in monoculture
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(mean ± 1.96 standard error), IC90 = 0.326 ± 0.024 µg/mL in coculture. We
analysed the difference between both IC90 using a Wilcoxon rank sum test
with ranksum = 100, and p = 1.55 · 10−4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
3.3 Model of the minimal selective concentration (MSC).19 Fitness, typically
measured as growth rate after 24h of growth, is represented in the y-axis as
a function of the concentration of antibiotic, represented in the x-axis. This
model assumes the existence of a ‘cost of resistance’,87 whereby mutations
conferring resistance to antibiotics are also associated with lower fitness.
Thus, in the absence of antibiotics, the drug-sensitive competitor (hereafter
denoted by ‘s’) has a higher growth rate after, say, 24h of growth, than the
resistant type (denoted by ‘r’). However, the s-type has a higher sensitivity
to the antibiotic and therefore MICs < MICr . As a consequence, the addition
of antibiotic to a mixed culture of s and r forces a ‘crossing point’ between
these two dose-response profiles. This crossing point defines the MSC, a
concentration at which both competitors have the same fitness and whereafter
selection on the resistant competitor begins. Note that MICs and MICr are
measured in monoculture only. We conducted competition experiments at
concentrations at which only the sensitive type is predicted to have changes
in fitness (pink). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
3.4 Diagram of the mathematical model formalised in EQUATION 3.1. A0 and
C denote the concentrations of antibiotic and carbon, respectively, in the
environment. Each cell contains an enzyme (black) able to take C from
the environment and process it to grow (the growth rate function is defined
as G(C) = y · VC/(Km + C), y denoting the yield per molecule of C, V
the maximum rate at which C is processed, and Km the enzymatic half-
saturation constant). A0 diffuses into the cells at a rate ϕ, binding to the
enzyme and reducing the growth of the cell (a growth inhibition function is
defined to be γ(A) = 1/(1 + κjA2j ), G(C) being redefined as Gj (C, A) =
y · VC0/(Km + C0) · 1/(1 + κjA2j )). Here j denotes the type of bacterium,
either sensitive (S) or resistant (R), κR  κS. We assume that antibiotic
degrades through time at a rate d . Finally, the growth function GR (C, A) is
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modulated by the cost of resistance parameter Γ > 0.. . . . . . . . . . . . . . . . . . . . . . 50
3.5 Our theory predicts that the S strain is more sensitive to tetracycline in the
presence of a competitor than in its absence. A) The monoculture dose
response of the S (plasmid-free) and R (resistant plasmid carrying) strains of
E. coli. This shows that the R strain can be considered completely resistant
over the range of dosages applied but the S strain has an IC50 over 0.14µg/mL
of tetracycline. B) Co-culture experiment with the 50-50 inoculum of S and
R strains, where the IC50 of the S strain has now shifted to 0.074µg/mL.
Moreover, 0.2µg/mL tetracycline is the IC91 in co-culture whereas it is the
IC63 in monoculture. The numerical values for the parameters are S0 = 0.001
cells, R0 = 0.001 cells, A0 = 0.2µg/mL, C0 = 100µg/mL, V = 2,400µg/cell/hour,
Km = 1µg/mL, γ= 0.75, ϕ = 103ml/cell, κ = 400mL/µg, d = 0.1 /h, η = 0.01,
carbon conversion factor = 0.00075 cells/µg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
3.6 Predicted inhibition per molecule of drug in the absence, and in the presence,
of a competitor with different sensitivities to the antibiotic tetracycline. The
sensitive competitor (S) is inhibited with less tetracycline in the presence of a
resistant competitor (R) due to competitive supression. Equally, the growth
of R is promoted due to a similar phenomenon with opposite effect, namely
competitive release,35 whereby the eradication of a competitor (in this case by
the use of antibiotics) leaves the unaffected competitor with more resources
to grow. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
3.7 Theoretical prediction of the existence of a concentration of antibiotic at which,
within a mixed culture, sensitive (s, green) and resistant (r, red) competitors
have identical fitness (MSC). The thin and thick lines represent the predictions
after one day and seven days of mixed growth, respectively. The crossing
point defines the MSC, which is here predicted to be different after seven
days of competition. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
3.8 Overlapped dose-response profiles for Tetrm (red), and Tet
s
m (green) in mono-
culture. Culture growth is represented as left) optical density estimated from
normalised fluorescence (ODe600), centre) per capita growth rate, and right)
maximum increase in ODe600 per hour on the y -axis, whereas the concentra-
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tion of tetracycline is represented on a logarithmic scale on the x-axis. Upon
detection, the MSC is represented in dark grey the IC90 for Tets in green,
and that for Tetr in red. For each case, we quantified the costs of resistance
as the difference between Tetr and Tets in the absence of tetracycline (data
shown on the y -axis). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
3.9 Left) Overlapped, culture density dose-response profiles for each competing
strain grown in monoculture. For more information see FIG. 3.8. Right)
Overlapped, culture density dose-response profiles for each competing strain
grown in coculture over 24h. We quantified the costs of resistance as the
difference between Tetr and Tets in the absence of tetracycline (data shown
on the y -axis). We used a Wilcoxon rank sum test to analyse the differences
in IC90 (p = 1.55 · 10−4 and ranksum = 100). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
3.10Overlapped, growth rate dose-response profiles for each competing strain
grown in monoculture (left) and 24h of coculture (right). For more information
see FIG. 3.8. Upon detection, the MSC is represented in dark grey the IC90
for Tets in green, and that for Tetr in red. We quantified the costs of resistance
as the difference in between Tetr and Tets in the absence of tetracycline (data
shown on the y-axis). We used a Wilcoxon rank sum test to analyse the
differences in IC90 (p = 1.55 · 10−4 and ranksum = 100) and MSC (p = 0.019
and ranksum = 42). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
3.11Overlapped dose-response profiles for Tetr (red), and Tets (green) during
the seven days of co-culture. Changes in A) optical density estimated from
normalised fluorescence (ODe600), B) relative frequency, C) per capita growth
rate, and D) maximum increase in ODe600 per hour as a function of the con-
centration of tetracycline. Upon detection, mean ± 95% confidence intervals
are shown for the MSC, represented in dark grey, and the IC90 for Tets, in
green. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
3.12Change in the IC90 as a function of the growth conditions (monoculture
or coculture) and competition length based on culture density (left), and
maximum increase in ODe600 per hour (right). We analysed the difference in
the IC90 between that measured in monoculture (label M) and after 24h of
L I S T O F F I G U R E S X X X I
coculture using a Wilcoxon rank sum test with p = 1.55 · 10−4 and ranksum =
100 for data based either on culture density (left) or growth rate as ODe600 per
hour (right). We also quantified differences in the IC90 measured after 48h
of coculture, with p = 3.10 · 10−4 and ranksum = 92 for the data based on
culture density (left), p = 0.002 and ranksum = 89 for data based on growth
rate as ODe600 per hour (right). The linear model IC
c
90 = a + bt is represented
in dark grey, the parameter b not being significantly different from zero. . . . . . 59
3.13Relative concentration of tetracycline per optical density unit (ODe600) for the
sensitive strain Tets in monoculture (labelled M), after 24 and 168 hours of
competition (labelled C). The barplots represent mean ± standard error (n =
7), whereas the raw data is shown as circles. We analysed the differences
between M and C(24h) using a Wilcoxon rank sum test with p = 0.011 and
ranksum = 33. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
3.14Overlapped, culture density dose-response profiles for each competing strain
grown in coculture over 24h (left) and 168h (right). Upon detection, the MSC
is represented in dark grey the IC90 for Tets in green, and that for Tetr in
red. For each case, we quantified the costs of resistance as the difference
in between Tetr and Tets in the absence of tetracycline (data shown on the
y-axis). We used a Wilcoxon rank sum test to analyse the differences in
IC90 (p = 5.84 · 10−4 and ranksum = 77). The costs of resistance are shown
on the y-axis as the difference between Tetr and Tets in the absence of
tetracycline. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
3.15Overlapped, growth rate dose-response profiles for each competing strain
grown in coculture over 24h (left) and 168h (right). Upon detection, the MSC
is represented in dark grey the IC90 for Tets in green, and that for Tetr in
red. For each case, we quantified the costs of resistance as the difference
in between Tetr and Tets in the absence of tetracycline (data shown on the
y -axis). We used a Wilcoxon rank sum test to analyse the differences in IC90
(p = 0.00408 and ranksum = 31) and MSC for which no statistical difference
was found. The costs of resistance are shown on the y -axis as the difference
between Tetr and Tets in the absence of tetracycline. . . . . . . . . . . . . . . . . . . . . . . 60
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3.16The main figure shows the 7-season distribution of the number of plasmids
in the R-cell types when σ = 0.01. Note how these distributions are more
skewed towards higher plasmid numbers as the dose of drug increases. The
inset shows three particular plasmid distributions after 7 seasons, including
the inoculum distribution which sees a random distribution of both s and r cell
types, with a uniform distribution of plasmids in the latter case. . . . . . . . . . . . . . 62
3.17Left) New predicted outcome of a competition between the strains Tets and
Tetr . This prediction is not qualitative different from the previous version of
the model. Right) Relative frequency of the plasmid as a function of the dose
(coloured), assuming a uniform distribution at inoculation time (t = 0h).. . . . . . 63
3.18Relative copies of the plasmid pGW155B per cell of Tetr after 24h of coculture
with Tetr . We robustly fitted the linear model y = a + bx where the 95%
confidence interval for a is (19.76, 41.35) and for b is (26.52, 284.56), with
R2adj = 0.198. This highlights a weak, but significantly positive correlation
between number of plasmids per cell and dose of tetracycline. . . . . . . . . . . . . . 64
4.1 A schematic of our implementation of the antibiotic susceptibility test: an
antibiotic drug held at high dosage at the centre of an agar plate diffuses out
into a bacterial lawn, producing a killing zone or zone of inhibition where by
the higher the dose, the larger the zone. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
4.2 A) Raw data: an image of a bacterial lawn (in false colour) showing how the
zone of inhibition on that lawn increases in area with increasing dose, here at
1, 2, 4,...., 128 times the MIC dose determined in liquid culture conditions. B)
The increase in area for the tetracycline drug for strains MG1655 and AG100
follow a power law with coefficient close to a value of two: a quadratic. This is
consistent with increases in zone of inhibition being described by a threshold
killing model whereby escape of the drug fro the centre following a diffusion
equation, as shown in the text (Statistical note: correlation coefficients are
R2 = {0.898, 0.959} respectively, F-statistics versus constant models are
F = {728, 1930} and corresponding p-values are given by: p = {1.43 ·
10−82, 3.45 · 10−115}.) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
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4.3 The leftmost plot shows the decay in drug concentration as a function of
distance from the drug source, where the latter has been deployed at a value
Ac. As the drug diffuses outwards, it maintains a value above the minimal
bactericidal concentration (MBC) for a while, thus enlarging the zone of
inhibition (ZoI), up to a maximum time point. Beyond this time, dose is too
low to ensure bacterial killing occurs. The middle plot is analogous to the first,
but with double the dose supplied, 2 × Ac . This calculation illustrates that the
zone of killing increases in size by a factor
√
2 according to diffusion theory.
The rightmost plot shows the dynamics of the drug dosage as a function of
time both inside and also right at the very edge of the zone of inhibition. . . . . 69
4.4 A) The basic structure of an operon: a promotor region in light grey, followed
by a gene coding a protein that represses transcription of the same operon,
followed by a second protein that encodes part of an efflux pump. We use
the green font colour to highlight the fact that we have a strain which has
GFP fused to the protein P, we also have strains without GFP fused to P. We
have in mind that P represents the A and B proteins of the acrRAB operon.
B) E.coli can duplicate the number of copies of the acr operon in its genome
which leads to a novel network structure following duplication in which the
two copies repress each other. C) Following a further duplication of one of
the operons, a three-node network results with all nodes repressing each
other. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
4.5 A) We took a fluorescence microphotography showing the localisation of
GFP within a section of an E. coli cell close to the moment of division. Using
this labelled strain of bacterium we are able to deduce how the dynamics
of regulation of the protein AcrB correlates with the use of the macrolide,
erythromycin (labelled ‘ERY’). In the absence of the drug (grey curve) the
protein is down-regulated through lag and exponential phase (less than 12h)
before being up-regulated and then stabilising in stationary phase (12h and
beyond). When drug dosage is applied, first at a low dosage of 5µg/ml ,
the concentration of AcrB per cell increases substantially to level about 40%
higher at its maximum in the absence of drug. However, as the dose is
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further increased we observed a negative correlation between drug and
AcrB concentration per cell. (b) The negative correlation so-described is
significant across a wide range of ERY dosages, as shown by the results
of determining a t-statistic (for the derivative of GFP per cell with respect to
dose) following a linear regression that is testing for the increase or decrease
in AcrB concentration as dose changes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
4.6 The analysis of the photographs from a spatial dose-response assay, using
the strain eTB108, shows the expression of AcrB using the proxy of green flu-
orescence levels (shown next to optical density (i.e. white light) at A) 24h and
B) 48h . This yields a per cell measure of AcrB concentration which is done
by calculating fluorescence observed per optical density. This measure is
shown in the inset of both plots which indicates a positive correlation between
drug dose and pumps per cell. We designed an algorithm in Matlab, using
the image analysis toolbox, to extract the information from the photographs
FIG. S.16.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
4.7 A) The intersection of the line and the quadratic functions give the values of
the environmental sugar concentration, S, for which growth rate has a local
extremum (a maximum). In this illustrate example, it is only in those regions
for which S lies between 2 and 3µg/ml (at the intersection of the red and
black lines) for which growth rate can have a local maximum and, then, it
is only for a certain range of the number of additional gene copies. B) The
analogous plot to that given in A), but showing dependence on A rather than
S. C) From A) and B) we deduce that, for the correct values of A and S, there
can be local spatial maxima with respect to growth rates whose location can
change with the number of copies of the resistance operon, acr.. . . . . . . . . . . . 76
4.8 Bullseye pattern formation due to the duplication of the acr operon as pre-
dicted by EQUATION 4.6. The distance from the centre of the plate is repre-
sented on the x−axes, whereas on the y−axes we represent the nutrient
and drug concentrations, and bacterial density all in arbitrary units. The first
ring (A top) is due to the increased bacterial growth produced by the higher
availability of nutrients (A, bottom plot in green) and extremely low concen-
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trations of drug (A bottom plot in red) in the boundary of the killing zone.
More nutrients are available beyond this boundary, but the concentrations
of drug in these coordinates impede the growth of the bacterial cells. Only
when the cells carry a second copy of this operon (b1), translated into higher
drug resistance, they are able to grow conforming an ‘inner rings’ of bacteria
(B top) until the concentration of drug is too high for these resistant cells (B
bottom). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
4.9 A (relative) dose-response of three strains of E.coli with respect to the drug
erythromycin using units of optical density measured at 600nm. The acr
knockout strain AG100-A is most sensitive to the drug, followed by TB108
which has a GFP physically fused to AcrB, followed by the strain MG1655.
These antibiotic sensitivity tests, required for experiments in CHAPTER 2,
show that, overall, bacterial growth declines monotonically with increasing
drug supply over a 24h incubation period. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
4.10An erythromycin dose-response curve of the E.coli AG100 strain with a Hill
function fit super-imposed onto the data. The latter is used to determine
an IC99 within a certain confidence and define the classic mutant selection
window (grey). Drug dose is shown on a linear scale on the x-axis, optical
density at 24h is shown on the y-axis. Data from experiment described in
CHAPTER 2 (FIG. 2.8). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
4.11Frames from a video showing the transition from monotone to non-monotone
dose response in the inhibition of E.coli growth by kanamycin held in the
central circular region. The top-most image was taken at time, t = 0h, the
bottom-most at t = 24h. The right column shows the mean dose-response
determined from each image in the left-hand column. . . . . . . . . . . . . . . . . . . . . . . 85
4.12The result of quantifying the transition in the dose-response data of FIG.
4.11. Plot A) shows how the data exhibits a low degree of non-monotonicity
at early on the in the experiment because the best monotone fit to data
is a good descriptor of the dose-response. Plot B) shows, at a later time,
that the best monotone fit to data gives a relatively poor fit. The right-hand
images in A) and B) show the difference between filtered data and the best
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monotone fit. C) Tracing the goodness of fit of the best monotone descriptor
of the dose-response data shows deterioration through time, indicative of a
transition from monotone to non-monotone dose-response. . . . . . . . . . . . . . . . . 86
4.13Measures of non-monotonicity (the oscillation profile and bumpiness mea-
sure) using the winding number of some synthetic data. In each of (A-F)
one can see, in the left column of the two images, a function representing
a particular dose-response pattern with zero drug at the x = 0 position
and higher drug where x  0. Plot (A) shows a monotone dose-response
which is reflected in the oscillation profile equation, shown in the middle
figure of plot A), to the zero function. Plots (B-F) have increasing degrees of
non-monotonicity which is reflected in the oscillation profile in the right-hand
figure of each plot whereby the grey regions have increasing area. In each
window, the right-most plot corresponds to the bumpiness spectrum. Plot (F)
accords with what one might expect from intuition: the bumpiness spectrum
of a cos(2pi · x ) function, suitably normalised, is (0, 2, 0, ...) as it exhibits ex-
actly two bumps. Plot (a) shows that the bumpiness spectrum of a monotone
function is the zero sequence (0, 0, ....).. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
4.14The left-hand image shows the mean optical density of two bacterial strains
at 24h, AG100 and AG100-A, the latter does not have a functional acr
operon whereas the former does. The two right-hand images are false colour
representations of two different agar plates on which the respective strains
were cultured. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
4.15A) The left-most plot shows an analysis of the dose-response profile which
constitutes the observed mean optical density as a function of the spatial
distance from the source of the drug (at position zero), and in this case it
is derived from strain AG100-A that lacks the efflux pump operon, acr. The
left-hand plot shows (in red) the best monotone function fit to data, filtered
data (in blue) and the dash blue lines indicate the leftmost point where the
optical density has been established to be significantly above zero using a
t-test with significance level p = 0.05. To the right of this point we assume
that optical density is significantly positive. The middle plot is the oscillation
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profile O(f )(α) for this AG100-A data and the rightmost plot is the bumpiness
spectrum that is derived from the oscillation profile. Neither of the latter two
measures are consistent with the presence of oscillations. B) This is the
analogous analysis to A) but now for the strain AG100 that possesses the
acr operon. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
5.1 Diagram of the metabolic rate-yield trade-off theory. A) Rate of ATP production
is shown on the y -axis as a function of the yield, η, on the x-axis. This function
reaches its maximum at η/2.37 B) The dynamics of ATP production depicted
in A) may change if part of the ATP synthesised is used to increase the
production rate. This investment of ATP comes at a cost of lower maximum
yields.38 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
5.2 A) Non-linear, monotonic increase in the carrying capacity, K , shown on the
y -axis, as a function of the concentration glucose of glucose supplied to the
media, shown on the x-axis. B) Landscape of possible carrying capacities as
a function of both glucose supplied and copies of the rrn operon. Contour lines
show the combination of glucose and number of rrn operons with identical K . 96
5.3 A) Representation of yield, measured as the ratio between K and glucose
supplied, on the y-axis and the glucose supplied to the media, on the x-
axis. The decrease in yield as a function of glucose supplied describes a
hyperbola that is consistent with formerly hypothesised RYTOs based on
a branched pathway, each branch leading to different yields.42,114 B) Upon
variation in environmental conditions, here in glucose supplied, the relative
maximum yield (green, strains in black) is achieved by strains with different
number of rrn operons. Per-strain hyperbola, as formalised in p. 97, shown in
grey. C) Landscape of possible yields achieved as a function of the glucose
supplied and the number of rrn operons. Contour lines show the combination
of glucose and number of rrn operons with identical yield. . . . . . . . . . . . . . . . . . . 98
5.4 Representation of the change in yield, shown on the y-axis, as a function
of the number of rrn operons. Each subplot shows this relationship when
different concentrations of glucose is supplied of the media. Overall, there is
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a linear, significant increase in yield as the number of rrn operons is reduced
when the concentration of glucose is above 0.25 mg/mL (black). However,
we observed no significant change when this concentration is equal or lower
than 0.25mg/mL. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
5.5 A) Change in per capita growth rate, shown on the y -axis, as a function of the
glucose supplied to the media, on the x-axis. We modified Monod’s growth
model (in black, see p. 97) to include, explicitly, the glucose-dependence
property of the yield. We observed an absolute, overall optimum per capita
growth rate at ≈0.5 mg/mL of glucose. B) Upon variation in environmental
conditions, here in glucose supplied, the relative maximum per capita growth
rate (green, strains in black) is achieved by strains with different number of
rrn operons. Per-strain hyperbola, as formalised in p. 97, shown in grey. C)
Landscape of possible per capita growth rates achieved as a function of the
glucose supplied and the number of rrn operons. Contour lines show the
combination of glucose and number of rrn operons with identical yield. . . . . . 100
5.6 Representation of the change in per capita growth rate, shown on the y-
axis, as a function of the number of rrn operons. Each subplot shows this
relationship when different concentrations of glucose is supplied of the media.
We compared whether the change in per capita growth rate is linear (light
grey) or non-linear (black). We tested the non-linearity of the data by fitting
the quadratic model r (G) = a + b ·G + b ·G2 to the data. Here r denotes per
capita growth rate, G the concentration of glucose, a per capita growth rate
when G = 0, and b and c phenomenological coefficients. . . . . . . . . . . . . . . . . . . 101
5.7 Left) Relationship between the per capita growth rate, measured as doublings
per hour on the y -axis, and yield, defined as cell density in OD units generated
per mg of glucose after 24h of growth, on the x-axis. The black line represents
the predicted, overall RYTO profile based on the predictions for yield (FIG.
5.3A) and per capita growth rate (FIG. 5.5A). Right) When we compare
the data in A) with the concentration of glucose, we observe RYTO at low
glucose concentrations, whereas at higher concentrations the RYTO turns
into a rate-yield trade down (RYTD). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
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5.8 Relationship between the per capita growth rate, measured as doublings per
hour on the y-axis, and yield, defined as cell density in OD units generated
per mg of glucose after 24h of growth, on the x-axis. Each subplot represents
this relationship for every strain, and hereby demonstrates the robustness of
this RYTO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
5.9 Relationship between the per capita growth rate, measured as doublings per
hour on the y-axis, and yield, defined as cell density in OD units generated
per mg of glucose after 24h of growth, on the x-axis. Each subplot represents
this relationship as a function of the number of rrn operons and glucose
supply. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
5.10A) Culture growth rate, rmax , shown on the y-axis as a function of glucose
supply, shown on the x-axis. The black line represents the overall growth
rate as predicted by Monod’s growth, as opposed to that predicted per strain,
represented in B). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
5.11A) Relationship between the population growth rate, rmax , shown on the
y-axis, and yield on the x-axis. The size of the data points is indicative
of the number of rrn operons, from seven copies in the wild-type strain
MG1655 (labelled WT) to just two copies in the strain with five deletions,
∆5.Relationship between power output,37 shown on the y-axis, and yield,
on the x-axis. The black line represents the quadratic model P (Y ) = a + b ·
Y + b · Y 2, P denoting the power output, Y the yield, a the growth rate when
y = 0, and b and c phenomenological coefficients. The 95% confidence for a
is (-0.003, 0.0004), for b (0.042, 0.086), and for c (-0.220, -0.110). The trend
is analogous to that observed in FIG. 5.7. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
5.12Relative yield, defined as OD units generated per mg of glucose per rrn
operon, is shown on the y-axis as a function of the glucose supplied to the
media, on the x-axis. Lines represent the best model fit: exponential (light
grey) or sigmoidal (dark grey), chosen depending on the corrected Akaike
Information Criterion (AICc). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
5.13Shape of the RYTO profile when relative yields are taken into account. The
strains containing seven to three rrn are clustered within a group with high
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per capita growth rate but low relative yield, whereas the strain with two
rrn operons, ∆5, forms a second cluster characterised by lower per capita
growth rates and higher yields. Black lines correspond to the estimation from
a quadratic model. Regression for the wild-type (WT): R2 = 0.56, F-statistic
versus constant model: 11.7, p = 0.000562. Regression for ∆5: R2 = 0.27 ,
F-statistic versus constant model: 3.44, p = 0.0541. . . . . . . . . . . . . . . . . . . . . . . . 108
5.14Effect of the number of rrn operons on the metabolic rate-yield trade-off
when relative yield is taken into account. Each plot represents this effect
when different concentration of glucose is supplied to the media. In each
subplot, per capita growth rate is represented on the y-axis, whereas the
yield, defined as cell density in OD units generated per mg of glucose after
24h of growth, is represented on the x-axis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
5.15Left) Relationship between the population growth rate, measured as the
maximum increment in OD per hour, shown on the y -axis, and relative yield,
defined as cell density in OD units generated per mg of glucose after 24h of
growth, on the x-axis. Right) Relationship between biomass production,37
shown on the y -axis, and relative yield, on the x-axis.. . . . . . . . . . . . . . . . . . . . . . 109
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S.1 Growth profiles for E. coli AG100 based on OD600 measured every 20min
(1/3h), for 24h, during 7 days. Each subplot contains the growth profile of eight
replicates as a function of time, and as a function of the dose of erythromycin
(columns). The different rows show the fit, and the data for different days
ranging from days 1 to 7. We used the degree of overlap of the data (grey)
and the model (blue) to validate the appropriateness of the models that we
used to calculate the growth rate in each case. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
S.2 Growth profiles for E. coli AG100-A based on OD600 measured every 20min
(1/3h), for 24h, during 7 days. Each subplot contains the growth profile of eight
replicates as a function of time, and as a function of the dose of erythromycin
(columns). The different rows show the fit, and the data for different days
ranging from days 1 to 7. We used the degree of overlap of the data (grey)
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and the model (blue) to validate the appropriateness of the models that we
used to calculate the growth rate in each case. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
S.3 Growth profiles for E. coli TB108 based on OD600 measured every 20min
(1/3h), for 24h, during 7 days. Each subplot contains the growth profile of eight
replicates as a function of time, and as a function of the dose of erythromycin
(columns). The different rows show the fit, and the data for different days
ranging from days 1 to 7. We used the degree of overlap of the data (grey)
and the model (blue) to validate the appropriateness of the models that we
used to calculate the growth rate in each case. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
S.4 Growth profiles for E. coli TB108 based on normalised fluorescence (nGFP)
measured every 20min (1/3h), for 24h, during 7 days. Each subplot contains
the growth profile of eight replicates as a function of time, and as a function
of the dose of erythromycin (columns). The different rows show the fit, and
the data for different days ranging from days 1 to 7. We used the degree of
overlap of the data (grey) and the model (blue) to validate the appropriateness
of the models that we used to calculate the growth rate in each case. . . . . . . . 125
S.5 Growth profiles for E. coli TB108 based on relative fluorescence per OD600
unit (nGFP · OD−1) measured every 20min (1/3h), for 24h, during 7 days.
Each subplot contains the growth profile of eight replicates as a function of
time, and as a function of the dose of erythromycin (columns). The different
rows show the fit, and the data for different days ranging from days 1 to 7. We
used the degree of overlap of the data (grey) and the model (blue) to validate
the appropriateness of the models that we used to calculate the growth rate
in each case.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126
S.6 Growth profiles for E. coli eTB108 based on OD600 measured every 20min
(1/3h), for 24h, during 7 days. Each subplot contains the growth profile of eight
replicates as a function of time, and as a function of the dose of erythromycin
(columns). The different rows show the fit, and the data for different days
ranging from days 1 to 7. We used the degree of overlap of the data (grey)
and the model (blue) to validate the appropriateness of the models that we
used to calculate the growth rate in each case. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
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S.7 Growth profiles for E. coli eTB108 based on normalised fluorescence (nGFP)
measured every 20min (1/3h), for 24h, during 7 days. Each subplot contains
the growth profile of eight replicates as a function of time, and as a function
of the dose of erythromycin (columns). The different rows show the fit, and
the data for different days ranging from days 1 to 7. We used the degree of
overlap of the data (grey) and the model (blue) to validate the appropriateness
of the models that we used to calculate the growth rate in each case. . . . . . . . 128
S.8 Growth profiles for E. coli eTB108 based on relative fluorescence per OD600
unit (nGFP · OD−1) measured every 20min (1/3h), for 24h, during 7 days.
Each subplot contains the growth profile of eight replicates as a function of
time, and as a function of the dose of erythromycin (columns). The different
rows show the fit, and the data for different days ranging from days 1 to 7. We
used the degree of overlap of the data (grey) and the model (blue) to validate
the appropriateness of the models that we used to calculate the growth rate
in each case.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
S.9 Adaptive landscapes for E. coli AG100 according to the best model fit (left),
finite difference approximation (centre), and area under the curve (right). The
analysis reflects the robustness of the existence, and location of the evolu-
tionary ‘coldspots’ and ‘hotspots’ as a function of the dose of erythromycin.
The colorbar indicates the rate of adaptation, black being the lowest rate of
adaptation and white being the highest. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
S.10Adaptive landscapes for E. coli AG100-A according to the best model fit
(left), finite difference approximation (centre), and area under the curve
(right). The analysis reflects the robustness of the existence, and location
of the evolutionary ‘coldspots’ and ‘hotspots’ as a function of the dose of
erythromycin. The colorbar indicates the rate of adaptation, black being the
lowest rate of adaptation and white being the highest. . . . . . . . . . . . . . . . . . . . . . 130
S.11Adaptive landscapes for E. coli TB108 according to the best model fit (left),
finite difference approximation (centre), and area under the curve (right)
based on readings for OD600 (A), normalised fluorescence (B), and relative
fluorescence per OD600 unit (C). The analysis reflects the robustness of
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the existence, and location of the evolutionary ‘coldspots’ and ‘hotspots’ as
a function of the dose of erythromycin. The colorbar indicates the rate of
adaptation, black being the lowest rate of adaptation and white being the
highest. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
S.12Adaptive landscapes for E. coli eTB108 according to the best model fit (left),
finite difference approximation (centre), and area under the curve (right)
based on readings for OD600 (A), normalised fluorescence (nGFP, B), and
relative fluorescence per OD600 unit (C). The analysis reflects the robustness
of the existence, and location of the evolutionary ‘coldspots’ and ‘hotspots’
as a function of the dose of erythromycin. The colorbar indicates the rate
of adaptation, black being the lowest rate of adaptation and white being the
highest. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132
S.13Fast Fourier transform (FFT) spectra for E. coli eTB108. The frequency of
the oscillations is shown on the x-axis and the energy of such oscillations
on the y-axis. Each column represents the FFT for the data measured in
different days, in different concentrations of erythromycin (here shown in
rows). A feature is shared overall: a peak every ∼3/4 of an hour. This feature
corresponds to the small oscillations observed in FIGURES 2.15 and S.8.
Mean signal in black, per replicate signal in light grey.. . . . . . . . . . . . . . . . . . . . . . 134
S.14Fast Fourier transform (FFT) spectrum for the inocula-free, negative control.
The frequency of the oscillations is shown on the x-axis and the energy of
such oscillations on the y -axis. The presence of the same signature, a peak
every 3/4 of an hour, suggests a mechanical cause for these oscillations.
Mean signal in black, per replicate signal in light grey.. . . . . . . . . . . . . . . . . . . . . . 135
S.15A) Model fit for the tetracycline sensitive (Tetsm, green), and the tetracycline
resistant (Tetrm, red) strains grown in monoculture. Model fitted to optical
density at 600nm (OD600) and optical density estimated from fluorescence
(ODe600). B) Ratio of normalised fluorescence units (RFUn) per optical density
unit. This ratio is robust to changes in optical density. . . . . . . . . . . . . . . . . . . . . . . 139
S.16Pilot experiment for the development of the image analysis pipeline. A) Binary
mask created to detect circular shapes from B) grey scaled photographs. C)
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The image is corrected by subtracting the photo taken at t = 0h and read.
D) Profile plot, showing mean growth ± standard error on the y−axis as a
function of the distance to the centre of the inhibition zone, on the x−axis. . . 141
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I I N T R O D U C T I O N
“[resistance] is a purely chemical question which can only be solved by chemical means.”
—Paul Ehrlich,1 considered father of chemotherapy.
ANTIBIOTICS heralded a new era in the treatment of bacterial infections in whichdeadly infections, such as bacterial meningitis, could be cured. The discovery
of the β-lactam penicillin and subsequently of other antibiotics defined the so-called
golden age of antibiotic discovery,2 when the drugs were classified in different classes
(i.e. tetracyclines or macrolides) based on their biochemical properties. The ability
of bacteria to become resistant to toxic substances, such as antibiotics, was well
known since the early twentieth century,3 but the variety of these drugs led “society
and the scientific community to become complacent about the potential of bacterial
resistance”.4 Such are the dimensions of resistance today that, during 2014, the World
Health Organization (WHO) published a report stressing that resistance to commonly
used antimicrobials is both widespread and, to quote the report directly, “few if any
antimicrobial options are available”.5 The same report also highlights the “virtually
empty pipeline for the development of new antibacterial drugs”. Whilst the efforts to
discover new antibiotics are of course an essential effort, perhaps it led us to overlook
what has been termed “insufficient information about the conditions and factors that
can lead to the mobilisation, selection and movement of these [resistant] bacteria”.6
This was already asked in the 1950s. When doctors started to quantify antibiotic
resistance in the clinic, feared that “if the supply [of antibiotics] should cease (. . . ) the
time may come when a few of the more enterprising [bacterial] species will flourish
more or less unhindered”.7 An editorial note in the British Medical Journal then asked
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about the conditions in which resistance was acquired.8 Thus, very little progress has
been made ever since. The small molecule antibiotic itself, in particular the discovery of
new ones, will play an essential part of the ongoing fight in the antimicrobial crisis, but
the clinical deployment of those molecules is an equally important part of the problem
and we contend that this represents an under-studied set of scientific questions.
Therefore, in response, this thesis presents a theoretical and empirical study of such
conditions, motivated by clinical treatments, and asks, exactly, what are the conditions
that lead to the most rapid onset of bacterial resistance to antibiotics? A number of
metabolic and physiological questions are addressed as a direct result of the questions
we ask about antibiotics. More immediately, in this chapter, we will introduce a number
of fundamental problems associated with antibiotic therapy design that we would like
to resolve.
1.1 ANTIBIOTIC RESISTANCE (I): QUANTIFIED WITHIN 24H, TREATED FOR WEEKS
Antibacterial drugs are, by definition, toxic to bacterial-type microorganisms. Antibiotic
therapy design is based on a principle, assumed to be true for more than a century,
whereby higher dosages of a drug necessarily lead to fewer observed bacterial cells
in the presence of that drug.9–12 Now, in practise, antibiotic sensitivity tests (ASTs)
quantify the precise dosage in vitro prior to use in the clinic. In these standardised
tests media, growth conditions and incubation times are clearcut, defined and, by
now, almost seen by the community as immutable.11 However, I contend that there
is potential for a fundamental flaw in the relationship between ASTs and clinical
therapies and it is this: the incubation time of ASTs is typically 24h, whilst therapies
last substantially longer in the clinic.13,14 Whether or not the sensitivity quantified by
ASTs is maintained for longer incubation times has been experimentally demonstrated
many times over in the field. However, this understanding has not been translated
into improved clinical treatments. Whilst the latter is well beyond the purpose of this
thesis, I will aim to show that prolonged treatments, beyond 24h, do lead to increases
in resistance in a consistent, and even possibly, a prior predictable, manner.
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FIGURE 1.1. A) ‘Mutant Selection Window’ (MSW) model, adapted from REFERENCE 17. The black bars represent bac-
terial density in number of cells or strains. The selective gradient, as a function of antibiotic concentration, is represented
in red. Below or above this window there is no selection on resistance. B) Sub-inhibitory selective window model. Growth
rates of a sensitive (S, in green) and a resistant populations (R, in red) as a function of antibiotic dose. Assuming the
existence of costs of resistance, here represented as the difference in growth rate in the absence of antibiotic, the mini-
mum selective concentration (MSC) is defined as the concentration of antibiotic at which S and R have identical growth
rates, and thus selection on R begins. Note that this selection takes places below the minimum inhibitory concentration
of the wild-type strain (MICs). Adapted from REFERENCE 19.
1.2 SELECTION ON RESISTANCE IS PROPORTIONAL TO ANTIBIOTIC DOSE
Resistance to antibiotics is caused by transmissible genetic elements but also sponta-
neous chromosomal mutations.15,16 But it is important to know at which drug dosages
these genes are most selected for. This question has been studied and the outcome of
those studies has concluded that the concept of a ‘selection window’ in which resistant
mutants are strongly selected within a narrow range of concentrations of antibiotic
resolves this question.17 However, where this window, if it does indeed exist, resides
remains a matter of some discussion in the field due to what could be said to be
poorly supported criteria whereby the boundaries of the selective window are defined
(FIG. 1.1).17–19 In this thesis we therefore use a specific model system to address the
question of where these windows can indeed be found.
But what does ‘strongly’ mean in terms of selection? The strength of selection can
be objectively measured and quantified with the selection coefficient. In population
genetics theory, selection “applies to the organism as a whole”20 and therefore the
selection coefficient is considered to be a “complicated function of the entire system of
gene frequencies and can only be dealt with qualitatively”.20 Thus, the simplest case
of study of selection in population genetics has typically been that of one gene with a
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constant selection coefficient.20–24 This concept has been applied to study antibiotic
resistance in the clinic, and the strength of selection on resistance is considered to
be proportional to antibiotic dose.25–27 In this thesis, our data leads to a different
conclusion, namely one whereby selection on specific resistance genes can be shown
to vary in a nonlinear and, indeed, non-monotone fashion with respect to antibiotic
dose. We will find hotspots and coldspots in the spectrum of dosages where selection
is maximised and minimised, respectively.
1.3 ANTIBIOTIC RESISTANCE (II): TESTED ON A SPECIFIC STRAIN, USED AGAINST
BACTERIAL COMMUNITIES
A second likely flaw in the relationship between antibiotic sensitivity tests (ASTs) and
their utility in terms of predicting the outcome of clinical therapies in hospital patients
may stem from a fundamental property of microbial ecologies. These tests always, by
design, quantify the sensitivity to antibiotics of a single, isolated strain of bacterium.
Yet, in the clinic, antibiotics are not only deployed to target this particular strain, but
they also target commensal microbes and the entire gamut of species that constitute
the patient’s microflora. Moreover, some infections can be polyclonal and, indeed,
polymicrobial.28–30
Although therapies designed using isolated strains have been said some time ago to
provoke a minimum disturbance on the microflora,31 these microbes necessarily set the
context for competition for resources with the bacteria being targeted. Whether or not
the competition modifies the sensitivity to antibiotics of the targeted strain, previously
quantified on isolation, is poorly understood.
Competition, and indeed cooperation, of the targeted species with other microbial
species represents just one aspect of the ASTs that departs from the reality of a
pathogen’s lifestyle, but there are others. In particular, the immune system of a healthy
host is known to play a large part in the success, and failure, of antibiotic treatments,
but immunity plays almost no role in this thesis. This is not because it lacks importance,
rather, it is a highly relevant part of the entire problem, however we have endeavoured
to keep this work centred on a body of tractable experimental in vitro systems which
has precluded the use of animal models.
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1.4 IN MIXED POPULATIONS, FAST DIVIDING CELLS OUTCOMPETE SLOW DIVIDING CELLS
The effect of antibiotics on bacteria is often measured as the reduction in bacterial
fitness,32 which is defined in terms of generation times (per capita growth rate).19,32–35
Therefore, fitter types of bacteria divide quicker than less fit types. In the case of mixed
populations of bacteria it has been proposed that, if mutations providing resistance to
antibiotics have a cost associated so that resistant cells are less fit, sensitive stains of
bacteria may outcompete resistant populations, less fit, when the use of antibiotics is
interrupted.36
But slow dividing cells can also surpass fast dividing cells. Stemming from certain
thermodynamic constraints,37,38 it has been proposed that high growth rates are not
compatible with simultaneous high growth yields (biomass produced per molecule of
carbon source) and, hence, there must be a metabolic trade-off between rate and
yield.38 Under such circumstances, assuming the constant supply of resources, slow
dividing but efficient cells can, in fact, outcompete fast dividing but inefficient cells.38
Now, bacterial growth rate is coupled to the cell’s capacity to synthesise proteins,39
and this capacity depends on the concentration of ribosomes within the cell.40 So whilst
the use of ribosome-binding antibiotics is expected to reduce bacterial fitness, and
therefore the growth rate,41 it is important to ask if the addition of such antibiotics leads
to slow dividing, yet more efficient, resistant bacterial cells. This could be described
as the potential for resistant cells to exploit an inevitable trade-off in growth. Empirical
datasets supporting the aforementioned trade-off are scarce42 meaning predictions
based on these trade-offs, in terms of how antibiotic-resistant cells might outcompete
drug sensitive cells, are very limited. We therefore sought to address this.
1.5 QUESTIONS AND THESIS OUTLINE
Using the bacterium Escherichia coli as a living model we answered a wide range of
questions that can be summarised as follow.
First, we explored whether the previously introduced principle whereby high dosages
always lead to low cell densities holds at all times during antibiotic treatment. E. coli is
known to possess an operon (acr) that encodes a pump with which the bacterium is
able to efflux a wide range of molecules, including antibiotics, from the cytoplasm of
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the cell into extracellular space, thus providing a generic resistance mechanism on this
operon. There are other mechanisms, more antibiotic-specific, that provide resistance
through random changes in the genome or mutations. These mutations may affect, by
chance, the molecule targetted by the antibiotic, or metabolic enzymes that can modify
the antibiotic molecule.43 Once these mutations occur de novo, they can be transmitted
and acquired through vectors such as plasmids,44 helping to spread resistance more
rapidly. However, due to its unusually broad specificity,45 we explored how selection on
resistance provided by the aforementioned operon is mediated by the dosage of the
ribosome-binding drug, erythromycin, supplied to the environment in which E. coli is
cultured.
We then looked into how selection on resistance is mediated by the presence of a
competitor microbial strain in the culture. Motivated by this question, we used a range
of multi-species experiments, including fungal microbial species that are known to
co-infect humans. We also sought to tackle the problem of determining the profile of
selection as a function of antibiotic dose using strains of E. coli which harbour a plasmid
that encodes the tetracycline resistance gene tet36. This gene provides ribosomal
protection against the tetracycline class of antibiotics so we explored whether, or not,
there is a minimal antibiotic dose at which selection on this plasmid begins.
Penultimately, we partially extended the first study (i.e. the one on acr selection) to a
spatially-extended context to understand spatial patterning effects of the acr operon.
For this we employed mathematical modelling, and used a bespoke spatial culture
device that was constructed as part of this PhD project.
Finally, we were interested in how the number, or concentration, of targets within the
cell of important antibiotics like erythromycin and tetracycline mediate key phenotypes
like growth rate and cell efficiency (per supplied molecule of carbon). Whilst this does
not relate directly to the presence of an antibiotic, we analysed whether by altering
the number of operons in a manner that is known to affect antibiotic susceptibility, we
could also mediate important growth parameters like cell efficiency and growth rate.
II E V O LV I N G A N E RY T H R O M Y C I N - S E N S I T I V E
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ANOMALOUS DRUG activity, also known in the literature as a paradoxical effect,is a phenomenon whereby higher doses of antibiotic do not necessarily yield
higher bactericidal, or indeed bacteriostatic, effects of that drug.10,46–48 In other words,
an inhibitor is not an inhibitor at all doses, but it can even appear to be a stimulant
of vegetative growth. This phenomenon, observed many decades ago after short (in
all likelihood, non-evolutionary) periods of 16 to 24h of exposure to antibiotics, has
been known since the 1940s but still remains poorly understood.49 In this chapter
we will demonstrate that a similar ‘paradox’ can be produced through selection for a
‘genomically scalable’ multi-drug efflux pump system, AcrAB-TolC, caused by genome
duplication events.
Previously this was deemed to be a paradox in the cited references and the so-
called ‘Eagle effect’ is one observation that fits this particular description. From a more
modern and evolutionary perspective, we will show that a paradox whereby greater
drug doses also produce higher population densities of a bacterium can be the result
of differential selection for a drug resistance mechanism. Such differential selection
can, as we will demonstrate, lead to a strong non-linear and, more importantly, non-
monotone relationship between selection on a resistance mechanism and the drug
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dose applied to the microbial population under study.
The purpose of this chapter is to provide the data supporting the existence of such a
non-monotone relationship. We will demonstrate that selection on resistance, in this
case by antibiotic efflux, is subsequently maximised in a ‘mid-dose region’. The latter
term will be explained in the remainder of this chapter.
Determining the drug dosing regions where selection for a resistance mechanism is
maximised is a key problem in the field of antibiotic pharmacology. As we discussed
in the introductory chapter various different theories have been postulated for this,
with a variety of empirical datasets put forward to support each view.17–19 With the
minimum inhibitory concentration of the wild-type (MIC) as the central parameter,
these theories are mutually exclusive: one establishes that selection on resistance
begins at concentrations above the MIC,17,18 whereas for the other theory it begins at
concentrations below the MIC.19
It is essential to determine which concentration maximises selection on resistance
and to determine selection on resistance in a precise way, we used a simple experi-
mental model based on Escherichia coli ’s multi-drug efflux pump AcrAB-TolC. We now
describe some of the features of this pump system.
2.1 DESCRIPTION OF THE MULTI-DRUG EFFLUX PUMP ACRB-TOLC AND ITS REGULATION
The role played by efflux pumps in clinical multi-drug resistance (MDR) has been
reconsidered in recent years.50,51 In the bacterium Escherichia coli there is, perhaps,
one of the best-described such pumps, the AcrAB-TolC efflux pump system (FIG. 2.1).
Its components are encoded by an different operons, acr, and tolC. The products
of these genes interact with each other to assemble the multi-drug efflux pump that
connects the bacterial cytoplasm with extracellular space, as shown in FIG. 2.1.45,52
With a proton-powered, rotational mechanism, this pump is able to collect antibiotics
as well as a broad range of small molecule substrates from within the periplasm and
translocate them to the outside of the cell. The specificity of this pump is known to be
‘unusually broad’45 and is believed that these pumps not only provide MDR but also a
fitness advantage in their natural environments.53
The complex, regulatory architecture of this efflux system has been determined to
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FIGURE 2.1. A) The proposed transport mechanism and (b) estimated structure of the multi-drug efflux pump AcrAB-
TolC taken from REFERENCES 54 in the case of A) and 52 in the case of B). The pump rests on a structure formed
by proteins AcrB and AcrZ in the inner membrane, opening out to the cytoplasm. In the outer membrane lies TolC that
forms a pore opened to the extracellular environment. AcrA connects both in the periplasm, and forms a vestibule in
the periplasm with AcrB. The drug binding pocket is hidden in the vestibule. The drug is captured and ejected to the
environment powered by protons (H+) from the periplasm. Note that further studies of this pump52 established the
cytoplasmic section of AcrB as a completely different component, AcrZ that is also produced by the acr operon.
some extent, where a role is played by several genes within the mar regulon which
mediate MDR levels via expression of the acr operon. From a literature search, we
constructed just a part of the regulatory network of the acr operon, as shown in FIG.
2.2 in order to provide background to the complex dynamics of Acr protein expression
that are likely following antibiotic challenge to the bacterial cell.
Using an even larger model of this regulatory network, we could also attempt to
link metabolic processes, such as the response to nutrient limitation, oxidative stress
molecules, or population densities to the expression level of the acr operon. We
presented FIG. 2.2 only to illustrate the fact that it is not even clear whether, for
example, acr expression is positively correlated with antibiotic dose. Nevertheless,
we remark that in the absence of antibiotics and due to the accumulation of stress
signals in the cell, this efflux pump system can be up-regulated to play a key role in
‘detoxifying’ the cell from hazardous metabolic byproducts, and down-regulated when
such byproducts are absent.
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FIGURE 2.2. Partial regulatory network of the operons mar and acr composed through a reverse-literature research
during this project (i.e. if acr is regulated by rob, what regulates rob?). There are at least three main signals for the acr
operon. First is guanosine tetraphosphate (ppGpp), a small nucleotide ‘alarmone’ that acts as a global gene expression
regulator in E. coli. 57 This signal is produced upon nutrient limitation and its accumulation leads to the down-regulation
of basic processes such as DNA replication, and the up-regulation of processes such as glycolysis, oxidative stress
and osmotic stress response.57 Second is the response to oxidative stress specifically mediated by the sox operon.
This operon is able to sense reactive oxygen species, known mutagenic byproducts of metabolism and activate a series
of downstream genes to remove such mutagenic byproducts.58 The third signal depends on population density, or
a quorum sensing mechanism, mediated by sdiA. This gene is involved in the density-dependant regulation of cell
division.67
2.2 QUANTIFYING THE DEGREE OF RESISTANCE PROVIDED BY THE ACRAB-TOLC EFFLUX
PUMP SYSTEM
To determine the role of the AcrAB-TolC efflux pump system in multi-drug resistance,
in E. coli, we used a number of strains with a modified AcrAB-TolC efflux pump (TABLE
2.1). Our wild-type strain here is one denoted AG100, a K-12 strain of E. coli. This
strain was modified with the transposable element Tn909 to interrupt the sequence of
the genes acrA and acrB within the acr operon. Thus, this derivative strain, namely
AG100-A, produces nonfunctional versions of the proteins AcrA and AcrB, which are
two key components of the AcrAB-TolC efflux pump system. In order to measure
the relative abundance of AcrAB-TolC within the cell exposed to different antibiotic
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TABLE 2.1. Strains of Escherichia coli used to perform the experiments described in this chapter. The strain TB108 was
kindly provided by Dr. Tobias Bergmiller.
Strain Genotype Reference
E. coli AG100 K-12 argE3 thi-1 rpsL xyl mtl ∆(gal-uvrB)
supE44
68
E. coli AG100-A AG100 ∆acrAB::Tn903 68
E. coli TB108 MG1655 acrB-sfGFP-FRT Unpublished
E. coli eTB108 MG1655 acrB-sfGFP-FRT ± ? This thesis
environments we used derivatives of a K-12 strain that we denote TB108.
The latter is derived from another K-12 type strain, this time MG1655, and in TB108
the original acrB is replaced with a copy of acrB which has been tagged (physically
fused) with sfGFP (the superfolder green fluorescent protein), inserted downstream
and in-frame. The result is a fully functional, although partially ‘damaged’, efflux
protein AcrB with sfGFP attached in the cytoplasmic c-terminal end. By measuring the
fluorescence produced by sfGFP, we will be able to measure the relative abundance of
the AcrAB-TolC efflux pump system as a function of time and antibiotic dose. By doing
so we can determine the strength of selection for this efflux system at different doses.
In order to quantify the loss of efflux efficacy due to the GFP construct imposed
upon the cell relative to the wild-type strains, we measured the resistance to the
macrolide erythromycin using the broth dilution method in 96-well microtiter plates,
as shown in FIG. 2.3. The strain AG100 displayed the highest MIC for this protein
synthesis-inhibiting drug, followed by TB108 and then AG100-A. This latter strain
showed the lowest MIC, thus demonstrating that the lack of a functional AcrAB-TolC
efflux pump system leads to an increased sensitivity to erythromycin. However, strain
TB108 showed a phenotype that rests between the strain AG100 and that with the
nonfunctional copy of acrAB, AG100-A. In order to verify that sfGFP was physically
interfering with the function of AcrB, and to repair this if possible, we evolved this strain
in the presence of 10µg/mL of erythromycin for seven days (experimental details are
given below within this chapter). Our working hypothesis for this procedure was that
sub-populations with a lower physical interference between these two components
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FIGURE 2.3. A comparative set of four dose-response profiles, using erythromycin, for the strains of E. coli AG100,
AG100-A, TB108, and eTB108 where optical density data has been measured at 600nm (OD600) after 24h of growth.
Note that OD600 is shown on the y -axis whilst the concentration of erythromycin is represented in a logarithmic scale on
the x-axis. The IC99 and its 95% confidence intervals, determined using n = 8, are shown for each strain on top of the
x-axis. Only three of these are visible as two of the strains have overlapping confidence intervals for their IC99 values
(eTB108 and AG100).
(AcrB and the GFP) would be preferentially selected in this evolutionary protocol.
After the selection process, a new strain labelled eTB108 (meaning ‘evolved TB108’),
subsequently had a sensitivity (i.e. MIC) to erythromycin that is indistinguishable to
that measured for the strain AG100. We labelled the resulting strain eTB108 and used
this for the subsequent studies that we now describe.
2.3 QUANTIFYING ADAPTATION: RATE OF CHANGE IN GROWTH RATE AS A FUNCTION OF
TIME AND DOSE
Whilst performing the aforementioned studies, we measured how these different strains
adapted to their environment. One way of doing this relied on finding rates of change
of growth rate as a function of time, and antibiotic dose, and calling this the rate of
adaptation. This is an approach already used in the literature,69 and the idea is based
on the assumption that growth rates will change as a function of time as the bacterium
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FIGURE 2.4. A shematic showing the key parameters involved in the quantification of the rate of adaptation with respect
to any phenotype on the y-axis, here taken to be the growth rate. The rate of adaptation is denoted α throughout the
text.
adapts to the environment. This phenotypic change can then be taken as a simple
measure quantifying the complex processes of adaptation (FIG. 2.4).
A key parameter for producing such datasets is the ‘adaptive time’, denoted tadapt .
Here r0 denotes the bacterial growth rate at the beginning of a bacterial culture
experiment, r (t ) is the growth rate at some time t and ∆r (t ) the difference between
r0 and r (t ). We can the define the adaptive time to be the time at which the condition
r (t ) = r0 +∆r (t )/2 is satisfied. Lastly, the rate of adaptation (denoted α) is defined as
the ratio between ∆r and tadapt so that α := (∆r/2)/tadapt ; for further details of the
calculation see REFERENCE 69.
2.4 HYPOTHESIS: IF THE STRENGTH OF SELECTION IS A LINEAR FUNCTION OF THE DOSE,
THEN RESISTANCE MUST ALSO BE A LINEAR FUNCTION OF THE DOSE
In population genetics theory, the strength of selection on a novel trait encoded by
some allelic variant is quantified by the selection coefficient. This coefficient, frequently
denoted s, is usually assumed to be constant for a given trait.20,21,23 One standard
version of this theory proposes that ‘sweeps to fixation’ of a novel trait encoded by an
advantageous allele occur in a manner that can be represented as a logistic function
of the time.
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FIGURE 2.5. A) Variation in strength of selection on resistance as a function of the dose of an antimicrobial: it has been
postulated to have a linear form.26,27 Thus one might anticipate a form whereby s(A) = σ · A for some coefficient σ.
B) The rate of the sweep to fixation of an advantageous trait of interest, assuming a constant selection coefficient s, see
REFERENCE 23. This is a logistic curve whose steepness, and therefore the rate of fixation, is positively correlated with
the value of s. From A) this rate of fixation is therefore also positively correlated with the value of A, if dose is indeed
positively correlated with the selection coefficient.
If an allele provides resistance to an antibiotic drug, the strength of selective pressure
exerted by the antibiotic has been frequently discussed in the literature, which recently
has stated that it ought to be proportional to the drug dose applied, as depicted in FIG.
2.5, see REFERENCES 26 and 27.
If this rationale holds in practise, we should observe an increase of the frequency
of resistance due to this allele, as a function of the dose of antibiotic supplied to the
environment and as a function of time. However, much classical population genetics
theory does not account for a dynamically changing population density; we address this
below. However, antibiotics, by definition, have strong density-dependent suppression
effects on growth and therefore control mutation supply because high doses will lead to
small population sizes and therefore a reduced number of novel alleles with potential
to provide resistance de novo. Our first approach to addressing these issues was
theoretical. Next, with the results of that study, we went on to validate the resulting
model experimentally.
So, the following model is a frequency- and density-dependent mathematical genetics
model of the evolutionary dynamics of the operon acr at different antibiotic doses. We
considered a situation whereby a monoclonal population of a bacterium, at density
B, is exposed to an antibiotic, A, for a period of time t . To grow, B consumes a
carbon source, S, supplied to the environment. To make our model compatible with
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experimental methodologies such as batch transfers, we further assume that B is
transferred to an environment with replenished S and A at time intervals indexed by
the letter i , usually at 12h or 24h duration, satisfying the expression
Bi (tstart; Sstart, Astart) = η · Bi−1(tstart; Sstart, Astart).
Here B(t , S, A) = (b1(t , S, A), ... , bn(t , S, A)) denotes a time-series vector containing
the density of n different genotypes that sum together to form B at time t , given S
and A; 0 < η  1 denotes the fraction of B transferred (typically η0.01), and i > 1
denotes the number of transfers, aka seasons or treatments. We will describe below
how these different genotypes are defined. This is a relationship implemented as part
of common evolutionary protocols that permit the propagation of a bacterial population
indefinitely through time so that multiple antibiotic treatments can be administered.
These are called ‘batch transfer protocols’ in which a small amount of biomass is
transferred from one experimental vessel to another on a seasonal basis, each season
typically lasting 24h, and indexed by i as mentioned above. Below we will write down
explicit differential equations so that we can predict the behaviour of B as a function of
t , S, A and i with the following rationale. Each cell contains a transporter that is able
to take S from the environment and process it to grow. Assuming that each molecule
of S is transformed into biomass (yield, c = 1), the growth rate function is defined
to have the Michaelis-Menten form G(S0) = c
VS0
(Km+S0)
. Here V and Km denote the
maximal uptake and half-saturation constants, respectively. The antibiotic, at initial
concentration A0, diffuses into the cells at a rate controlled by ϕ and binds to the
transporter, with affinity κ, reducing the growth of the cells. This type of inhibition (γ)
can be modelled as γ(A) = 11+κA
70 and the growth function is therefore redefined as
G(S, A) := c VS0(Km+S0) · γ(A).
The reduction in growth thus becomes a function of the antibiotic concentration
within each cell genotype and will be written ABj . Suppose the bacterium B may be
resistant to the antibiotic A by means of an efflux pump,51,71 whereby ABj is removed
from the cytoplasm of the bacterium at the maximal rate v . Different cell genotypes are
defined by the number of copies of this gene, j > 1, whereas the expression levels of
this system will be denoted 1 > p > 0. The abundance of this pump protein therefore
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depends on number of genes encoding efflux pumps (j) and on the expression of these
genes (p). The number of copies may change due to duplication mutations that we
modelled as a Poisson process at a certain rate δ per cell per hour, whereas the rate
of losing a copy of the gene is δ(1 +∆) > δ.
We then impose the conditions p1 = 0, and p2 > 0. This means that cells with one
gene copy must first express it before ABj can be pumped from the cell, thereafter
that gene may be duplicated. Finally, we assume a functional form for pj that is
monotonically increasing and bounded in j , controlled by a dimensionless constant g
in the Michaelis-Menten function pj = (j − 1)/(1 + g(j − 1). Thus, the cell phenotype
for which j = 1 has the gene for efflux pump, but does not express it. We based this on
the limited abundance of the DNA polymerase transcription complex,72 consequently it
has to ‘compete’ for each gene copy providing a limit on the number of efflux genes
that can be simultaneously expressed. If the genotypes within the vector B, namely
bj , represent the densities of bacteria that carry j copies of the efflux pump, a greater
value of j implies a greater resistance. The genetics of the mechanism by which this
occurs is represented by the following set of ordinary differential equations (ODEs):
d
dt
b1 = G(S, A1) · b1 − δ · (b1 − (1 +∆) · b2), (2.1a)
d
dt
bj = G(S, Aj ) · bj − δ · ((1 +∆) · bj − bj−1 − (1 +∆) · bj+1), (2.1b)
d
dt
bn = G(S, An) · bn − δ · ((1 +∆) · bn − bn−1), (2.1c)
d
dt
S = − V · S0
Km + S0
·
n∑
j=1
bj , (2.1d)
d
dt
A0 = −d · A0 −
n∑
j=1
bj ·
(
ϕ · (A0 − Aj ) − v · pjkm + pj · Aj
)
, (2.1e)
d
dt
Aj = −d · Aj + bj ·
(
ϕ · (A0 − Aj ) − v · pjkm + pj · Aj
)
. (2.1f)
We represented three different phenotypes (n = 3) containing a single but unex-
pressed efflux pump gene, a single and expressed efflux pump gene, and two copies
of the efflux pump gene that are fully expressed. At the end of the 24h hours season, a
sample of the current population is transferred to fresh medium where the next season
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of growth occurs. We set this sample to be 1% of the bacterial population at the end of
the season and repeated the protocol for a 7-season period in the model.
We solved this model numerically in Matlab using the function ode15s, which uses nu-
merical differentiation formulas (NDFs).73 The first prediction of the model is illustrated
in FIG. 2.6. At the earliest times during the protocol, the density of the drug-susceptible
population is seen to be decreasing monotonically, as a function of the increasing dose
of antibiotic A0. But the population density rapidly evolves to have a non-monotone
profile. Also, the IC90 (the drug concentration inhibiting 90% of growth, defined at 24h
for each day) clearly increases as a function of time as expected from adaptation to
the presence of the antibiotic. This adaptation, according to the nature of the model, is
an increase in frequency of cells that carry two or more copies of the efflux operon in
their chromosome.
EQUATION 2.1 makes a second prediction that is illustrated in FIG. 2.7. In the
case of a knockout strain, for example, meaning that the efflux pump cannot be
expressed by the cells, the population density decays monotonically at all times as
the concentration of antibiotic increases and there is no evidence of an increased IC90
through time. These are predictions that we can validate against experimental data,
given an appropriate protocol, as we now show below.
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FIGURE 2.6. A prediction from the theoretical model defined in EQUATION 2.1. The concentration of antibiotic is rep-
resented on a logarithmic scale on the x-axis, whereas the growth in terms of OD600 is represented as a linear scale
on the y -axis. This model predicts that the initial antimicrobial dose-response profile is monotone in accordance with
standard tests that are used to quantify sensitivity to antibiotics in the lab. In time, following adaptation, cells with a
higher number of pumps grow better at higher concentrations of antibiotic and they are selected through time, thus pro-
ducing a non-monotone dose-response profile, eventually. The parameters are as follows:74 V = 1139.6µg/OD600/h,
Km = 0.53882µg/mL, κ = 0.2mL/µg, v = 3987.3µg/OD600/h, km = 19.681(dimensionless), g = 0.5(dimensionless),
d = 0/day , ϕ = 93.068mL/OD600/h, δ = 0.0025/gene, ∆ = 18(dimensionless), and c = 0.000315OD600/µg with
initial conditions BIC = {0.01, 0, 0}. The dashed line highlights the culture density in the absence of drug.
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FIGURE 2.7. A second prediction from the theoretical model defined in EQUATION 2.1 when the ability of products of the
acr operon to pump antibiotic has been removed from the model. The concentration of antibiotic is represented using a
logarithmic scale on the x-axis, whereas growth in terms of OD600 is represented using a linear scale on the y -axis. The
black line shows the total population density. Due to the inability of the cells to increase their ability to efflux the drug,
and with the initial population lacking efflux pumps, the dose-response profile remains monotone at all times. In such
a case, the IC90 shows little variation through time. Parameters as in FIG. 2.6 with only one modification: δ = 0/gene.
The dashed line highlights the culture density in the absence of drug.
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2.5 VALIDATING OUR THEORETICAL HYPOTHESIS IN THE LABORATORY: THE TRANSITION
FROM MONOTONE TO NON-MONOTONE DOSE-RESPONSE PROFILE IN Escherichia coli
To validate our hypothesis we used a standard experimental setup that is often em-
ployed in evolutionary microbiology studies.69 For each of the bacterial strains shown
in TABLE S.5 we created a 96-well microplate with minimal media containing 0.2% (w/v)
of glucose, 0.1% (w/v) of casamino acids and eleven concentrations of erythromycin
(both 0-2 and 0-50µg/mL, depending on the strain). Next, we inoculated this microplate
with an overnight culture (>16h) of the corresponding strain and transferred the culture
to another microplate with an identical setup at 24h intervals for seven days. Between
each transfer, we monitored the growth of the cultures by measuring the optical density
at 600nm (producing a density we denote OD600, or just OD) every 20min. The results
of this experiment are shown in FIGS. 2.8 to 2.14. For every strain we compared
the dose-response data to a monotone control profile, which was derived from the
Hill function,75 using a data-fitting routine coded using Matlab. The following is the
mathematical definition of a Hill function used to model the dose-response data:
ODmodel(C) = OD0 · *,1 − Imax ·C
h
ICh50 +C
h
+- . (2.2)
Here ODmodel(C) is the growth observed as a function of the erythromycin concentra-
tion (C), OD0 the growth observed in the absence of erythromycin, Imax the maximum
inhibition observed, IC50 the concentration of erythromycin achieving 50% of Imax and
h the Hill coefficient which controls the ‘sigmoidicity’ of this dataset. This coefficient
is non-dimensional and non-negative. Using Matlab to generate the aforementioned
monotone control profile, we used our datasets to determine the best fit to the Hill
model using a nonlinear regression method and we then quantified the difference
between the data and the control profile by determining the area under the curve
between the difference of the two (AUCd (E )). This procedure allowed us to measure
the ‘non-monotonicity’ of the dose-response data.
When we did this for the wild-type strain AG100 (see FIG. 2.8), bacterial growth
as a function of the concentration of erythromycin has a monotonically decaying
profile during the first 48h. After this time, there was a transition of that dose-response
beyond which formed a non-monotone dose-response profile as a function of the
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FIGURE 2.8. Experimental data on the growth of E. coli AG100 shown on the y-axis as the mean of OD600 ± standard
error (n = 8, black), as a function of the concentration of erythromycin (Ery) on the x-axis. Data is plotted at the moment
of inoculation (t = 0h) each season (one day per season) and every 6h thereafter. The vertical dashed line represents
the IC99 measured after 24h of growth. This IC99 is often said to be the lower boundary of the mutant selection window
(MSW), here represented in grey. In blue we represent the best Hill fit to data. This clearly shows a transition from
monotone to non-monotone behaviour of the density data through time as the quality of the blue line datafit deteriorates
through time.
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concentration of erythromycin. This observation is compatible with the mathematical
model defined in EQUATION 2.1. The observed deviation from monotonicity computed
in this measure shows that AUCd (E ) for AG100 crosses the zero point twice, leading
to the development of a spike at t = 84h where this deviation is maximised (FIG.
2.10, p < 0.001; one-way ANOVA). The development through time of a non-monotone
dose-response profile, including an increase in the IC99, is also compatible with the
theoretical model defined in EQUATION 2.1.
To validate our second prediction, we repeated the above experiment using the efflux
knockout strain AG100-A, which produces nonfunctional of the proteins AcrA and AcrB.
Therefore it has a nonfunctional AcrAB-TolC efflux pump system. With this strain, the
growth measured by OD decayed monotonically at all measured times as a function
of the concentration of erythromycin (FIG. 2.9). For the strain AG100-A, the deviation
from the monotone control profile was considerably reduced (FIG. 2.10), and AUCd
reflected no defined shape (p ≈ 0.46; one-way ANOVA testing for differences between
treatments).
The data for these two strains, AG100 and AG100-A, is compatible with the pre-
dictions from our theoretical model and it shows the fundamental role played by the
AcrAB-TolC efflux pump system in driving this phenomenon (the transition from mono-
tone to non-monotone dose-response profile because of differential selection for the
efflux pump). Our model assumes that the efflux pump is scalable through genomic
amplification mutations whereby the number of copies of a gene or operon increases in
the chromosome. Thus, we decided to monitor the relative abundance of AcrAB-TolC
using the strains TB108 and eTB108, where AcrB has sfGFP as a fluorescent tag.
Here, we assumed that an increment in the number of copies of the genes involved in
this efflux pump is translated into a concomitant increment in the number of AcrAB-TolC
efflux pumps (i.e. a genomic duplication event would result in an increase of the number
of proteins conforming the AcrAB-TolC efflux pump system, therefore duplicating the
fluorescence detected). However, the strains we used only allowed us to measure
AcrB levels, they did not allow us to make any inferences regarding the structure of the
chromosome during adaptation to the presence of the drug.
We repeated the previous protocol using the strain TB108, the results were not
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FIGURE 2.9. Experimental data on the growth of E. coli AG100-A shown on the y-axis as the mean of OD600 ± standard
error (n = 8, black), as a function of the concentration of erythromycin (Ery) on the x-axis. Data is plotted at the moment
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containing the highest concentration of erythromycin in 1 out of 8 replicates after day 5).
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FIGURE 2.10. The difference between optical density data for the strain AG100 (left), AG100-A (right) and the best-
fit monotone (Hill) profile (fitted with respect to OD600) on the y-axis is plotted as a function of the concentration of
erythromycin on the x-axis (shown as ‘E’ in the subplots on the right). The area under the curve of the difference
between data and optimal datafit (AUCd ) is used to monitor the deviation from monotonicity as a function of time and
the concentration of erythromycin (central plot). This shows maximal deviation is achieved at an intermediate time point.
conclusive. On the one hand, growth decays monotonically at all measured times as a
function of the concentration of erythromycin, similar to our previous observation for
the strain with nonfunctional efflux pumps AG100-A (FIG. 2.11). This dose-response
profile was observed both for culture density (OD600) and for absolute abundance
of AcrB per cell (represented here as normalised GFP per OD). On the other hand,
the resistance of this strain to erythromycin is ∼25 times higher than that measured
for the strain AG100-A, but it is still more sensitive than the other K-12 wild-type
strain, AG100. Furthermore, there was no significant deviation from the monotone
control profile during the first six days both in OD600 and normalised GFP (FIG. 2.12,
p > 0.5; one-way ANOVA testing for between-dose differences in deviation from the
monotonic profile). Our interpretation was that the fluorescent tag, sfGFP, interfered
with the normal function of AcrB and the whole AcrAB-TolC efflux pump system, thus
diminishing the the strength of selection on the pump and therefore removing the effect
we originally observed with AG100 above.
Nevertheless, at t = 156h a deviation from monotonicity was observed, which was
different from earlier observations both in OD600 and OD-normalised GFP (i.e. the
AcrB per cell proxy, FIG. 2.12). This deviation was produced by the cultures grown
in the presence of 10µg/mL of erythromycin. We tested the sensitivity of this evolved
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FIGURE 2.11. Experimental data on the growth of E. coli TB108 shown on the y-axis as the mean of OD600 ± standard
error (n = 8, black), as a function of the concentration of erythromycin (Ery) on the x-axis. Data is plotted as OD600 (top)
and as normalised GFP (nGFP, bottom) plotted at the moment of the inoculation (t = 0h) and every 6h thereafter. The
vertical dashed line represents the IC99 measured after 24h of growth. In blue we show the best-fit Hill function.
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FIGURE 2.12. The difference between the optical density data for the strain TB108 and the best-fit monotone (Hill) profile
in OD600 (top) and normalised GFP (nGFP, bottom) on the y-axis as a function of the concentration of erythromycin on
the x-axis (E, subplots in the right). The area under the curve of this difference (AUCd ) is used to monitor the deviation
from monotonicity as a function of time and the concentration of erythromycin (central plot).
culture of TB108 (called ‘eTB108’ hereafter) to erythromycin, the IC99 being identical to
that for AG100 (FIG. 2.3 in p. 12). The new data was interpreted to potentially indicate
a mitigation, by adaptation to erythromycin, of the interference between AcrB and its
fluorescent tag, sfGFP, thus permitting the AcrAB-TolC efflux system to perform as
expected. We had no clear indication as to the mechanism of this ‘repair process’ and
at the time of writing this thesis, these strains have been submitted to a sequencing
centre in Germany in order to assess what the genetic basis of those adaptations might
be. The details of that study are considered outside of the scope of this thesis because,
as we will now show, we are able to exploit this strain to correlate non-monotone
dose-response profiles with hotspots for selection on AcrB, using this new strain.
This evolved strain, eTB108, was used to repeat the protocol and validate our
assumption that the monotone to non-monotone profile transition is mediated by
changes in the relative abundance of the AcrAB-TolC efflux pump system per bacterial
cell. For this strain, in terms of culture density (OD600), the growth measured by OD
decays monotonically as a function of the concentration of erythromycin (FIG. 2.13).
The properties of the dose-response profile do, however, change through time. In some
aspects this resembled the changes observed in the prior K-12 wild-type strain AG100.
For example, at t = 24h we observed a change in the slope of the dose-response
profile that is nearly identical to that noted in AG100 (FIG. 2.13).
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FIGURE 2.13. Experimental data on the growth of E. coli eTB108 shown in the y-axis as the mean of OD600 ± standard
error (n = 8, black), as a function of the concentration of erythromycin (Ery) on the x-axis. Data for OD600 (top) and
normalised GFP (nGFP, bottom) plotted at the moment of the inoculation (t = 0h) and every 6h thereafter. The vertical
dashed line represents the IC99 measured after 24h of growth. In blue we show the best-fit Hill function.
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FIGURE 2.14. The difference between the optical density data for the strain eTB108 and the best-fit monotone (Hill) pro-
file in OD600 (top) and normalised GFP (nGFP, bottom) on the y-axis as a function of the concentration of erythromycin
on the x-axis (E, subplots in the right). The area under the curve of this difference (AUCd ) is used to monitor the deviation
from monotonicity as a function of time and the concentration of erythromycin (central plot).
We compared this to the readings for OD-normalised GFP (the proxy of per-cell
abundance of AcrB, FIG. 2.13). The development and expansion of a plateau in the
dose-response data for culture density shown in this figure, follows the monotone to
non-monotone transition profile in the abundance of AcrB, and therefore of AcrAB-
TolC, seen in the same figure. A further observation of this figure, highlighted how
the data crosses the monotone control profile twice, confirming the presence of a
spike, or candidate selection hotspot. This is where the deviation from monotonicity is
maximised (FIG. 2.14, p < 0.001; one-way ANOVA). Therefore, as predicted by our
model, a change in abundance of the AcrAB-TolC efflux pump system may be the
cause behind the phenomenon hereby described, namely a transition from a monotone
to a non-monotone dose-response profile. The effect is clearer in the data related to
AG100 than it is for eTB108.
2.6 NON-MONOTONE DOSE-RESPONSE PROFILES: INCREMENTS IN BACTERIAL GROWTH
FROM INCREMENTS IN THE CONCENTRATION OF ANTIBIOTIC
A corollary of the existence of a non-monotone dose-response profile is the idea that
increments in the concentration of an antibiotic can lead to increases in bacterial
growth. This is counter-intuitive and the basis of the ‘paradox’ we described above. The
purpose of this section is to dig a little deeper into the reasons why this might occur
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using the strain eTB108. We were particularly interested in whether or not the increase
in antibiotic dose leads to an increase, or a decrease, in the amount of efflux pump
protein expressed per cell. Intuitively, we hypothesised a positive correlation between
the number of these efflux pumps, and the dose of antibiotic supplied. But, in fact, we
saw that this was untrue in the case of the strains of E. coli we used and the antibiotic
erythromycin. We did verify that, at some specific doses, this hypothesis was true only
after a period of adaptation to the drug.
To perform this analysis, we quantified changes in the dose-response profiles as
a function of the concentration of erythromycin. We compared the data gathered for
every concentration with a ‘zero-slope’ model, using t-tests to estimate whether the
slopes are greater, lower, or equal to zero (FIGS.2.16 to 2.19). This test was performed
for culture densities (OD600), absolute abundances of AcrB (normalised GFP), and
also the relative abundance of AcrB (a proxy for AcrAB-TolC per cell, assuming one
copy of the operon in the chromosome in the absence of antibiotic).
To quantify the relative abundance of AcrB-sfGFP , thus of the AcrAB-TolC efflux
pump system, we divided the absolute abundance of AcrB by culture density (OD600).
This normalises the abundance of AcrB, read as AcrB per cell, when the culture is
grown in media without antibiotic. We used this number as a reference when comparing
the quantity of AcrAB-TolC per cell in different growth conditions.
FIG. 2.15 contains a sub-network of the regulation network of the acr operon.
Previously, we stated that the role of this pump is to detoxify the cell during metabolism
and that AcrAB-TolC would be up-regulated when hazardous byproducts accumulate
in the cell and down-regulated when these stressors are absent. What we observed
when we calculated the relative abundance of AcrB per cell (and shown inFIG. 2.15)
was more subtle than this. For example, in the absence of drug we saw that AcrB
per cell stayed fairly constant through the lag phase period, between 0 and 10h after
inoculation/transfer, but then up-regulated through exponential growth (10-17h after
inoculation/transfer). This is consistent with the previous comment regarding AcrB
regulation, and it remained at a static value through stationary phase. However, when
a small amount of erythromycin was supplied into the growth medium, it delayed the
exponential phase, and we saw a continual climb of AcrB per cell through stationary
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FIGURE 2.15. Top) A partial view of the regulation network of the acr operon (see p. 10 for details). Bottom) The
expression profile of AcrB-sfGFP is shown as a function of time over 24h at different concentrations of erythromycin
for the strain eTB108. A proxy for the relative abundance of AcrB-sfGFP per cell is shown on the y -axis as a function
of time (bottom). Different concentrations of erythromycin are denoted by different colours. We note that the small
oscillations observed are seemingly produced by mechanical components of the microplate reader and not by any
oscillatory dynamic produced by the above network (see FIG. S.13).
phase. This rise in AcrB was much higher than had been the case in the absence of the
drug. This appears to indicate that AcrB expression is, in a general sense, positively
correlated with the presence of this antibiotic. Yet, the same figure showed that further
increases in drug concentration actually lead to decreases in the amount of observed
AcrB per cell, with greater drug leading to lower AcrB at all higher drug doses. As the
network in FIG. 2.15 indicates, there is potential complex regulations of the AcrAB-TolC
efflux pump due to the overlap between the mar, population density sensing, and
resource stress networks to control pump expression levels.
The decay in the up-regulation rate of this efflux pumps can be explained by the
mechanism whereby erythromycin inhibits cell growth (protein synthesis inhibition).76
But why this reduction in up-regulation rate leads to higher relative numbers of pumps
per cell is beyond the scope of this chapter. In CHAPTER 5 we explore the theoretical
framework that proposes, based on thermodynamic constrains to be explained in that
chapter, the existence of a trade-off between the rate of production of a biochemical
pathway (i.e. to produce ATP or AcrB) and the production per molecule of substrate
or yield of that pathway. A demonstration that such trade-off between rate and yield
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FIGURE 2.16. Erythromycin dose-response profiles for evolved E. coli AG100 measured every 24h. The growth mea-
sured as OD600 is shown on the y -axis as a function of the concentration of erythromycin, represented on the x-axis.
For the subplots, the y -axis represent the point-to-point slope changes of the dose-response profiles and significantly
positive (green) or negative (red) slopes are highlighted accordingly (α = 0.01). These numbers indicate whether an
increase or decrease in drug dose increases or decreases the OD values.
exists could provide an insight to, for example, why the addition of a protein synthesis
inhibitor leads to an increase in total AcrB protein produced.
In these strains where sensitivity to erythromycin is reduced due to the increase in
the relative number of multi-drug efflux pump AcrAB-TolC, following several days of
adaptation to the drug, the drug-by-drug changes in AcrB expression described above
can undergo changes as a function of the concentration of erythromycin (FIGS. 2.16,
2.17, 2.18, and 2.19). In particular, FIGURE 2.18 clearly shows the phenomenon to
which we are referring: the initial negative correlation between drug and AcrB becomes
a positive correlation at later times. This, however, is total AcrB expressed in the
populations, not AcrB per cell.
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FIGURE 2.17. Erythromycin dose-response profiles for E. coli eTB108 measured every 24h. The growth measured as
OD600 is represented on the y -axis as a function of the concentration of erythromycin, represented on the x-axis. For the
subplots, the y -axis represent the point-to-point slope changes of the dose-response profiles and significantly positive
(green) or negative (red) slopes are highlighted accordingly (α = 0.01).
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FIGURE 2.18. Erythromycin dose-response profiles for E. coli eTB108 measured every 24h. The absolute abundance
of AcrB measured as normalised GFP (nGFP) is represented on the y -axis as a function of the concentration of ery-
thromycin, represented on the x-axis. For the subplots, the y -axis represent the point-to-point slope changes of the
dose-response profiles and significantly positive (green) or negative (red) slopes are highlighted accordingly (α = 0.01).
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FIGURE 2.19. Erythromycin dose-response profiles for E. coli eTB108 measured every 24h. The relative abundance
of AcrB per cell measured as normalised GFP (nGFP) per OD600 is represented on the y -axis as a function of the
concentration of erythromycin, represented on the x-axis. For the subplots, the y -axis represent the point-to-point slope
changes of the dose-response profiles and significantly positive (green) or negative (red) slopes are highlighted accord-
ingly (α = 0.01).
Nevertheless, in FIG. 2.19 we observed the analogous change in correlation reported
in the previous paragraph. It is clear that adaptation to this antibiotic is changing the
way in which AcrB is regulated, consistent with known literature on adaptation of E. coli
to protein-synthesis antibiotics where mutations in MarR have been observed following
evolutionary experiments of this type.74 Importantly, the same figure shows a clear
increase in the relative abundance of AcrB per cell, shifting from 1 to almost exactly 2
‘copies of acrB per cell’ as a function of the concentration of erythromycin. This shift
in the relative abundance of AcrB is directly related to the ‘expansion’ of the plateau
formerly discussed with respect to the strain eTB108. The value ‘2’ we observed here
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FIGURE 2.20. Erythromycin dose-response profiles for E. coli TB108 measured every 24h. The absolute abundance
of AcrB measured as normalised GFP (nGFP) is represented on the y -axis as a function of the concentration of ery-
thromycin, represented on the x-axis. For the subplots, the y -axis represent the point-to-point slope changes of the
dose-response profiles and significantly positive (green) or negative (red) slopes are highlighted accordingly (α = 0.01).
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FIGURE 2.21. Erythromycin dose-response profiles for E. coli AG100-A measured every 24h. The growth measured as
OD600 is represented on the y -axis as a function of the concentration of erythromycin, shown on the x-axis. For the
subplots, the y -axis represent the point-to-point slope changes of the dose-response profiles and significantly positive
(green) or negative (red) slopes are highlighted accordingly (α = 0.01).
would seem to be closely related to the sweep through the population of a duplication
mutation, but we have not proven this, as yet. If we implement the same experiments
using the strain TB108, for which we do not observe the monotone to non-monotone
dose-response transition, the values of these same slopes are negative at all times
(see FIGS. 2.20, 2.21, and 2.22). This would indicate no measurable change in the
regulation of the pump following a period of adaptation using this strain. It also indicates
that increases in drug dose do correlate with a decrease in AcrB expression for this
strain at all times in these experiments.
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FIGURE 2.22. Erythromycin dose-response profiles for E. coli TB108 measured every 24h. The growth measured as
OD600 is represented in the y -axis as a function of the concentration of erythromycin, represented in the x-axis. For the
subplots, the y -axis represent the point-to-point slope changes of the dose-response profiles and significantly positive
(green) or negative (red) slopes are highlighted accordingly (α = 0.01).
2.7 ANALYSING PHENOTYPIC RATES OF ADAPTATION: THE MONOTONE TO NON-MONOTONE
TRANSITION PROFILES REVEAL ADAPTATION ‘HOTSPOTS’ AND ‘COLDSPOTS’
In the previous section we sought correlations between bacterial growth, AcrB expres-
sion levels and antibiotic concentration. We observed that these correlations could
change significantly during periods of adaptation to antibiotics. Such changes in expres-
sion profiles of the pump system are the cause of the non-monotone dose-response
profiles observed in those same experiments. Next we used a simple measure of
adaptation, observed above, to demonstrate that the non-monotone profiles are due to
doses that maximise selection on this pump. These we called ‘evolutionary hotspots’.
To quantify the existence, or absence, of evolutionary hotspots we analysed the rate
of adaptation measure (α, as defined in p. 13 and discussed above) calculated as the
ratio between growth at t = 24h and the area under the curve (AUC) of the 24h OD
data time series. An AUC version of growth rate, rAUC , is defined as
rAUC :=
OD(24h)∫ 24h
0 OD(t ) · dt
. (2.3)
This measure of growth rate, applied to a 24h times series denoted OD(t ), has the
appropriate units, namely ‘per hour’. Using rAUC , our analysis of the rate of adaptation
of this particular phenotype for all the different strains used in this chapter revealed the
existence of two ‘windows’ with opposite effects (as shown in FIGS. 2.23, 2.24, 2.25,
and 2.26). We could use different definitions of rAUC , so that if x (t ) is any series of
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phenotype data, then we will also write rAUC :=
x (24h)∫ 24h
0 x (t )·dt
. Although this is not a growth
rate, it is still a rate of change of x (t ).
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FIGURE 2.23. Selection statistics for E. coli AG100 as a function of the concentration of erythromycin: rate of adaptation
per replicate based on rAUC (αAUC , left). Darker greys represent lower rates of adaptation, eight replicates shown,
whereas brighter greys represent higher rates. Mean rate of adaptation as a function of the concentration of erythromycin
(right). The numbers shown correspond to the p-values of an unpaired t-test (α = 0.05). The error bars represent the
standard error of the mean (n = 8), and the grey area represents the mutant selection window (MSW).
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FIGURE 2.24. Selection statistics for E. coli AG100-A as a function of the concentration of erythromycin: rate of adapta-
tion per replicate based on rAUC (αAUC , left). Darker greys represent lower rates of adaptation, eight replicates shown,
whereas brighter greys represent higher rates. Mean rate of adaptation as a function of the concentration of erythromycin
(right). The numbers shown correspond to the p-values of an unpaired t-test (α = 0.05). The error bars represent the
standard error of the mean (n = 8), and the grey area represents the mutant selection window (MSW).
In relative terms, the first window is located at very low concentrations of ery-
thromycin, where the rate of adaptation to the low-drug environment is lower than in
the antibiotic-free control. We considered this to be an evolutionary coldspot ; the rate
of adaptation may be increased either by adding or removing erythromycin from this
coldspot. The second window sits between the evolutionary coldspot and the IC99. In
contrast to the coldspot, the rate of adaptation in this window is higher than in the
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FIGURE 2.25. Selection statistics for E. coli TB108 as a function of the concentration of erythromycin: A,C,E) rate of
adaptation per replicate based on rAUC (αAUC ). Data for A) OD600, C) absolute abundance of AcrB-sfGFP as normalised
GFP (nGFP), E) relative abundance of AcrB-sfGFP as normalised GFP per OD units. Darker greys represent lower rates
of adaptation, eight replicates shown, whereas brighter greys represent higher rates. B,D,F) Mean rate of adaptation as
a function of the concentration of erythromycin (right column). The numbers shown correspond to the p-values for an
unpaired t-test (α = 0.05). The errorbars represent the standard error of the mean (n = 8), and the grey area represents
the mutant selection window (MSW).
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FIGURE 2.26. Selection statistics for E. coli eTB108 as a function of the concentration of erythromycin: A,C,E) rate of
adaptation per replicate based on rAUC (αAUC ). Data for A) OD600, C) absolute abundance of AcrB-sfGFP as normalised
GFP (nGFP), E) relative abundance of AcrB-sfGFP as normalised GFP per OD units. Darker greys represent lower rates
of adaptation, eight replicates shown, whereas brighter greys represent higher rates. B,D,F) Mean rate of adaptation as
a function of the concentration of erythromycin (right column). The numbers shown correspond to the p-values for an
unpaired t-test (α = 0.05). The errorbars represent the standard error of the mean (n = 8), and the grey area represents
the mutant selection window (MSW)
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antibiotic-free control. We considered this to be an evolutionary hotspot and, from
this point, any change in the concentration of erythromycin leads to a reduced rate
of adaptation, as can be seen in the same figures. The existence of these windows,
hotspots and coldspots, is independent of the growth rate traits that we measured,
whether this be culture density (OD600), absolute abundance of AcrB (normalised
GFP), or relative abundance of AcrB (normalised GFP per OD600).
Importantly, for the latter trait, we measured the sweep to fixation as a function of
time (t), and dose. We observed in FIG. 2.27 (bottom plot) that AcrB-sfGFP increased
among the bacterial cells in a logistic fashion, in which a phase of non-linear increase
is followed by a stable phase (sweep to fixation, see FIG. 2.5 in p. 14). This increase is,
however, preceded by a non-linear decline of AcrB-sfGFP. The rate of sweep to fixation
can be calculated using a logistic model,23 so we included a simple non-linear term to
account for the loss of AcrB-sfGFP. Denoting the relative abundance of AcrB-sfGFP as
U, we fitted the following model to the data:
U (t ) = U0 +
Loss of AcrB︷︸︸︷
Ae−t ι +
Sweep of AcrB︷      ︸︸      ︷
c
1 + Be−tψ
. (2.4)
Here ι denotes the loss rate of AcrAB-TolC per OD600 unit, ψ the rate of sweep, c the
number of relative copies of acr per cell, U0 the relative abundance of AcrB at t = 0h,
and A and B are phenomenological coefficients. In FIG. 2.27 we see that such a rate of
sweep is maximised not only at the particular dose of 30µg/mL of erythromycin, within
the evolutionary hotspot, but also within the particular times of 48 and 96h (2-4 days).
Other notable features of the same dataset are: i) at a dose of 5µg/mL of ery-
thromycin, the levels of AcrB expression achieved a degree of stasis which may
indicate a stable mutation-selection balance whereby AcrB duplications reside at ap-
proximately 50% frequency in the population. The same can be said for slightly higher
doses with slightly higher percentages of the acr duplication. Finally, ii) we noted that
high erythromycin doses lead to a stable down-regulation of the AcrB protein that is
not overcome by adaptation. This is likely due to the low supply of mutants at these
doses, which are the result of the small populate sizes.
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FIGURE 2.27. Estimation of the number of AcrB proteins per cell for populations the strains E. coli TB108 (top) and
eTB108 (bottom) as time changes. The two main plots in the left-hand column represent the relative normalised GFP
per OD600 in each population (y -axis, shown are means ± standard error, n = 8) as a function of time (x-axis) and
the different concentrations of erythromycin have different colours. The subplots in the right-hand columns show sweep
rates per replicate as a function of erythromycin (Ery) whereby lighter squares have higher values (8 replicates shown).
The rate of sweep (ψ) is measured using AUC as implemented in EQUATION 2.4 (bottom), and the maximum rate of
change in the time-series dataset for nGFP ·OD−1600 (y ) for robustness as max0h≤t≤168h
dy
dt (top).
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2.8 GENOMIC DATA CONFIRMS DUPLICATION OF THE ACRAB-TOLC MULTI-DRUG EFFLUX
PUMP LOCI
Our hypothesis of genomic duplication events was previously based on the mathemati-
cal model in EQUATION 2.1. The changes on the relative abundance of AcrB-sfGFP
were based on the engineered, later evolved, strain E. coli eTB108 (FIG. 2.27). Dr
Gunther Jansen, from the University of Kiel in Germany, performed the preliminary
whole genome sequencing (WGS) using a pipeline designed elsewhere.74 The data
proved that the increase through time in the relative abundance of this pump was due
to the duplication of the number of copies of the acr operon (FIG. 2.28A).
Using the routine described in EQUATION S.1, we observed the rate of sweep not
as a linear but rather as a non-linear function of the dose. FIG. 2.28B shows that
the non-linear sweep rate is maximised at certain concentrations of erythromycin.
Concentrations above or below these result in, overall, lower sweep rates.
A)
0 1 2 3 4 51
1.2
1.4
1.6
1.8
2
Time (Days)
R
el
at
iv
e 
co
pi
es
 o
f  
a
cr
 
o
pe
ro
n
 
 
No Drug
10µg/mL
15µg/mL
20µg/mL
25µg/mL
30µg/mL
40µg/mL
0 10 20 30 400.15
0.2
0.25
0.3
0.35
0.4
Erythromycin (µg/mL)
Sw
ee
p 
ra
te
 (C
op
ies
 ⋅ D
ay
−
1 )
B)
FIGURE 2.28. A) Genomic data for E. coli AG100. Coverage of the acr operon, relative to the genome background, as
a function of the concentration of erythromycin and time (x-axis, mean ± s.e.m, n = 3). B) Rate of sweep as the increase
in acr copies per day as a function of the concentration of erythromycin on the y -axis, of the acr operon based on the
genomic data.
Using our proxy system, based on relative abundance of AcrB-sfGFP, we found the
same optimal concentrations (FIG. 2.29A). This proxy also provided information that
is not captured by the WGS data: the regulation of the AcrAB-TolC efflux pump due
to the addition of erythromycin. In our experimental set up this pump is immediately
down-regulated with the addition of the antibiotic and, only after a period of adaptation,
the efflux pump is up-regulated. We are currently developing a similar pipeline to further
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FIGURE 2.29. A) Estimation of the number of AcrB proteins per cell for populations the strains E. coli as time changes.
The main plot in the left-hand column represents the relative normalised GFP per OD600 (y -axis, shown are means
± standard error, n = 8) as a function of time (x-axis) and the different concentrations of erythromycin have different
colours. The subplots in the right-hand columns show sweep rates per replicate as a function of erythromycin (Ery)
whereby lighter squares have higher values (8 replicates shown). The rate of sweep (ψ) is measured using both AUC
(bottom), and finite difference approximations (top) for robustness. B) Rate of sweep, measured as the increase in acr
copies per day as a function of the concentration of erythromycin on the y -axis, of the acr operon based on the genomic
data.
analyse the WGS data, and reveal whether or not there are change in the regulation of
the efflux pump and if these precede the duplication event.
2.9 CONCLUSIONS
In SECTION 1.1 we introduced the principle on which antibiotic sensitivity tests stand
on, whereby higher dosages of the drug always lead to fewer bacterial cells. We demon-
strated that this relationship may change and the monotone decrease of bacterial cell
density, as a function of antibiotic dose, may become non-monotone. Consequently,
we quantified a range or window of antibiotic concentrations in which, though time,
the antibiotic has little effect on bacterial growth density. In our case, this transition
is led by the duplication of the acr operon and subsequently selection on cells with
extra copies (mutation window). Moreover, we also developed a theoretical framework
that is able to predict, qualitatively, the evolution of resistance to antibiotics when
the underlying mechanism of resistance is based on duplications of efflux pumps.
Our resulting mutation window therefore refutes the arbitrarily set boundaries of the
so-called mutant selection window introduced in SECTION 1.2.
Also, our whole genome sequence (WGS) datasets show the relationship between
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acr operon copy number. These datasets show a monotone increase in the number of
acr operons, provided the appropriate dose. This conflicts with the dataset obtained
through the quantification of the fluorescent protein AcrB-sfGFP, in which a decrease
in AcrB-sfGFP production precedes a monotone increase of AcrB-sfGFP. The later
dataset is not only result of the number of copies of the acr operon, but it also
summarises the expression and translation processes required for protein synthesis.
Thus, the pipeline that we are currently developing will highlight mutations that may
have occurred, presumably in the acr regulation network, to explain the difference
between WGS and AcrB-sfGFP datasets.
III A N T I M I C R O B I A L S E N S I T I V I T Y I N T H E
P R E S E N C E O F C O M P E T I T O R S
SENSITIVITY TO ANTIBIOTICS is quantified by exposing an isolated bacterial strainto increasing concentrations of antibiotic. The use of mixed isolates in these
tests is considered to lead to unreliable results and to be a poor indicator of clinical
practice.31 Whilst this seems logical from a quantification perspective, in practice
pathogenic microbes are not found in isolation. Instead, they form part of ecological
communities with intricate ecological relationships between a variety of microbial
species that make up both the infection and the host’s microflora.
We argue that during an infection, the integration of the pathogen within the host’s
microbial communities could quite easily affect the applicability of antibiotic sensitivity
data. So, in this chapter we will demonstrate, both theoretically and empirically, that
antibiotic sensitivity tests (ASTs) can both underestimate and overestimate the potency
of antibiotics in polymicrobial contexts. We observed that which of these two outcomes
occurs in practise depends crucially on the sensitivity of the second microbial isolate
used in co-culture as a competitor for resources with the first.
So, when the competitor is not sensitive to the antibiotic used, due to either the
presence of a resistance mechanism or an inherent lack of sensitivity (e.g. the use of
antibacterials with fungal co-cultures), we observe that the bacteria targeted had an
increased sensitivity to the antibiotic. We believe this phenomenon can be explained
by competitive suppression.77 This is a process whereby the growth rate of one
microorganism is reduced by another acting as a ‘resource thief’ and, at least from a
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growth-reduction perspective, this theft is a process that synergyses with the action of
the antibiotic. However, when the aforementioned competitor species is as sensitive to
the antibiotic as the bacteria targeted, we found that the latter was less sensitive to the
drug. In this case each competitor is exposed, in relative terms, to lower concentrations
of the antimicrobial and thus the competition process antagonised with the antibiotic.
We also observed that when the competition for resources is extended for several
seasons, where each season represents one treatment of 24h duration, the synergistic
effect of the competition can be further increased leading to even higher sensitivities to
the antibiotic. This effect can be maintained if the competition lasts even longer still, in
which case no significant change of sensitivity was observed.
We note that within this chapter, interestingly, none of the evolutionary drug-adaptation
tests performed in the presence of competitors for resources created conditions that
could lead to a monotone to non-monotone profile transition.
3.1 PROBLEM: ANTIBIOTIC SENSITIVITY IS QUANTIFIED ON ISOLATED STRAINS, BUT
ANTIBIOTICS ARE USED AGAINST MICROBIAL COMMUNITIES
In nature, microorganisms, such as bacteria, proliferate in conditions surrounded by
cells with the same and different genotypes. Like-genotypes naturally cluster due to
the dynamics of two daughter cells emerging from a single mother cell. In any case,
all these genotypes reside in permanent competition for resources such as amino
acids, oxygen, carbon, salts and water.78–81 In the clinic, however, antibiotic sensitivity
tests are performed on specific clonal isolates. This procedure is sustained by the idea
that therapies eradicate these isolates without significant disturbance of the patient’s
microflora.31 Whilst this idea is now known to be incorrect,82,83 antibiotic susceptibility
tests remained highly standardised and do not reflect the change in the understanding
of how antibiotics mediate between-species competition.
3.2 HYPOTHESIS: ECOLOGICAL CONTEXT CAN ALTER DOSE RESPONSE PROFILE
Motivated by whether or not the ecological context of a given microbial isolated can
interfere with its sensitivity to antimicrobial drugs, we performed sensitivity tests both in
the absence (monoculture) and in the presence (co-culture) of a competitor species. To
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FIGURE 3.1. Dose-response profiles for C. albicans showing the change in growth rate as a function of the concentration
of fluconazole in the absence (dark grey, n = 2), and in the presence (light grey, n = 3) of the fluconazole-resistant
competitor C. glabrata. Growth rate in the absence of fluconazole is plotted on the y-axis. The vertical dotted lines
represent the concentration at which 90% of the growth measured in the absence of fluconazole condition is inhibited,
coloured accordingly (IC90 = 1.821 and 1.811 µg/mL in monoculture, IC90 = 1.563, 1.823, and 0.978 µg/mL in coculture).
Data provided by Emily Cook, University of Exeter.
better understand this phenomenon, we also competed the human pathogenic Candida
albicans with a fungal competitor, and strains of E. coli with a bacterial competitor
(see FIGS. 3.1 and 3.2, strain details in TABLE 3.1). The sensitivity to the antimicrobial
drug was measured as the concentration of drug able to inhibit 90% of the growth
observed in the absence of drug (IC90 hereafter). Next we compared monoculture dose
responses with co-culture dose-responses to assess changes in drug sensitivity due
to the presence of a competitor species.
FIG. 3.1 illustrates the sensitivity of Candida albicans to the antifungal fluconazole,
measured in the presence and in the absence of a competitor species. When this fungi
was grown in the presence of Candida glabrata as competitor species, the resulting
IC90 for C. albicans was lower than that measured in a monoculture. Note that in this
case C. glabrata is naturally resistant to fluconazole. We will demonstrate that this is
also the outcome when both competitors are bacteria later on in this chapter.
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TABLE 3.1. Strains used for the validation of the competition model
Strain Genotype Reference
Escherichia coli Wyl MC4100 galK::YFP, ampR , pCS-λ 84
Escherichia coli GB(c) MC4100 galK::CFP, ampR , pGW155B 85
Candida glabrata – ATCC 2001
Candida albicans SBC153 ura3∆::imm434/ura3∆::imm434
RPS1/rps1∆::CIp10 ACT1/ACT1p-GFP-
NAT1
86
FIG. 3.2 displays the outcome of two competing bacterial species, each being
sensitive to the antibiotic tetracycline to a similar degree. The competitors are the
cyan fluorescence-tagged strain of Escherichia coli Wcl, and the human pathogen
Salmonella typhimurium. As opposed to the previous figure, in which competitors had
different sensitivities to the antimicrobial drug, the IC90 for the strain of Escherichia coli
Wcl was higher in the presence of the competitor but that for S. typhimurium did not
significantly change.
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FIGURE 3.2. Dose-response profiles for E. coli Wcl showing the change in growth rate as a function of the concentration
of tetracycline in the absence (dark grey), and in the presence (light grey) of the competitor S. typhimurium, where the
latter is sensitive to this antibiotic. Growth rate in the absence of tetracycline is plotted on the y-axis. The vertical dotted
lines represent the concentration at which 90% of the growth measured in the absence of tetracycline is inhibited,
coloured accordingly: IC90 = 0.245 ± 0.004 µg/mL in monoculture (mean ± 1.96 standard error), IC90 = 0.326 ± 0.024
µg/mL in coculture. We analysed the difference between both IC90 using a Wilcoxon rank sum test with ranksum = 100,
and p = 1.55 · 10−4.
These datasets suggest that ecological relationships with other microorganisms can
modulate the sensitivity of a given microbial cell to an antimicrobial drug. They also
suggest that such relationships can be complex, as demonstrated by the asymmetric
modulation between the bacterial species E. coli Wcl and S. typhimurium in which only
one of the species was affected by the competition. The cause of such asymmetry is
beyond the scope of this PhD project, therefore we sought to simplify the protocol by
instead using two strains of the same bacterial species in order to better understand
how direct competition for a common resource can mediate drug resistance.
This common genetic background would provide identical metabolic profiles of each
competitor and the sensitivity to antibiotics of one of the competitors can be controlled
with the introduction of specific resistance genes on a plasmid. This artificially creates
a competition that is analogue to the datasets represented above and is a simple
proxy for the kind of microbial community that motivated this study. A theoretical
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FIGURE 3.3. Model of the minimal selective concentration (MSC).19 Fitness, typically measured as growth rate after
24h of growth, is represented in the y-axis as a function of the concentration of antibiotic, represented in the x-axis. This
model assumes the existence of a ‘cost of resistance’,87 whereby mutations conferring resistance to antibiotics are
also associated with lower fitness. Thus, in the absence of antibiotics, the drug-sensitive competitor (hereafter denoted
by ‘s’) has a higher growth rate after, say, 24h of growth, than the resistant type (denoted by ‘r’). However, the s-type
has a higher sensitivity to the antibiotic and therefore MICs < MICr . As a consequence, the addition of antibiotic to a
mixed culture of s and r forces a ‘crossing point’ between these two dose-response profiles. This crossing point defines
the MSC, a concentration at which both competitors have the same fitness and whereafter selection on the resistant
competitor begins. Note that MICs and MICr are measured in monoculture only. We conducted competition experiments
at concentrations at which only the sensitive type is predicted to have changes in fitness (pink).
framework developed elsewhere19 (FIG. 3.3) is relevant to the analysis of our proxy for
a multi-species, drug-treated community.
We used the above framework to mimic selection on antibiotic resistance in mixed
bacterial populations composed of species with different sensitivity to antibiotics. It has
been proposed that mutations, or plasmids, that provide resistance to antibiotics are
often associated with low relative growth rates in the absence of the antibiotic.87 Thus
the difference in sensitivities assumed by this framework results in different growth
rates,19 as part of an effect known as resistance mutations having fitness ‘costs of
resistance’.
FIG. 3.3 illustrates the case of a competition between two bacterial strains, each
with different sensitivities to an antibiotic and the existence of costs of resistance. If
antibiotic sensitivity is measured for each strain separately (in monoculture) using the
minimum inhibitory concentration or MIC, then MICS < MICR must be satisfied (S and
R denote the sensitive and resistant strains, respectively). Moreover, the growth rate
after 24h of growth in monoculture (r ) must satisfy that rS > rR due to the existence of
costs of resistance. With these conditions, the resulting dose-response profiles cross
each other when they are overlapped. The crossing point highlights the existence of a
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concentration at which both strains have the same growth rate or fitness. Known as
the minimum selective concentration or MSC, this concentration sets the drug dosing
boundary at which selection on the resistant strains begins (FIG. 3.3). This allowed us
to frame basic predictions of the drug dosages which select for or against the most
resistant strain: below the MSC dose it is the drug-susceptible strain that has the higher
growth rate, whereas above the MSC it is the drug-resistant.
However, this statement is based on fitness (growth rate) determined in monoculture.
In terms of changes in sensitivity to the antibiotic that are observed in the presence
and in the absence of competition, this framework makes no predictions. We therefore
sought to also refine the notion of the MSC using our two-strain microbial community
and asked whether the monoculture dose-response data is relevant to predict the
MSC.
Our first approach to these questions was theoretical and we present a mathematical
model, shown below, that implements the costs of resistance discussed above with the
following rationale. We considered two monoclonal populations of bacteria with different
sensitivities to an antibiotic, where the density of the sensitive population is denoted
as S and R denotes that of the resistant population. The growth of these populations
depends on a source of carbon, C, which these cells take from the environment
using a transporter (FIG. 3.4). Thus, as we explained in the previous chapter, we
defined the growth function for these two populations as Gx (C0) =
VC0
Km+C0
. Note that
the growth parameters V and Km for both populations, generically denoted as x , are
identical. These parameters denote the maximal uptake and half-saturation constants,
respectively. Then an antibiotic A is supplied at the concentration A0. As mentioned in
the previous chapter, A diffuses into the cells at a rate ϕ and binds to the transporter,
with affinity κ, to reduce the growth of the cells. The resulting inhibition function is
γ(A) = 11+κA2 , where 2 is the Hill coefficient.
75 The growth function of the sensitive
population is herefore redefined as Gs (C0, A0) =
VC0
Km+C0
· γ(A0) whereas the growth
of R remains as Gr (C0) =
VC0
Km+C0
for simplicity. The concentration of A found in each
population is noted as As or Ar , depending on whether the population is sensitive or
resistant. However, as proposed by the authors of REFERENCE 19, the resistance of R
will come at a cost that reduces the growth rate or fitness (Γ).
5 0 C H A P T E R I I I
C0
Growth
A0
AS
ϕ
κS
y
C0
Growth
A0
AR
ϕ
κR
y
(sensitive) (resistant)
FIGURE 3.4. Diagram of the mathematical model formalised in EQUATION 3.1. A0 and C denote the concentrations of
antibiotic and carbon, respectively, in the environment. Each cell contains an enzyme (black) able to take C from the
environment and process it to grow (the growth rate function is defined as G(C) = y · VC/(Km + C), y denoting the
yield per molecule of C, V the maximum rate at which C is processed, and Km the enzymatic half-saturation constant).
A0 diffuses into the cells at a rate ϕ, binding to the enzyme and reducing the growth of the cell (a growth inhibition
function is defined to be γ(A) = 1/(1 + κj A2j ), G(C) being redefined as Gj (C, A) = y · VC0/(Km + C0) · 1/(1 + κj A2j )).
Here j denotes the type of bacterium, either sensitive (S) or resistant (R), κR  κS . We assume that antibiotic degrades
through time at a rate d . Finally, the growth function GR (C, A) is modulated by the cost of resistance parameter Γ > 0.
To make this model compatible with experimental methodologies we assumed that a
sample of the entire culture, either mono- or co-culture, is transferred to an environment
with replenished antibiotic and resources. These transfers occur at 24h intervals and
are indexed by the letter i , satisfying the expressions
Si (tstart , Cstart , Astart ) = η · Si−1(tend , Cend , Aend )
, and
Ri (tstart , Cstart , Astart ) = η ·Ri−1(tend , Cend , Aend ).
Here, 0 < η  1 denotes the fraction of S and R transferred (∼ 1% of the culture), and
i > 1 the number of transfers, or seasons. We formalised this model with the following
set of ordinary differential equations (ODEs)
d
dt
S = Gs (C, A0) · S, (3.1a)
d
dt
R = (1 − Γ) ·Gr (C, A0) ·R, (3.1b)
d
dt
C = − V ·C
km +C
· (R + S), (3.1c)
d
dt
As = −d · As + ϕ · (A0 − As) · S, (3.1d)
d
dt
Ar = −d · Ar + ϕ · (A0 − Ar ) ·R, (3.1e)
d
dt
A0 = −d · A0 − ϕ · (A0 · (R + S) − (AsS + Ar R)) , (3.1f)
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We considered the cases where the initial inoculum was formed by i) the strain S
(monoculture), ii) the strain R (monoculture), and iii) a mixture of equal proportions
of both strains (50%S + 50%R) in co-culture, and solved the model numerically in
Matlab using the function ode113, a variable order Adams-Bashforth-Moulton PECE
solver.88 This model makes several predictions. The first prediction was that antibiotic
sensitivity increases depending on whether or not a second microbial population is
present (FIG. 3.5). There is no explicit definition of how the strains interact with each
other in our model, which leaves the use of a common source of carbon as the only
explanation for this prediction. The reduction in growth by ‘carbon theft’ is known as
competitive suppression77 and it also enhanced the potency of the antibiotic according
to our model (FIG. 3.6).
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FIGURE 3.5. Our theory predicts that the S strain is more sensitive to tetracycline in the presence of a competitor than
in its absence. A) The monoculture dose response of the S (plasmid-free) and R (resistant plasmid carrying) strains of
E. coli. This shows that the R strain can be considered completely resistant over the range of dosages applied but the S
strain has an IC50 over 0.14µg/mL of tetracycline. B) Co-culture experiment with the 50-50 inoculum of S and R strains,
where the IC50 of the S strain has now shifted to 0.074µg/mL. Moreover, 0.2µg/mL tetracycline is the IC91 in co-culture
whereas it is the IC63 in monoculture. The numerical values for the parameters are S0 = 0.001 cells, R0 = 0.001 cells,
A0 = 0.2µg/mL, C0 = 100µg/mL, V = 2,400µg/cell/hour, Km = 1µg/mL, γ= 0.75, ϕ = 103ml/cell, κ = 400mL/µg, d = 0.1 /h,
η = 0.01, carbon conversion factor = 0.00075 cells/µg.
The other predictions apply if the competition lasts more than a 24h season. For
example, our model predicted that the competitive suppression previously observed
was intensified and sustained through time (FIG. 3.7). It also predicted the arrangement
of the co-culture in three different ‘niches’ mediated by antibiotic dose. The most
sensitive strain outcompeted its resistant counterpart in the first of these niches, which
was defined at relative low concentrations of antibiotic. The next niche was defined
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sensitivities to the antibiotic tetracycline. The sensitive competitor (S) is inhibited with less tetracycline in the presence
of a resistant competitor (R) due to competitive supression. Equally, the growth of R is promoted due to a similar
phenomenon with opposite effect, namely competitive release, 35 whereby the eradication of a competitor (in this case
by the use of antibiotics) leaves the unaffected competitor with more resources to grow.
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FIGURE 3.7. Theoretical prediction of the existence of a concentration of antibiotic at which, within a mixed culture,
sensitive (s, green) and resistant (r, red) competitors have identical fitness (MSC). The thin and thick lines represent the
predictions after one day and seven days of mixed growth, respectively. The crossing point defines the MSC, which is
here predicted to be different after seven days of competition.
at relative high concentrations of antibiotic and was dominated by the most resistant
strain. In this niche the sensitive strain was outcompeted. Finally, the third niche sat
in between the previous two. In this niche both competitors were co-maintained, as
opposed to the other niches in which only one of the strains survived.
The aforementioned minimal selective concentration (MSC) was located in the
third niche. The arrangement of these niches, however, was not immediate. The
precise boundary concentrations for each of them changed through time until they
eventually reached an equilibrium, in which the concentrations defining the niches no
longer changed. The MSC also changed through time and met an equilibrium, which
depended on the volume of the culture transferred with every season. Thus the MSC
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at equilibrium can be higher or lower than the MSC measured after a 24h season. With
our transfer volume, previously defined as 1% of the culture, the model predicts an
increase through time of the MSC. This latest prediction contradicts the role of the
MSC, measured after 24h of growth, as the parameter defining where selection on
resistance begins. Our model demonstrates that this concentration is dynamic and
sits within a stable interface in which two competing species can be co-maintained.
This interface separates the niche which selects for the most sensitive competitor from
that which selects for the most resistant competitor. Finally, we sought to test these
predictions in the laboratory.
3.3 VALIDATING THE THEORETICAL MODEL EXPERIMENTALLY: WE SHOW ANTIBIOTIC
SENSITIVITY IN COMPETITION IS NOT CONSISTENT WITH ASTS, AND THE IC90 CAN SHIFT
TOWARDS LOWER CONCENTRATIONS
Many bacterial species are able to produce antibiotic-like substances called ‘bacteri-
ocins’ which are used to remove neighbouring competitor species.81 These substances
are highly specific and can lead to cross-resistance with antibiotics.89 Thus, bacteri-
ocins would be a confounding factor that could confound a study of competing microbial
species in the presence of an antibiotic. To avoid such effects we decided to compete
bacteria with a common genetic background. We used two strains derived from E. coli
MC4100 that had different fluorescent markers inserted in the chromosome (TABLE
3.1). This allowed us to track each strain in mixed cultures. Moreover, one of the strains
was modified to contain the plasmid-borne locus tet(36), which confers resistance to
the tetracycline class of antibiotic. We labelled this strain as Tetr , and its sensitive
counterpart as Tets.
Consequently these strains are consistent with our theoretical model in which the
only difference between them was the degree of resistance to the antibiotic. Our
experimental protocol also implemented other conditions introduced in our model. We
began the co-culture experiment using a mixed culture which contained equal number
of cells for Tetr and Tets as inoculum. Also, the experiments were conducted for seven
24h seasons and the initial conditions of the following season were set by transferring
1% of the culture. We set up a 96-well microplate with minimal media containing
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0.4% (w/v) of glucose, 0.1% (w/v) of casamino acids and eleven concentrations of
tetracycline ranging from 0 (control) to 0.5 or 15µg/mL, depending on the strain. The
cultures were incubated for 24h and later transferred to microplates with an identical
conditions using a 96-well pin replicator. For experiments involving monocultures or
co-cultures a sample for each strain was grown overnight (>16h), which were later
used as inoculum.
As before with the above theoretical study, we first quantified the sensitivity to
tetracycline of each bacterial strain separately. We naturally named this condition
monoculture and denoted it by the letter m, as opposed to the condition where both
strains were grown together in a mixed culture or co-culture. We noted the latter using
the letter c. Next, the optical density was read at 600nm (OD600 or just OD) for each
strain grown in monoculture as well as the fluorescence (RFU). The fluorescence was
read at 505nm/540nm (excitation/emission wavelengths) for yellow fluorescent protein
and at 430nm/480nm for cyan fluorescent protein. The OD600 readings were used to
normalise the fluorescence signal (RFUn) and correlate fluorescence with the densities
of each bacterial strain in co-culture. We denoted yellow (YFP) and cyan (CFP) reads
in the plate-reading device as y and c, respectively, and calibrated the values y0 and c0
so that 1 ×OD600 = y0 · YFPmax and 1 ×OD600 = c0 ·CFPmax . These values provided
the number of OD600 units per yellow and cyan fluorescence unit. We read the data
triple (yr , cr , ODr ) from the plate reader and defined the expected values of optical
density (ODe) for each strain as yod = yr · y0 and cod = cr · c0 so that yod + cod = ODr
was satisfied. We also estimated the fraction of each strain in the mixed culture as
fy =
yod
yod + cod
and fc =
cod
yod + cod
.
Finally we calculated the growth rate of each strain, r , using the following finite
difference (forward Euler) approximation. We represented the change through time of
RFUn as F (t ) and defined its derivative as
F ′(t ) =
Ft+∆t − Ft
∆t
where
r = max
0≤t≤24h
F ′(t ).
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Here ∆t is the read frequency in hours and r is expressed as maximum increase in
RFUn per hour. To test whether or not the MSC is sensitive to the way the growth
rate is calculated, we also estimated the per capita growth rate using the routine in
EQUATION S.1. This growth rate is expressed as doublings per hour.
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FIGURE 3.8. Overlapped dose-response profiles for Tetrm (red), and Tet
s
m (green) in monoculture. Culture growth is
represented as left) optical density estimated from normalised fluorescence (ODe600), centre) per capita growth rate,
and right) maximum increase in ODe600 per hour on the y -axis, whereas the concentration of tetracycline is represented
on a logarithmic scale on the x-axis. Upon detection, the MSC is represented in dark grey the IC90 for Tets in green, and
that for Tetr in red. For each case, we quantified the costs of resistance as the difference between Tetr and Tets in the
absence of tetracycline (data shown on the y -axis).
FIG. 3.8 displays the dose-response profiles of each strain grown in monoculture
in the presence of the antibiotic tetracycline. For convenience, these profiles were
overlapped and used to calculate parameters such as the MSC, and IC90. We observed
the MSC to be highly sensitive to the way it was calculated. The numerical value for this
concentration was different between either form of growth rate and we were also unable
to measure it using ODe. The sensitivity to tetracycline was rather similar despite of
the data used, Tets being ∼ 30 times more sensitive to the drug than Tetr . Finally we
measured the costs of resistance as the difference in growth rates and culture density
between both strains in the absence of antibiotic. The resulting costs also were highly
sensitive to whether we used culture density or growth rates.
Next, we repeated the previous measurements when the strains were grown in co-
culture. Due to such difference in sensitivity, Tets set a limit as to how much tetracycline
we could use, so we used a range of concentrations wide enough to be toxic for Tets
but not for Tetr . As predicted by our theoretical model, the resulting MSC and IC90
were different from those measured in monoculture (FIGS. 3.9 and 3.10). The IC90 was
reduced between 30 to 50% depending on whether the concentrations were calculated
using cell density or growth rate. The MSC was reduced in such conditions by 80%
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FIGURE 3.9. Left) Overlapped, culture density dose-response profiles for each competing strain grown in monoculture.
For more information see FIG. 3.8. Right) Overlapped, culture density dose-response profiles for each competing strain
grown in coculture over 24h. We quantified the costs of resistance as the difference between Tetr and Tets in the
absence of tetracycline (data shown on the y -axis). We used a Wilcoxon rank sum test to analyse the differences in
IC90 (p = 1.55 · 10−4 and ranksum = 100).
and was coupled with the nearly total reduction of the costs of resistance. Although
this last observation is not entirely consistent with our mathematical model, the MSC
did change when the strains were grown in co-culture just as our model predicted.
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FIGURE 3.10. Overlapped, growth rate dose-response profiles for each competing strain grown in monoculture (left)
and 24h of coculture (right). For more information see FIG. 3.8. Upon detection, the MSC is represented in dark grey
the IC90 for Tets in green, and that for Tetr in red. We quantified the costs of resistance as the difference in between Tetr
and Tets in the absence of tetracycline (data shown on the y -axis). We used a Wilcoxon rank sum test to analyse the
differences in IC90 (p = 1.55 · 10−4 and ranksum = 100) and MSC (p = 0.019 and ranksum = 42).
The IC90 for the most sensitive strain Tets was reduced in the presence of Tetr in
accordance with our theory. To quantify the inhibition per molecule of tetracycline, first
we calculated the inhibition of growth in the presence of T µg/mL of tetracycline as GT .
If we label the growth in the absence of the drug as G0, then I(T ) := 1 −GT/G0. We
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finally defined the inhibition per molecule of tetracycline as the ratio between I(T ) and
T . When the antibiotic inhibits the growth of the culture this ratio is positive, otherwise
it is negative. FIG. ?? shows that the effect of tetracycline on Tets was stronger in the
presence of Tetr , with the strongest inhibition being produced by a comparatively lower
antibiotic dose.
FIG. 3.11 displays the raw data for the co-culture grown during seven 24h seasons,
with transfers of ∼ 1% of the culture at 24h intervals. We presented the data as expected
culture density (ODe) obtained from fluorescence readings, relative frequency, per
capita growth rate (doublings per hour) and growth rate (ODe per hour) of each strain
as a function of tetracycline dose. The dataset aligns well with the predictions of the
model, which predicted the competitive suppression to be sustained and enhanced
through time (FIG. 3.12). It also shows an increase in the number of molecules of
tetracycline per cell, especially between the growth measured in monoculture and after
24h of co-culture (FIG. 3.13). To calculate this, we labelled the growth read at IC90 in
each condition as G90 and used the ratio between IC90 and G90 as a proxy to estimate
the concentration of tetracycline per cell.
In terms of culture density, Tets overcame the ‘benefits of resistance’ observed for
Tetr in the absence of tetracycline. This was coupled with the emergence of a crossing
point (MSC) between the dose-response profiles of some of the replicates (FIG. 3.14).
During the length of the experiment, the MSC shifted towards higher concentrations of
tetracycline as predicted by our model (FIG. 3.7). When we measured the MSC using
growth rates it remained unchanged during the seven days (FIG. 3.15). However, Tet r
was not able to outcompete Tets until the dose of tetracycline was well beyond the MSC.
We interpreted this as the niche predicted by our model in which both competitors could
be co-maintained, mediated by antibiotic dose, and where we would find the MSC.
When the dose of tetracycline was higher we could no longer measure the presence
of the most sensitive strain Tets and therefore these concentrations defined the niche
which selects on the most resistant competitor Tet r . The existence of a niche selecting
for the most sensitive strain was not observed.
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FIGURE 3.11. Overlapped dose-response profiles for Tetr (red), and Tets (green) during the seven days of co-culture.
Changes in A) optical density estimated from normalised fluorescence (ODe600), B) relative frequency, C) per capita
growth rate, and D) maximum increase in ODe600 per hour as a function of the concentration of tetracycline. Upon
detection, mean ± 95% confidence intervals are shown for the MSC, represented in dark grey, and the IC90 for Tets , in
green.
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FIGURE 3.12. Change in the IC90 as a function of the growth conditions (monoculture or coculture) and competition
length based on culture density (left), and maximum increase in ODe600 per hour (right). We analysed the difference in
the IC90 between that measured in monoculture (label M) and after 24h of coculture using a Wilcoxon rank sum test with
p = 1.55 · 10−4 and ranksum = 100 for data based either on culture density (left) or growth rate as ODe600 per hour (right).
We also quantified differences in the IC90 measured after 48h of coculture, with p = 3.10 · 10−4 and ranksum = 92 for
the data based on culture density (left), p = 0.002 and ranksum = 89 for data based on growth rate as ODe600 per hour
(right). The linear model ICc90 = a + bt is represented in dark grey, the parameter b not being significantly different from
zero.
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FIGURE 3.13. Relative concentration of tetracycline per optical density unit (ODe600) for the sensitive strain Tet
s in
monoculture (labelled M), after 24 and 168 hours of competition (labelled C). The barplots represent mean ± standard
error (n = 7), whereas the raw data is shown as circles. We analysed the differences between M and C(24h) using a
Wilcoxon rank sum test with p = 0.011 and ranksum = 33.
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FIGURE 3.14. Overlapped, culture density dose-response profiles for each competing strain grown in coculture over
24h (left) and 168h (right). Upon detection, the MSC is represented in dark grey the IC90 for Tets in green, and that
for Tetr in red. For each case, we quantified the costs of resistance as the difference in between Tetr and Tets in the
absence of tetracycline (data shown on the y -axis). We used a Wilcoxon rank sum test to analyse the differences in
IC90 (p = 5.84 · 10−4 and ranksum = 77). The costs of resistance are shown on the y -axis as the difference between
Tetr and Tets in the absence of tetracycline.
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FIGURE 3.15. Overlapped, growth rate dose-response profiles for each competing strain grown in coculture over 24h
(left) and 168h (right). Upon detection, the MSC is represented in dark grey the IC90 for Tets in green, and that for
Tetr in red. For each case, we quantified the costs of resistance as the difference in between Tetr and Tets in the
absence of tetracycline (data shown on the y -axis). We used a Wilcoxon rank sum test to analyse the differences in
IC90 (p = 0.00408 and ranksum = 31) and MSC for which no statistical difference was found. The costs of resistance
are shown on the y -axis as the difference between Tetr and Tets in the absence of tetracycline.
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3.4 FURTHER PREDICTIONS: THE NUMBER OF RESISTANCE PLASMIDS PER R CELL IS
PREDICTED TO INCREASE WITH THE DOSE
Above we noted that the most resistant competitor, Tetr , carries a plasmid-borne
mechanism of resistance (tet(36)). Yet the mathematical model in EQUATION 3.1 does
not include explicitly resistance as a function of the number of plasmids. We now rectify
this omission by introducing the following theoretical model.
d
dt
S = Gs (C, A0) · S (3.2a)
d
dt
R =M
(
(1 − Γ) ·Gr (C, A0) ·R
)
(3.2b)
d
dt
C = − V ·C
Km +C
· *.,
∑
j
Rj + S
+/- , (3.2c)
d
dt
As = −d · As + ϕ · (A0 − As) · S, (3.2d)
d
dt
Ar = −d · Ar + ϕ · (A0 − Ar ) ·
∑
j
Rj , (3.2e)
d
dt
A0 = −d · A0 − ϕ · *.,A0
*.,
∑
j
Rj + S
+/- −
*.,AsS + Ar
*.,
∑
j
Rj
+/-
+/-
+/- , (3.2f)
where the sum is taken over the number of R cells with different numbers of plasmids
(j). During cell division, plasmids are replicated alongside the bacterial chromosome
and equally segregated between the two daughter bacterial cells.90 In the model we
assume that such segregation is not perfect, and only one plasmid can be gained or
lost at a time with equal probability σ. We modelled this as a Markov process with the
following transition probability matrix
M =
*................,
1 σ 0 · · · 0
0 1 − σ σ 0 ...
0 1 − σ σ . . .
0 1 − σ . . . 0
... . . . . . . σ
0 · · · 0 1 − σ
+////////////////-
for a population of R formed by j subpopulations with j − 1 plasmids per cell. Note that
if the subpopulation with one plasmid per cell loses the plasmid, we assume that it
cannot be recovered.
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FIGURE 3.16. The main figure shows the 7-season distribution of the number of plasmids in the R-cell types when
σ = 0.01. Note how these distributions are more skewed towards higher plasmid numbers as the dose of drug increases.
The inset shows three particular plasmid distributions after 7 seasons, including the inoculum distribution which sees a
random distribution of both s and r cell types, with a uniform distribution of plasmids in the latter case.
FIG. 3.16 illustrates the purpose of using this model. We solved this model numeri-
cally using the Matlab function ode15s, which uses numerical differentiation formulas
(NDFs),73 and used it to predict the existence of different distributions of plasmid
numbers observed per cell at the end of seven seasons, which can be determined
for each dosage. In the simulated case presented in this figure, we see that higher
dosages (in red) led to higher numbers of plasmid per cell and vice versa. This oc-
curs because because we assumed the plasmid had no copy number control and is
therefore susceptible to copy number changes. These changes can occur during cell
division, creating differential segregation of plasmid numbers within the dividing cell.
There are different ways of representing the same phenomenon and FIG. 3.17 shows
that this new model predicts the existence of dynamics on the distribution of plasmids
in the Tet r -subpopulation as a function of the concentration of tetracycline that has a
switch-like structure that occurs around 0.05µg/mL. The validation of this prediction is
technically demanding, but we approximated it by measuring the mean copy number of
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plasmids per cell using quantitative PCR (qPCR). We therefore calculated the number
of plasmids using a protocol published elsewhere91 (FIG. 3.18). The result of this
qPCR-based protocol showed a significant positive correlation between the number of
plasmids contained in each Tetr cell after just 24h of competition with Tets (F -statistic
versus constant model = 4.4, p = 0.047). Thus, selection on the plasmid can occur
very rapidly and lead to changes in the distribution of plasmids per Tet r -cell.
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FIGURE 3.17. Left) New predicted outcome of a competition between the strains Tets and Tetr . This prediction is not
qualitative different from the previous version of the model. Right) Relative frequency of the plasmid as a function of the
dose (coloured), assuming a uniform distribution at inoculation time (t = 0h).
3.5 CONCLUSIONS
During the introductory chapter, in SECTION 1.3, we highlighted a fundamental problem
in antibiotic therapy design in which antibiotic sensitivity is quantified on an isolated
bacterial population. The drug is, however, used on the natural microbiota of a patient
(be this a person, pet or farm animal). Here we demonstrated, supported by a theoreti-
cal framework developed during this chapter, the sensitivity to antibiotics of a sensitive
species can be further increased in the presence of other micro-organism when the
latter is not affected by the drug. The stress produced by the antibiotic is added to the
reduction of carbon and oxygen by the competing micro-organism due to an ecological
phenomenon known as competitive suppression.
For convenience, in our case the micro-organism is resistant to the antibiotic tetra-
cycline and thus we measured when the selection for this resistant bacterial species
begins. This resistant species confronts a cost, a reduced growth rate, consequence
of the plasmid-born resistance mechanism. In such circumstances it has been sug-
gested that selection on resistance begins at a particular concentration resistance,
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FIGURE 3.18. Relative copies of the plasmid pGW155B per cell of Tetr after 24h of coculture with Tetr . We robustly
fitted the linear model y = a + bx where the 95% confidence interval for a is (19.76, 41.35) and for b is (26.52, 284.56),
with R2adj = 0.198. This highlights a weak, but significantly positive correlation between number of plasmids per cell and
dose of tetracycline.
the so-called minimal selective concentration or MSC (FIG. 3.3). This concentration
sets when both sensitive and resistant species have identical growth rate and, thus,
higher dosages would select for the most resistant species. However, we showed
that the MSC is not robust to different ways of measuring growth rate and therefore
different definitions of growth rate yield different MSCs. Whether the MSC is calculated
overlapping the dose-response profiles of both species, or empirically from a mixed
culture also yield different MSCs. We also demonstrated that the MSC changes during
the experiment. Thus, the MSC is a poor predictor of where selection on resistance
begins.
In our case the resistant species harbours a plasmid with the ribosomal protection
gene tet36. We also quantified how dose affects the plasmid copy number per cell but
a weak correlation was found with the experimental setup presented in this chapter.
IV S E L E C T I O N O N T H E D U P L I C AT I O N O F
A C R A B - T O L C I N S PAT I A L LY D I S T R I B U T E D
C U LT U R E S
BY IMPLEMENTING AN analogy of the laboratory protocol used to determine antibi-otic susceptibility, the so-called E-test, we are able to quantify aspects of selection
for antibiotic resistance in a spatial drug gradient. Our main result is this. Although one
might expect greater drug dose to correlate with lower population densities, we show
that this expectation is not met in practice and the reasons for this are both ecological
and evolutionary. We therefore show, using a combination of theoretical modelling and
spatially-extended laboratory microbial growth experiments, that the growth rate of
a bacterial population with genetically distinct subpopulations can be maximised at
intermediate distances from the antibiotic drug. Moreover, each subpopulation, distin-
guishable by the number of resistance genes they carry, can have a maximal growth
rate at a different spatial location.
One prediction from this observation is that microbes growing in an antibiotic gradient
can exhibit, at least temporally, a certain ‘bullseye’ pattern formed from concentric
rings. Experiments using Escherichia coli provide evidence for the existence of these
rings and we show, using genetic manipulation of the resistance genes in question,
that such a genetic manipulation can move the location of this pattern.
This chapter represented the work of an unusually large within-lab collaboration
between the following people who each contributed to different aspects of the project.
Their contributions are detailed as follows.
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R. C. Reding Roman: implemented experimental protocols, analysed data, designed
experiments and mathematical models;
M. Hewlett: designed and implemented experimental protocols, analysed data;
F. Gori: implemented computer codes to simulate mathematical models;
S. Gardner: developed a multi-fluorescence video capture device based on an Arduino
controller and a commercial camera;
I. Gudelj: designed experiments, provided funding for the project from a NERC grant;
R. Beardmore: provided funding from an EPSRC grant, wrote and analysed mathemat-
ical and computer models.
4.1 INTRODUCTION: SELECTION FOR RESISTANCE AT DIFFERENT DOSAGES
The purpose of this study is to test the following hypothesis: is it true that a greater
antibiotic dose necessarily yields fewer bacterial cells? The Eagle effect, observed
many years ago,46 provides one of the earliest answers to this question, and that
answer is negative for it can be the case that bacterial densities increase with increasing
antibiotic dose. However, how Darwinian selection for resistance might also produce
datasets like those reported by Eagle, and others, has received little attention in
the literature. We therefore study this question from an evolutionary and ecological
perspective, focusing on how resistance by efflux can contribute to datasets that
also lead to the rejection of the above hypothesis. In short, we will conclude that
a phenomenon known as competitive release can combine with selection on gene
duplication mutations that mediate drug resistance by efflux to produce spatiogenomic
patterns in which more drug need not correlate with fewer bacteria.
One of the most common assays performed in hospitals is the antibiogram,92,93 it
is an in vitro test for susceptibility to a range of antibiotics. At the core of antibiotic
susceptibility testing is a simple laboratory test that determine zones of inhibition, these
are often performed using manufacturers’ so-called E-strips.94 The E-strip is impreg-
nated with a gradient of antibiotics and it is placed onto a bacterial lawn whereupon
killing and growth inhibition of some of the bacteria can result. From this killing, a
clearance appears on the lawn up to a certain drug concentration from which one can
read concentrations at which the microbe is sensitive to the drug used.
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As this protocol by its very design creates a spatial gradient of antibiotic, we are
interested in ecological and evolutionary features that might result from the implemen-
tation of such a test. The bespoke implementation in our laboratory of an analogue of
the test is illustrated in FIG. 4.1.
A(x)
spatial coord (x)
Ac
0
bacterial 
density
killing 
zone
growth
Ac
drug
FIGURE 4.1. A schematic of our implementation of the antibiotic susceptibility test: an antibiotic drug held at high dosage
at the centre of an agar plate diffuses out into a bacterial lawn, producing a killing zone or zone of inhibition where by
the higher the dose, the larger the zone.
This drug susceptibility protocol is performed on an agar plate containing minimal
growth medium, a carbon source, salts and amino acids. At the centre of the plate
a circular region of agar is excised by hand and replaced with agar that has been
impregnated with an antibiotic at a controlled dose, an antibiotic gradient therefore
ensues across the plate.
It is thought that antibiotic gradients are associated with rapid selection for resistance,
the idea being that a microbial population is exposed to small increments of drug which
can be easily dealt with. A little like the tale in which a frog that can be boiled slowly
by steadily increasing the temperature of the water of the pan in which it sits, so a
microbe is thought to readily survive small increments in antibiotic dosage when an
abrupt change would be lethal.95
We therefore use a laboratory model system in which changes in antibiotic resistance
can be measured over short timescales. This system sees the bacterium Escherichia
coli K12, strains TB108, MG1655 and AG100, treated with tetracycline and macrolide
antibiotics, we use this combination because K12 has a clinically important efflux
pump96 formed from the products of the operon acr and the protein TolC.97 Moreover,
acr resides in a genomic region that can be recombined to produce duplications and
triplications very rapidly under antibiotic selection pressure involving macrolides and
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tetracyclines.98
A)
0.1 Di↵usion and clearance zone in MG1655 and AG100
For both MG1655 and AG100 strains, bacteria were inoculated into soft agar supplemented with 1% glucose.
The central circle of the plate was made with concentrations of doxycycline ranging from 1xMIC (all doses refer
to concentrations used in liquid media) to 128xMIC, in 8 two-fold steps. The clearance zone was measured by
fitting a circle to the radius of no growth, and by measuring pixels until growth reached an arbitrary threshold
(e.g., 0.3 ⇤maxgrowthintensity). The raw pictures, profiles and clearance zones are shown below.
Raw image − false colour
Polar Transformed Image
Figure 1: Raw pictures of AG100 at various Dox concentrations.
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Figure 2: AG100 profile plots, whereby pixel intensity (brightness) is used as a proxy for optical density, and
thereby, growth.
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FIGURE 4.2. A) Raw data: an image of a bacterial lawn (in false colour) showing how the zone of inhibition on that lawn
increases in area with increasing dose, here at 1, 2, 4,...., 128 times the MIC dose determined in liquid culture conditions.
B) The increase in area for the tetracycline drug for strains MG1655 and AG100 follow a power law with coefficient close
to a value of two: a quadratic. This is consistent with increases in zone of inhibition being described by a threshold killing
model whereby escape of the drug fro the centre following a diffusion equation, as shown in the text (Statistical note:
correlation coefficients are R2 = {0.898, 0.959} respectively, F-statistics versus constant models are F = {728, 1930}
and corresponding p-values are given by: p = {1.43 · 10−82, 3.45 · 10−115 }.)
4.1.1 Inreases in the zone of inhibition of MG1655 and AG100 with dose are
consistent with linear diffusion theory. The fundamental solution of the linear
diffusion equation
At = σAxx ,
on an infinite two-dimensional domain with Dirac delta initial condition of mass Ac is
given by the expression
A(t ) =
Ac
4piσt
exp
(
−(x2 + y2)/4tσ
)
which represents a temporally-modulated normal distribution. If we assume, as is
natural, that extracellular and intracellular drug concentrations are highly correlated
and, also, that the concentration of A leads to bacterial killing provided it is of a
sufficiently high value, Ad say, a value known as the minimal bactericidal concentration
(MBC), then the zone of inhibition, or killing, is given by those pairs (x , y ) for which
Ad < max
t>0
Ac
4piσt
· exp
(
−(x2 + y2)/4tσ
)
.
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Let us write r =
√
x2 + y2. By taking the derivative with respect to t of the function
A(t ) defined within the latter inequality and setting this derivative to zero, we find this
maximum occurs when t = r2/4σ. At this value of t there results A(t ) = Ac/(pir2e).
Hence, equating Ac/(pir2e) with Ad , we deduce that killing occurs up to a certain
spatial radius, r < rd say, where
rd =
(
Ac/(Adpie)
)1/2 .
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FIGURE 4.3. The leftmost plot shows the decay in drug concentration as a function of distance from the drug source,
where the latter has been deployed at a value Ac . As the drug diffuses outwards, it maintains a value above the minimal
bactericidal concentration (MBC) for a while, thus enlarging the zone of inhibition (ZoI), up to a maximum time point.
Beyond this time, dose is too low to ensure bacterial killing occurs. The middle plot is analogous to the first, but with
double the dose supplied, 2 × Ac . This calculation illustrates that the zone of killing increases in size by a factor
√
2
according to diffusion theory. The rightmost plot shows the dynamics of the drug dosage as a function of time both
inside and also right at the very edge of the zone of inhibition.
If we therefore examine the plot of empirically-determined zones of inhibition, like
those in FIG. 4.2, we ought to observe that the increase in radius of that zone with
the dosage applied scales like the square root of the drug dose. From a nonlinear
regression p1 + p2xp3 , we observe that the value p3 = 1/2 lies within the 95% confi-
dence interval for the estimate of this power coefficient. We therefore cannot reject
the hypothesis that some value of the power coefficient provides a better fit than the
theoretically-predicted square root law. We shall modify this simple diffusion-based
theory later in order to provide more refined predictions of the nature of population
dynamics in the growth region outside these zones of inhibition.
4.1.2 The AcrAB-tolC efflux system, the acr operon and its duplications. Out-
side the zones of inhibition where drug dosage is so high that bacterial killing is assured,
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we anticipate a complex set of population dynamics between different tetracycline
and macrolide resistance mechanisms available to the E.coli cell. In particular, the
E.coli chromosome carries genes that encode proteins AcrA, AcrB and TolC which
form a membrane-spanning efflux pump that includes tetracyclines and macrolides in
the family of small molecule substrates that it can pump. Moreover, structure-altering
mutations in AcrB are known to mediate clinical resistance to a range of antibiotics.96.
R P R P R P
(a) (b)
R R
R
(c)
FIGURE 4.4. A) The basic structure of an operon: a promotor region in light grey, followed by a gene coding a protein
that represses transcription of the same operon, followed by a second protein that encodes part of an efflux pump. We
use the green font colour to highlight the fact that we have a strain which has GFP fused to the protein P, we also have
strains without GFP fused to P. We have in mind that P represents the A and B proteins of the acrRAB operon. B)
E.coli can duplicate the number of copies of the acr operon in its genome which leads to a novel network structure
following duplication in which the two copies repress each other. C) Following a further duplication of one of the operons,
a three-node network results with all nodes repressing each other.
The efflux proteins AcrA and AcrB are encoded within an operon acr, that we shall
also write acrRAB to highlight the fact that the operon contains a triple of proteins, two of
which form the pump but the first of which to be transcribed encodes a repressor of the
same operon. Now, acr is contained within a genomic region in the E.coli chromosome
that can be recombined into the chromosome to form a large mutation with a high
mutation rate consisting of about 8% of the entire bacterial genome. Under strong
selection for resistance as encoded by this pump, this region has been observed to be
duplicated in doxycycline monotherapy and triplicated in a doxycycline-erythromycin
cocktail treatment98 within five days of exposure to these antibiotic conditions at low
population densities.
When these operons are duplicated, triplicated, or held at an even greater copy
number, this creates a growing network of ever stronger co-repression, as depicted
in FIG. 4.4. Moreover, the acr operon is regulated by a complex stress network that
includes the mar regulon and regulatory mutations in this operon, through marR can
mediate expression of the AcrAB-TolC efflux pump.98
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FIGURE 4.5. A) We took a fluorescence microphotography showing the localisation of GFP within a section of an E. coli
cell close to the moment of division. Using this labelled strain of bacterium we are able to deduce how the dynamics
of regulation of the protein AcrB correlates with the use of the macrolide, erythromycin (labelled ‘ERY’). In the absence
of the drug (grey curve) the protein is down-regulated through lag and exponential phase (less than 12h) before being
up-regulated and then stabilising in stationary phase (12h and beyond). When drug dosage is applied, first at a low
dosage of 5µg/ml , the concentration of AcrB per cell increases substantially to level about 40% higher at its maximum
in the absence of drug. However, as the dose is further increased we observed a negative correlation between drug
and AcrB concentration per cell. (b) The negative correlation so-described is significant across a wide range of ERY
dosages, as shown by the results of determining a t-statistic (for the derivative of GFP per cell with respect to dose)
following a linear regression that is testing for the increase or decrease in AcrB concentration as dose changes.
In order to illustrate how this pump is regulated during different phases of bacterial
growth and in different antibiotic concentrations, we present the data in FIG. 4.5. Using
an altered MG1655 strain in which GFP is physically fused to AcrB, a strain denoted
TB108. The latter strain, which allows us to infer data on efflux pump numbers per cell,
shows that the pump decreases in concentration in lag and stationary phase, during the
period up to 12h in FIG. 4.5(a). In the absence of drug as stationary phase is entered,
the pump is up-regulated to a value deemed to be unity for this discussion. A region of
stasis is reached from 18h onwards in which the pump concentration neither declines
nor increases. When the drug erythromycin is used in the growth medium, a similar
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dynamic of regulation of the pump is observed except that the final concentration per
cell is much higher and it continues to increase in stationary phase, to a value about
40% higher than that observed in the absence of drug. Now, FIG. 4.5A and B both
show that an increasing down-regulation of the acrB protein is observed as more drug
is used in the growth medium. Thus, while it might be hypothesised that more drug
necessarily leads to an increase in pumps expressed per cell, this statement is only
true for certain dosages. The opposite is also observed in a single season of bacterial
growth.
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FIGURE 4.6. The analysis of the photographs from a spatial dose-response assay, using the strain eTB108, shows the
expression of AcrB using the proxy of green fluorescence levels (shown next to optical density (i.e. white light) at A) 24h
and B) 48h . This yields a per cell measure of AcrB concentration which is done by calculating fluorescence observed
per optical density. This measure is shown in the inset of both plots which indicates a positive correlation between
drug dose and pumps per cell. We designed an algorithm in Matlab, using the image analysis toolbox, to extract the
information from the photographs FIG. S.16.
4.1.3 A duplication of the acr operon does not double protein AcrB concentra-
tion. Consider the following differential equation model of the acr operon shown in
FIG. 4.4. The auto-repressive nature of structure, whereby the repressor R is tran-
scribed, followed by the efflux protein, P, and then R represses the further transcription
of the operon leads to one possible model of the following form:
d
dt
P = −d0P + ρM, (4.1a)
d
dt
M = −d1M + g V1 + kP +M0. (4.1b)
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Here d0 and d1 are degradation rates of the protein, P, and of mRNA associated
with the transcription of the operon. We assume that the concentration of the repressor
protein, R is proportional to that of P, which is reasonable given they are encoded
by the same operon. The parameter M0 is a basis level of transition of the operon,
gV +M0 is the maximal rate of transcription, where the parameter g is a proxy for the
number of copies of the operon held in the genome.
In steady-state, EQUATION 4.1a-b satisfies the following. First, P = ρM/d0, and
therefore M0 + gV/(1 + kP) = d1m = d1d0P/ρ. This is a quadratic in P which, when
solved, gives
P = P∗(g) := α +
√
1 + β · g,
where α = (k−1− ρM0/(d0d1))/(k−1+ ρM0/(d0d1)) and β = 4V ρd0d1k (k−1+ ρM0/(d0d1))−2.
Let us now assume that A(t ) is the internal concentration of antibiotic in the cell and
that A0 is extracellular concentration of the drug, and then
d
dt
A = ϕ(A0 − A) − ρA · P. (4.1c)
Then, in steady-state,
A = A∗(g) :=
ϕA0
ϕ + ρP
=
A0
1 + ϕρ (α +
√
1 + β · g) .
We therefore deduce, because of the auto-repressive nature of the efflux operon, that
internal drug concentration and concentration of the efflux protein itself, scale as
√
g,
the square root of the number of copies of the operon in the genome.
At this point we make the following remark. In the above, the value of M0 is assumed
to be small and should in fact be g ·M0 in this analysis. This reflects the idea that if a
gene is copied in the chromosome, then the basal transcription rate could well, indeed
should, increase approximately linearly with the number of copies of the transcribed
gene. This modification has the effect of changing the terms α and β above so that they
also depend on g. However, if M0 is small enough, then the above predicted square
root dependence of A∗(g) on g will be largely unaffected, although there clearly do
exist parameter regions where that dependence will be lost. In short, the replacement
M0 → g ·M0 in the above manipulations makes clear in which parameter regimes that
can happen. Throughout the remainder, for simplicity, we assume that α and β do not
depend on g.
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4.2 THEORETICAL PREDICTIONS: THE BULLSEYE PATTERN
4.2.1 The bullseye pattern: a heuristic derivation. Assume for now that environ-
mental, meaning extracellular, antibiotics degrade sufficiently during the time of an
experimental protocol in order for the diffusion equation with decay to be a reasonable
description of the dynamics of the antibiotic molecules through space, ignoring uptake
and efflux for the moment. Thus we suppose that the parameter that was denoted A0
above now depends on space and time in such a way that
At = σAxx − dA,
where A(x = 0, t ) = Ac and A(x → ∞, t ) = 0 hold for all t > 0. In steady-state, this
equation has solution
A = A(x ) = Ac · e−(σ/d )1/2x .
Consistent with the experimental protocol depicted in FIG. 4.1, if we assume the
existence of a diffusing extracellular nutrient, call it S, then we may also introduce two
further diffusion and decay parameters, this time for the carbon source glucose, and
write S = S(x ) = Sc · e−(σ/d )1/2x . We use the latter form as a coarse approximation of
the true nature of the nutrient concentration, S, because no cells can be found within
the red, high-drug region in the centre of FIG. 4.1. However, cells are found inside
the grey region and they will begin to ingest those nutrients and grow, this will create
a nutrient gradient whereby more nutrients can be found inside the red region than
outside it. Thus, we assume for now that the nutrient has a similar form to the drug
profile. As this is a heuristic derivation, to makes matters simpler still we will assume
S = S(x ) ≈ Sc · e−(σ/d )1/2x .
Now, suppose that bacteria grow through time according to Michaelis-Menten-Monod
kinetics in the sense that their growth rate, G, can be written
G = G(S, A) = c · vS
κ + S
· f (A),
where f (A) is an A-dependent inhibition function which slows growth as a function of
intracellular drug concentration, A. Thus, following the dependencies in this simple
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model, G is a function of x . We are interested in where the maxima of this function,
G(x ), might occur and so we now compute ∂∂x G(S, A). So, we first note that
∂
∂x
G(S, A) = f ′(A)A′
cvS
κ + S
+ f (A)
cvS′
κ + S
− f (A)S′ cvS
(κ + S)2
and as we are seeking maxima with respect to x of this quantity, we now determine
whether, or not, the latter expression has zeros. This occurs if and only if
0 = f ′(A)A′S + f (A)S′ − f (A)S′ S
κ + S
. (4.2)
Now, collating the information we have so far and using the fact that A represents
intracellular drug concentration, by relating this to extracellular drug concentration, we
have A0 = Ac · e−(σ/d )1/2x and, therefore,
A =
Ac · e−(σ/d )1/2x
1 + ϕρ (α +
√
1 + β · g) = A
∗(g)
S
Sc
.
Thus, EQUATION 4.2 has a solution if and only if the following quadratic in S does too:
0 =
A∗(g)
Sc
· f
′(A)
f (A)
· S(κ + S) + κ. (4.3)
We have reached a point beyond which we cannot easily continue without specifying
a form for the function f (A) which denotes the rate of decrease in growth rate as a
function of antibiotic. These are not generally well-understood75 and, in the absence of
any better model, we assume that we are working with a protein synthesis inhibitor that
binds to a pocket on the ribosome and that growth rate is proportional to the number of
drug-free ribosomes. If we impose mass-action kinetics onto the following standard
schema whereby antibiotic, A, binds to the ribosome, R, to form the inhibited complex,
[AR],
A +R
k1−−⇀↽−−
k−1
[AR]
then one can readily derive
R
R + [AR]
=
1
1 + qA
as being the fraction of antibiotic-free ribosomes. We therefore set f (A) = 1/(1 + qA)
where q is a parameter. Given this set of assumptions, we deduce that equation
(EQUATION 4.3) is equivalent to
S · (κ + S) = qκ
(
qS +
Sc
A∗(g)
)
. (4.4)
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Equation (EQUATION 4.4) can be re-written with respect to antibiotic too, whereupon it
takes the form
A ·
(
κS−1c A∗(g) + A
)
= qκ (1 + A) . (4.5)
It is clear from the linearity and quadratic nature of their respective left and right hand
side that equations (EQUATION 4.4) and (EQUATION 4.5) have solutions that depend
on g and, as illustrated in FIG. 4.7, the growth rate function G, defined above, can
have local maxima in space that are located in different places for different values of g.
In order words, an antibiotic can create a spatio-genomic pattern with a multi-bump
structure with respect to the drug gradient.
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FIGURE 4.7. A) The intersection of the line and the quadratic functions give the values of the environmental sugar
concentration, S, for which growth rate has a local extremum (a maximum). In this illustrate example, it is only in those
regions for which S lies between 2 and 3µg/ml (at the intersection of the red and black lines) for which growth rate can
have a local maximum and, then, it is only for a certain range of the number of additional gene copies. B) The analogous
plot to that given in A), but showing dependence on A rather than S. C) From A) and B) we deduce that, for the correct
values of A and S, there can be local spatial maxima with respect to growth rates whose location can change with the
number of copies of the resistance operon, acr.
Whether, or not, the potential for such a multi-bump structure is realised in practise
depends on many parameters within the model. For example, not only is an antibiotic
gradient required in the theory, a resource gradient has to be created by virtue of the
fact that the use of high antibiotic dosages kills so many cells that their resources are
‘released’. This also requires the presence of cells some distance from the drug source
in exactly the manner depicted in FIG. 4.1.
In that figure, the indicated ‘killing zone’ contains no bacterial cells but it does contain
antibiotic and glucose, and other nutrients, in the agar that will both diffuse outwards to
create the requisite gradients. The glucose, or any other sugar, gradient is created by
virtue of the greatest population densities being present furthest from the drug at the
start of the experiment.
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4.2.2 A theoretical genetics model of drug efflux. Having used a highly stylised
form of mathematical modelling to infer that a spatio-genomic pattern, in the form of a
bullseye, can appear in an antibiotic gradient because of a spatial nutrient gradient, as
illustrated in FIG. 4.7, we now turn to a mathematical model that is more explicit in its
ability to capture both the diffusing nature of different bacterial and chemical species
and the manner in which ecological dynamics mediate the potential existence of the
bullseye pattern.
To begin the specification of the model, we first define the radial diffusion operator,
written L, of a function f (r ), by
L(f ) =
∂2f
∂r2
+
1
r
∂f
∂r
.
This is defined for sufficiently smooth functions, f that satisfy f ′(0) = 0 and f ′(r0) = 0
where r0 > 0 is a positive constant that defines the radius of the circular domain in
which the diffusion processes are assumed to take place.
The following partial differential equations are now used to describe the spatial
dynamics of antibiotic inhibition to which we allude above:
∂
∂t
B0 = G0(S, a0)B0 + δ(1 +∆)B1 − δB0 + ρbL(B0), (4.6a)
∂
∂t
B1 = G1(S, a1)B1 − δ(1 +∆)B1 + δB0 + ρbL(B1), (4.6b)
∂
∂t
a0 = −ηa0 + B0ϕ(aext − a0) − B0 vp0k + p0 a0 + δ(1 +∆)a1 − δa0 + ρaL(a0), (4.6c)
∂
∂t
a1 = −ηa1 + B1ϕ(aext − a1) − B1 vp1k + p1 a1 − δ(1 +∆)a1 + δa0 + ρaL(a1), (4.6d)
∂
∂t
aext = −ηaext −
1∑
i=0
Biϕ(aext − ai ) −
1∑
i=0
Bi
vpi
k + pi
ai + ρeL(aext), (4.6e)
∂
∂t
S = − vS
κ + S
1∑
i=0
Bi + ρuL(S), (4.6f)
subject to initial conditions as depicted in the schema of the protocol in FIG. 4.1 and
using no-flux (Neumann) boundary conditions so that no mass can spill out of the
simulated experimental agar plate at any time.
The model (EQUATION 4.6) captures the densities of two bacterial subpopulations
having density Bi (t ) at time t and expressing different numbers of copies of an efflux
gene or operon, where the i = 1 genotype has one more than the i = 0 genotype,
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where this gene codes a protein, or protein complex, that transports drug from the cell.
The intracellular drug concentrations for each subpopulation Bi is denoted by ai and is
measured per unit volume. The variable aext is the extracellular concentration of drug,
S denotes the concentration of a limiting carbon source, glucose in our experimental
systems.
Note that we assumed that mutations increasing the number of efflux pump-encoding
genes (B0 → B1) are less likely than those reducing the number of such genes
(B1 → B0). We have done this because the genomic region in which acr resides is
unstable in the sense that replication of the chromosome usually leads to just one
copy of the operon, and mother cells with a duplication are more likely to have two
‘daughter’ cells where one such daughter is without that duplication than to have two
daughters where both daughters carry it. In other words, there is strong physiological
purifying selection acting against the duplication mutation.
EQUATION 4.6a and b) describe the variation of bacterial density with respect to time.
The model assumes that this variation is caused by three phenomena, one for each
term of the equation. The first part of these equations describes the temporal variation
of bacterial density Bi due to the growth and division of bacteria with intracellular drug
concentration ai and in an environment with glucose concentration S. This phenomenon
is modelled as an exponential growth of the bacterial population, with cellular growth
rate
Gj (S, A) := cj · 11 + pA ·
vS
k + S
,
where c is cell yield per glucose supplied, v and k are the maximal uptake rate and
half-saturation constants associated with Michaelis-Menten uptake of the single carbon
source S, and p is the reciprocal of the half-saturation constant due to the inhibition
from ribosome-antibiotic binding.
To represent the cost of expressing the efflux gene, we chose the yield of ci of each
sub-population, Bi , to satisfy the condition that their respective yields are ordered such
that the greater resistance genotype has a lower per-glucose cell yield, in other words
c1 < c0. We have assumed this because the chromosomal recombination events that
produce increases in the copy of the acr operon carry with them 8% of the entire set
of genes held in the chromosome. It is highly likely that the duplication will therefore
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come at a large ‘protein cost’ whereby many proteins will be over-expressed following
the duplication that have no selective advantage and yet energy in the form of carbon
and ATP is used in order to express those genes.
The second terms of EQUATION 4.6a and EQUATION 4.6b describe the variation
of Bi caused by down/up-regulation of the efflux gene in some of the bacteria. The
down-regulation of the efflux gene in some of the B1 cells make them become B0,
while B0 that up-regulate that gene become B1. The process of up-regulation of efflux
genes is assumed to occur randomly as a Poisson process at a certain rate δ per cell
per hour (the probability of expression and amplification of the gene per cell per unit
time are assumed, for simplicity, to be the same); similarly, the down-regulation is a
Poisson process with rate δ(1+∆), a value necessarily greater than δ. The final terms
of EQUATION 4.6a and EQUATION 4.6b give the variation of bi (t ) due the radial diffusion
of bi with rate ρb.
The process of up-regulation of efflux genes and both increases and decreases in the
copy number of the efflux genes are assumed to occur randomly as a Poisson process
at a certain rate δ per cell per hour (the probability of expression and amplification of
the gene per cell per unit time are assumed, for simplicity, to be the same).
We assume a functional form for pj that is monotone increasing and bounded
in j , controlled by a dimensionless constant g (the Michaelis-Menten function pj =
(j − 1)/(1 + g(j − 1))). Thus pj is also dimensionless and the quantity pj/(k + pj ) is
the probability of finding a pump in the state where it momentarily is bound to drug.
The rationale for this is that the polymerase transcription complex, assumed limited in
number, has to compete for each gene copy, thus providing a limit on the number of
efflux genes that can be simultaneously expressed.
The remaining variables in EQUATION 4.6 have the following meaning: ϕ is the
antibiotic diffusion rates across the cell membrane, v is the maximal antibiotic efflux
rates and k is half-saturation constants associated with efflux pump-antibiotic molecule
binding; V and K are the maximal uptake rate and half-saturation constant associated
with Michaelis-Menten uptake of the single carbon source, glucose S; Gj (S, A) is the
per hour growth rate of each cell detailed above; δ is the rate of amplification of the
efflux gene and δ(1 +∆), a value necessarily greater than δ, is the rate of decay of
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the efflux protein expressed by this gene. Finally, therefore, n − 1 is the maximum copy
number of the gene.
We solved EQUATION 4.6 numerically in python using the package odeint from
the SciPy library (www.scipy.org), which uses a linear multistep method (predictor-
corrector) or backward differentiation formula methods (the Gear methods) depending
on whether the problem is stiff or non-stiff. In the resulting prediction, shown in FIG. 4.8,
there is a clear difference in the nature of the spatio-genomic pattern depending on
whether the antibiotic efflux operon present in the chromosome can be duplicated, or
not. In the case where it cannot be duplicated, the spatial pattern is simple and consists
of a single ‘growth ring’ where bacterial densities have achieved a local optimum. This
is consistent with the analysis illustrated in FIG. 4.7, but it indicates that only one of the
predicted rings is realised using the diffusion model (EQUATION 4.6). FIG. 4.8 shows
that in order to achieve something like the bullseye pattern predicted by FIG. 4.7, we
must use a strain of bacterium that is able to duplicate the efflux operon, acr. These
provide testable experimental predictions that we address in the following section.
A) B)
FIGURE 4.8. Bullseye pattern formation due to the duplication of the acr operon as predicted by EQUATION 4.6. The
distance from the centre of the plate is represented on the x−axes, whereas on the y−axes we represent the nutrient
and drug concentrations, and bacterial density all in arbitrary units. The first ring (A top) is due to the increased bacterial
growth produced by the higher availability of nutrients (A, bottom plot in green) and extremely low concentrations of
drug (A bottom plot in red) in the boundary of the killing zone. More nutrients are available beyond this boundary, but
the concentrations of drug in these coordinates impede the growth of the bacterial cells. Only when the cells carry a
second copy of this operon (b1), translated into higher drug resistance, they are able to grow conforming an ‘inner rings’
of bacteria (B top) until the concentration of drug is too high for these resistant cells (B bottom).
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4.3 EXPERIMENTAL DATA
We now provide an analysis of the result of some bacterial growth experiments that,
we believe, show evidence of the bullseye pattern predicted in theory. Before we are
able to do this, we first present some mathematical measures of monotonicity that we
can apply to dose-response curves in order to provide a quantitative description of how
many rings a spatial dose-response pattern possesses.
4.3.1 Mathematical measures of (non-)monotonicity.
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FIGURE 4.9. A (relative) dose-response of three strains of E.coli with respect to the drug erythromycin using units of
optical density measured at 600nm. The acr knockout strain AG100-A is most sensitive to the drug, followed by TB108
which has a GFP physically fused to AcrB, followed by the strain MG1655. These antibiotic sensitivity tests, required for
experiments in CHAPTER 2, show that, overall, bacterial growth declines monotonically with increasing drug supply over
a 24h incubation period.
4.3.1.1 A First Numerical Measure of Non-Monotonicity: the Hill function. The basic
idea of an empirical antibiotic dose-response is encapsulated in FIG. 4.9. In it, an
exponential scale of increasing dosages is presented on the x-axis and the y-axis
contains data relating to the growth of the microorganism in question, in that case
optical density although other measures, such as growth rate, are also used in the
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antibiotic literature. It is common, as we have also done using the dose-response data
in FIG. 4.10(a), to assume that the data decreases monotonically with dose and to
numerically fit a Hill function to it. A Hill function takes the form
H (A) = H0 · K
n
K n + An
where H0, K and n are three parameters to be determined as part of the data fit.
Using this fit, we can then estimate ICx values which are the dosages that give an x%
reduction in growth. In other words, ICx satisfies the relationship H (ICx ) = x100 · H0,
thus the value of K is the IC50 of the data.
However, as FIG. 4.10B shows, Hill functions are not accurate descriptors of dose-
response data when one is interested in studying, as we are here, the effect selection
for resistance has at different dosages. For the latter figure shows the effect on the
Hill function-like data, gathered at 24h, after that E.coli data has been evolved in
the presence of erythromycin for a further 72h. The details of how this is done are
contained in the methods section, but it is clear from the figure that the monotone nature
of the data has changed; while there is short-term monotonicity of dose-response the
strength of selection at different dosages differs in such a way that monotonicity is not
preserved through adaptive and evolutionary changes. This observation is consistent
with the theory of SECTION 4.2.1 which shows that the maximal growth rates for
different genotypes can occur at different dosages and it is difference of these growth
rates between genotypes that determine the strength of selection for resistance.
We therefore require statistical methods for quantifying the the non-monotonicity
properties of dose-responses. One could, of course, use the goodness of fit, or poor-
ness of fit, of a Hill curve to dose-response data but this would not capture information
about the oscillatory properties of the dose response. Another approach is to perform
a best-monotone function fit to data, this could be achieved as follows.
4.3.1.2 A Second Numerical Measure of Non-Monotonicity: monotone data fitting.
Suppose that (u0, u1) ∈ H := R × L2((0, 1),R), we can define a monotonic function
M (u) ∈ W 1,1((0, 1),R) by
M (u0, u1)(x ) = u0 +
∫ x
0
u1(y )2dy .
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FIGURE 4.10. An erythromycin dose-response curve of the E.coli AG100 strain with a Hill function fit super-imposed
onto the data. The latter is used to determine an IC99 within a certain confidence and define the classic mutant selection
window (grey). Drug dose is shown on a linear scale on the x-axis, optical density at 24h is shown on the y -axis. Data
from experiment described in CHAPTER 2 (FIG. 2.8).
Note that ddx M (u0, u1) = u
2
1 ≥ 0 almost everywhere and u21 is an element of L1 by
definition, justifying our claims on the properties of M.
Now, any dataset resulting from the experimental construction of a dose-response
curve gives rise to a function in W 1,1 through linear interpolation: if (xi , yi ) defines
a discrete set of points with 0 = x1 < x2 < ... < xN = 1 representing a series of
antibiotic dosages, we take the maximal dose to be xN = 1 which should be thought of
simply as a normalisation to unity, then the linear interpolant of the data points yi is
not only a continuous function, but it is in fact Lipschitz. It is therefore a member of the
space W 1,∞ which is contained within W 1,1. We can therefore apply the operator M to
experimental data.
Given a function d (·) ∈ W 1,1, supposed to represent an empirical dose response
dataset, we then define the best monotone approximation of d to be the element
(v0, v1) ∈ H that achieves
min
{‖M (u0, u1) − d ‖L2 : (u0, u1) ∈ H, ‖M (u0, u1)‖∞ ≤ ‖d ‖∞} .
If we define r (u0, u1) := ‖M (u0, u1) − d ‖L2 then r is a sum and composition of convex
and linear functionals and operators and H is a Hilbert space on which infimising
sequences of M are bounded and from these observations one can prove that there
is a unique minimiser of r . Moreover, approximations to this can be readily computed
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using a direct optimisation algorithm if d is the piecewise linear interpolant of a discrete
dataset. We call the value of r so obtained the measure of monotonicity of the function
or dataset d . It is not a fine measure of how the data oscillates, but it is a measure of
how ‘not monotone’ the data is.
In order to illustrate that the appearance of non-monotone dose-response profiles
with mid-dose local maxima can appear for a range of antibiotic drug molecules, we
applied this numerical measure of non-monotonicity to a video of E.coli AG100 growth
in the presence of kanamycin, see FIG. 4.12. The raw data is contained within a
video, a few frames of which are illustrated in FIG. 4.11. Consistent with the theories
developed earlier, this data exhibits a transition from monotone to non-monotone dose
response.
4.3.1.3 A Third Numerical Measure of Non-Monotonicity: the oscillation profile.
Although a metric with respect to monotonicity allows one to quantify the loss of
monotonicity in the dose-response profile through time, the above theoretical modelling
arguments have indicated that there is the opportunity, given the right environmental
conditions, for the presence of subtle structures within those nonlinear profiles. For
example, the non-monotonicity may be due to selection for certain copies of specific
drug resistance operons occurring at different drug dosages. In order to discern those
effects, which are predicted to be associated with multi-bump dose-response patterns,
we need a finer measure of these oscillation that we can apply to experimental data.
We therefore turn to the winding number of a given function, call the function f (t )
and let W (f ) denote its winding number about the number α. We consider f to be
normalised in two ways such that its domain is [0, 1] and, over this domain, inf(f ) = 0
and sup(f ) = 1. Its winding number is the value W (f , α) = w (f − α, f ′) where
w (x , y ) =
∫
xdy − ydx
x2 + y2
.
We say that the oscillation profile of f (t ), is the function of α defined by
O(f )(α) := W (f , α)
defined for all values of α, but potentially non-zero only for α ∈ ran(f ) where ran(f ) :=
(inf(f ), sup(f )) = (0, 1). Note that O(f )(α) = 0 for values of α outside that range,
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FIGURE 4.11. Frames from a video showing the transition from monotone to non-monotone dose response in the
inhibition of E.coli growth by kanamycin held in the central circular region. The top-most image was taken at time, t = 0h,
the bottom-most at t = 24h. The right column shows the mean dose-response determined from each image in the
left-hand column.
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FIGURE 4.12. The result of quantifying the transition in the dose-response data of FIG. 4.11. Plot A) shows how the data
exhibits a low degree of non-monotonicity at early on the in the experiment because the best monotone fit to data is a
good descriptor of the dose-response. Plot B) shows, at a later time, that the best monotone fit to data gives a relatively
poor fit. The right-hand images in A) and B) show the difference between filtered data and the best monotone fit. C)
Tracing the goodness of fit of the best monotone descriptor of the dose-response data shows deterioration through time,
indicative of a transition from monotone to non-monotone dose-response.
inside that range O(f ) only takes integer values. If we now define a sequence On :=∫
O(f )(α)<n O(f )(α)dα, with O0 = 0, and then set
Bn = On+1 −On,
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we call the latter the bumpiness spectrum of the function f .
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FIGURE 4.13. Measures of non-monotonicity (the oscillation profile and bumpiness measure) using the winding number
of some synthetic data. In each of (A-F) one can see, in the left column of the two images, a function representing a
particular dose-response pattern with zero drug at the x = 0 position and higher drug where x  0. Plot (A) shows a
monotone dose-response which is reflected in the oscillation profile equation, shown in the middle figure of plot A), to
the zero function. Plots (B-F) have increasing degrees of non-monotonicity which is reflected in the oscillation profile in
the right-hand figure of each plot whereby the grey regions have increasing area. In each window, the right-most plot
corresponds to the bumpiness spectrum. Plot (F) accords with what one might expect from intuition: the bumpiness
spectrum of a cos(2pi · x ) function, suitably normalised, is (0, 2, 0, ...) as it exhibits exactly two bumps. Plot (a) shows
that the bumpiness spectrum of a monotone function is the zero sequence (0, 0, ....).
In order to illustrate how the oscillation profile and the bumpiness spectrum might be
used to provide insight into the non-montone and multi-bump nature of empirical data,
we turn to FIG. 4.13. It shows synthetic examples of both monotone dose-repsonse
profiles and also non-monotone profiles. The figure also shows how the bumpiness
spectrum encapsulates the oscillatory character of those profiles in a manner that is
reminiscent of Fourier series coefficients.
4.3.2 Applying the bumpiness spectrum to laboratory spatial dose-response
data. We will now claim that the bumpiness spectrum so-defined can be used to
corroborate visual evidence for an emergent pattern exhibiting concentric rings of
increasing radius when E.coli grows in a spatial antibiotic gradient, as predicted by the
above theory.
First, the experimental data for this is a pair of images that we present in FIG.
4.14A and B. The left-hand image shows the optical density profile as a function of
the distance from the source of the drug at the centre of the plate whereby drug
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FIGURE 4.14. The left-hand image shows the mean optical density of two bacterial strains at 24h, AG100 and AG100-A,
the latter does not have a functional acr operon whereas the former does. The two right-hand images are false colour
representations of two different agar plates on which the respective strains were cultured.
dosage necessarily decreases towards the edge of the plate. Images taken from these
agar plates are shown in the right-hand image of the same figure whereby the white
semi-circular region is the drug source. This figure illustrates bacterial population
density at 24h and, to the eye, appears to exhibit bullseye ring patterns. This appears
consistent with the density images on the left, and although the acr knockout strain
has an essentially increasing density profile with decreasing drug, as may be expected,
the AG100 wild-type strain has an altogether different, and clearly non-monotone,
character.
To quantify this apparent non-monotonicity, effectively in order to produce numerical
measures of what the human eye perceives in FIG. 4.14B, we present FIG. 4.15. It
shows the oscillation profile of the population density data as a function of the spatial
coordinate for the two E.coli strains AG100 and AG100-A, FIG. 4.15 is an analysis of
data taken from FIG. 4.14A).
The population density data relating to AG100-A in the left-hand image of FIG.
4.15 looks almost monotone to the human eye and, indeed, FIG. 4.15(a) shows little
quantitative evidence of non-monotonicity. There is some evidence of a mutli-bump
profile to be seen in the bumpiness spectrum, but certainly not to the same extent as
that seen in the analogous data for strain AG100. This data can be seen in FIG. 4.15(b).
The latter data alluded to, for AG100, shows in quantitative terms what appears to
the human eye in FIG. 4.14 whereby distinct rings highlighting regions of growth can
be seen for this strain, consistent with predictions made earlier using mathematical
models.
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FIGURE 4.15. A) The left-most plot shows an analysis of the dose-response profile which constitutes the observed
mean optical density as a function of the spatial distance from the source of the drug (at position zero), and in this
case it is derived from strain AG100-A that lacks the efflux pump operon, acr. The left-hand plot shows (in red) the best
monotone function fit to data, filtered data (in blue) and the dash blue lines indicate the leftmost point where the optical
density has been established to be significantly above zero using a t-test with significance level p = 0.05. To the right
of this point we assume that optical density is significantly positive. The middle plot is the oscillation profile O(f )(α) for
this AG100-A data and the rightmost plot is the bumpiness spectrum that is derived from the oscillation profile. Neither
of the latter two measures are consistent with the presence of oscillations. B) This is the analogous analysis to A) but
now for the strain AG100 that possesses the acr operon.
4.4 CONCLUSIONS
The experiments described in CHAPTER 2 were carried out in 96-well microplates.
There, we set up a range of concentrations of antibiotic in which the concentration in
each well does not change. So here we created a 2D gradient of antibiotic, observing
that the non-monotone profile also occurs in a spatial context giving rise to bullseye
patterns. Using a fluorescence-tagged bacterial strain that allows us to track the relative
amount of AcrB, key component of the AcrAB-TolC efflux pump, we could also observe
that the relative abundance of this pump increases with higher dosages.
A key observation lies on the agreement between our empirical dataset and linear
diffusion theory, whereby an increase in antibiotic dose not involve a proportional
increase in bacterial killing or growth inhibition. To put this into context, the medical
orthodoxy in the clinic involves the use of aggressive chemotherapies for “radical
pathogen cure”.26 This practice is translated into higher dosages during a treatment
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with antibiotics. Yet, in a spatial context such as the human body, doubling the dose of
antibiotic therapies does not necessarily lead to doubling inhibition as we demonstrated
in this chapter.
V E F F E C T S O F T H E AVA I L A B I L I T Y O F
F U N C T I O N A L R I B O S O M E S O N T H E
R O B U S T N E S S O F M E TA B O L I C R AT E - Y I E L D
T R A D E - O F F S : I M P L I C AT I O N S F O R G R O W T H
R AT E I N H I B I T I N G A N T I B I O T I C S .
WE HAVE USED erythromycin, tetracycline and a tetracycline-derivative antibiotic,doxycycline, during this PhD project. These drugs are known to target different
binding pockets in the bacterial ribosome and lead to the inhibition of protein synthe-
sis.99,100 The ribosome is genetically encoded by seven rrn operons in the bacterium
Escherichia coli 101,102 and each of these operons is able to form a fully functional
ribosome. In this chapter we asked how the concentration of functional ribosomes
within the cells affected growth rate, a question motivated by the use of antibiotics. The
quantification of antibiotic-free ribosomes can be technically demanding, so instead
of using antibiotics we used strains in which the number of rrn operons had been
manipulated to limit the maximum production of these proteins.
Using a set of strains derived from the wild-type E. coli MG1655, which contain
cells with from two to seven (the wild-type) rrn operons, here we observe a potential
‘paradoxical’ increase in both growth rate and yield (biomass produced per molecule of
carbon source) as the number of rrn operons is reduced. Our dataset also provides
empirical evidence that supports previous theoretical studies on metabolic ‘rate-yield’
trade-offs (RYTO),37,38,103 which turn out to be highly dependent on the environmental
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richness of a carbon source supplied to the bacterial cells. Based on the evidence pre-
sented in this chapter, we hypothesised that our observations could also be mediated
by the presence of ribosome-binding antibiotics but this particular hypothesis has not
been tested.
5.1 QUESTION: CAN ANTIBIOTICS MEDIATE METABOLIC TRADE-OFFS, LIKE THE RATE-YIELD
TRADE-OFF?
Ribosomes are essential for the synthesis of proteins within the bacterial cell104 and this
process is known to be coupled to bacterial growth rate.39 A reduction in the number of
functional ribosomes, for example due to the presence of a ribosome-binding antibiotic,
translates into lower bacterial growth rates.41 However, while this relationship seems
self-evident, the situation is not quite so clearcut because there can be an optimal
number of ribosomal operons in very simple growth conditions supported by minimal
media.
The notion of ‘trade-offs’ in evolutionary biology stem from an idea that two beneficial
traits cannot both be improved simultaneously during evolution.105,106 Under normal
circumstances, the idea is that one previously-optimised trait can only improve at the
expense of the other; the traits are therefore said to antagonise each other. As an
example of this, cell growth rate is often compared with yield, defined as the biomass
produced per unit of carbon source supplied. Based on thermodynamic constraints,107
a theoretical study has suggested the existence of a metabolic trade-off between
growth rate and cell yield38 supported by the following rationale.107
Adenosine triphosphate (ATP) is the most common energy ‘currency’ in the cell and
it is produced during the biological oxidation of a carbon source. If this carbon source
is glucose, oxidised using the glycolitic pathway, we can describe the process as the
chemical reaction
{glucose} + 2ADP + 2P 
 {2lactate} + [2ATP]
if glucose is metabolised in the absence of oxygen, or as
{6O2 + glucose} + [36ADP + 36P] 
 {6CO2 + 6H2O} + [36ATP]
if glucose is metabolised in the presence of oxygen. The driver and driven reactions
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FIGURE 5.1. Diagram of the metabolic rate-yield trade-off theory. A) Rate of ATP production is shown on the y -axis as a
function of the yield, η, on the x-axis. This function reaches its maximum at η/2.37 B) The dynamics of ATP production
depicted in A) may change if part of the ATP synthesised is used to increase the production rate. This investment of ATP
comes at a cost of lower maximum yields.38
are indicated with curly and squared brackets respectively. In order for these reaction
to happen, the change in free energy (∆G) for the driver reaction is ∆G0 < 0, whereas
that for the driven reaction is ∆G1 > 0. The efficiency of the reaction is therefore
µ = −∆G1∆G0 and the production of ATP JATP = ∆G1υ, where υ denotes the reaction
speed. If the affinity of the reactions is defined as A = −(∆G0 +∆G1), and finite time
thermodynamics (FTT) and near-equilibrium irreversible thermodynamics (NEIT) are
used as described in REFERENCE 107, JATP can be redefined as the parabolic function
JATP = r · η · (ηmax − η).
In this parabola η denotes the yield of ATP production per glucose supplied to the
pathway and r the maximum rate of ATP production (FIG. 5.1A).37,107 Therefore any
investment of ATP towards the increase of the production rate necessarily leads to
lower ATP yields (FIG. 5.1B), hence the trade-off.37 This rationale has been extended
to the theory of metabolic pathways. For example the fermentation of glucose involves
high growth rates at the cost of lower yields, whereas the oxidative phosphorylation of
the glucose allows higher yields at the expense of lower growth rates.38 The study of a
trade off between the rate of ATP production and yield therefore gave rise to the study
of a trade off between cell growth rate and yield.
Given the relationship between growth rate and the number of functional ribosomes,
we asked whether or not is it possible that ribosome-binding antibiotics can mediate
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a metabolic trade-off between bacterial growth rate and yield. Our hypothesis is that
these type of antibiotics could lead to slowly dividing, and yet more efficient cells. Data
supporting the previous theories on this topic, however, is scarce.42 First we needed to
validate the hypothesis in the laboratory.
5.2 DIFFERENCES IN RIBOSOMAL CONTENT, MEDIATED BY THE rrn OPERONS,
SHAPE FITNESS LANDSCAPE AND ROBUSTNESS OF METABOLIC RATE-YIELD TRADE-OFF
PROFILES
To quantify metabolic rate-yield trade-offs (RYTOs) we used the derivative strains of E.
coli, described in TABLE 5.1, in cultures grown for 24h. These bacteria were grown in
minimal media with increasing concentrations of glucose, ranging from 0 to 3mg/mL
(0-0.3% w/v), complemented with equally increasing concentration of casamino acids,
from 0 to 0.75mg/mL.
TABLE 5.1. Strains of Escherichia coli used to perform the experiments described in this chapter. All strains from
REFERENCE 41. Number of rrn operons removed from the wild-type strain MG1655 indicated by ∆.
Strain Genotype
E. coli MG1655 K-12 F- λ− ilvF0 rfb-50 rph-1
E. coli ∆1 MG1655 ∆rrnE
E. coli ∆2 MG1655 ∆rrnGB
E. coli ∆3 MG1655 ∆rrnGBA
E. coli ∆4 MG1655 ∆rrnGADE
E. coli ∆5 MG1655 ∆rrnGADEH, ptRNA67
During a 24h period, we measured the optical density at 600nm (OD600) at a
frequency of 20min per readout. We therefore designed an algorithm in Matlab to fit
the mathematical models to cell growth data of the following form:
OD(t ) = a + bt , with r = b/a, (5.1a)
OD(t ) = a + bert , (5.1b)
OD(t ) = a +
K
1 + be−rt
, (5.1c)
where t denotes the time in hours, r the per capita growth rate, K the carrying capacity
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of the culture, a is an estimate of the optical density of the culture at t = 0 and
b a phenomenological coefficient. We used these models because they describe
three possible growth curves that we could observe in the experiment. For example
EQUATION 5.1(a) describes the case in which OD600 does not vary through time due
to the lack of cell growth, or when this is slow enough to be undetectable by our
plate-reader device. The other two models describe the case in which cell growth can
be detected, but it describes different curves. If the growth is slow enough and the
nutrients supplied are not depleted during a 24h period, we expect an exponential-like
growth curve, best described by EQUATION 5.1(b). But if the nutrients are depleted
during this period, after an exponential growth phase, bacteria enter a maintenance
mode in which culture density remains at a stationary level. This case is best described
by EQUATION 5.1(c).
We thus need to select objectively one of these model to extract meaningful informa-
tion from our datasets, so we designed an algorithm to score each model using the
corrected ‘Akaike Information Criterion’ (AICc). The Matlab routines fitlm and fitnlm
provide information about the AICc, where
AIC := N · log *,det *, 1N
N∑
1
ε(t , θN )(ε(t , θN ))T +-+- + 2np +N · (ny · (log(2pi) + 1))
and
AICc := AIC + 2np · np + 1N − np − 1.
Here N denotes the number of values in the estimation dataset, ε(t ) a ny − by − 1
vector of prediction errors, θN the estimated parameters, np the number of estimated
parameters, and ny the number of model outputs. The best model was then defined
as that with the lowest AICc.108 Next, we extracted the corresponding information for
per capita growth rate (r ) and carrying capacity (K ). In cultures grown with 0mg/mL of
glucose we defined, for convenience, that K would be the optical density measured
after the 24h incubation period. Finally we related our dataset for growth rate and
carrying capacity to the concentration of glucose.
FIG. 5.2 shows the relationship between carrying capacity and glucose supplied
to the media. This data is worthy of mention because it contains information on the
rate-yield trade off (the RYTO) we were seeking. The carrying capacity is a measure
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FIGURE 5.2. A) Non-linear, monotonic increase in the carrying capacity, K , shown on the y -axis, as a function of
the concentration glucose of glucose supplied to the media, shown on the x-axis. B) Landscape of possible carrying
capacities as a function of both glucose supplied and copies of the rrn operon. Contour lines show the combination of
glucose and number of rrn operons with identical K .
of the maximal cell density supported by each concentration of glucose. The ratio
between this capacity and glucose thus defines the number of cells produced per unit
of glucose, or yield. A constant yield would mean that the number of cells produced
by unit of glucose does not depend on the latter. If this were the case a straight line
would a good descriptor of our data in FIG. 5.2, but it was not. In fact our data was best
described by the Monod model in which the rate of change in cell density (dB/dt) is
defined as
dB
dt
= B
rmaxC
km +C
where B denotes bacterial cell density, rmax the maximum per capita growth rate,
C the concentration of carbon and km the associated half-saturation constant.109,110
Consequently, we observed that cells grown at higher glucose concentrations had
lower yields. Defining explicitly the yield as the ratio between K and glucose, FIG. 5.3
displays the dependence of yield on glucose concentration for all the strains used. The
maximum yield was achieved with the lowest concentrations of glucose and vice versa.
This transition defined a hyperbolic profile where the lower boundary set a minimum,
limiting yield. FIGS. 5.2 and 5.3 highlight the consistency of the profiles generated
irrespective of the number of rrn operons carried by the different strains. The number
of these operons, however, had subtle effects on how yield changes as a function
of the glucose supplied. We observed that strains with fewer copies of the operons
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normally had higher yields and carrying capacities (FIG. 5.4). The same phenomenon
was reported in the literature as a paradox,111 but it is consistent with the idea that an
excess of synthesis of ribosomes sets a metabolic burden in environment with little
nutrients.112,113 The phenomenon is still poorly understood.
Next we analysed the changes in per capita growth rate as a function of glucose
concentration and observed a concentration at which this growth rate was maximised
(FIG. 5.5). There was a range of concentrations of glucose in which this measure
of growth rate increased with the glucose supplied, but if the glucose was further
increased the growth rate declined, resulting in the aforementioned optimum glucose
supply. We demonstrated that this is consequence of a RYTO by fitting to our data the
model42
Growth rate(S) = c(S) · VmaxS
km + S
where the conversion factor from sugar, S, which is glucose, to biomass, c(S), is given
by
c(S) = clo
S
1 + pS
+ chi
1
1 + pS
.
Here p is a model parameter that controls the rate of decrease in cell yield, c(S), as a
function of increases in sugar, S. The parameters clo and chi are the lowest and highest
yields, respectively, that the model can achieve. In order to turn this yield model into a
growth rate, the value of c(S) is multiplied by an uptake rate of sugar into the cell and
this is taken to be of the standard Monod form, whereby Vmax is the maximal uptake
rate and km is the half-saturation constant associated with that uptake response.
This model of the dependence of yield on glucose was also used to fit the yield data
shown in FIG. 5.3. From FIGS. 5.3 and 5.5 it is clear that the form we presented for
c(S) was consistent with our data for both growth rate and yield. Note that c(S) is
one possible theoretical form of a RYTO and it was derived elsewhere.42 The form of
c(S) is a monotonic function that can either increase or decrease and it describes a
within-strain RYTO in the case whereby it is an decreasing function. FIG. 5.3 shows that
the data was consistent with the decreasing form of this model. Further analysis of our
data also revealed the existence of an optimal number of rrn operons that maximised
both yield and per capita growth rate (FIGS. 5.3B and 5.5B). To highlight this we used
a linear model for the yield (FIG. 5.4) and a non-mechanistic quadratic model for
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FIGURE 5.3. A) Representation of yield, measured as the ratio between K and glucose supplied, on the y -axis and
the glucose supplied to the media, on the x-axis. The decrease in yield as a function of glucose supplied describes a
hyperbola that is consistent with formerly hypothesised RYTOs based on a branched pathway, each branch leading to
different yields.42,114 B) Upon variation in environmental conditions, here in glucose supplied, the relative maximum
yield (green, strains in black) is achieved by strains with different number of rrn operons. Per-strain hyperbola, as
formalised in p. 97, shown in grey. C) Landscape of possible yields achieved as a function of the glucose supplied and
the number of rrn operons. Contour lines show the combination of glucose and number of rrn operons with identical
yield.
per capita growth rate (FIG. 5.6). The dataset presented in FIG. 5.6 resembles the
prediction of a theory115 in which bacterial growth rate depends on the abundance of
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FIGURE 5.4. Representation of the change in yield, shown on the y -axis, as a function of the number of rrn operons.
Each subplot shows this relationship when different concentrations of glucose is supplied of the media. Overall, there
is a linear, significant increase in yield as the number of rrn operons is reduced when the concentration of glucose is
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FIGURE 5.5. A) Change in per capita growth rate, shown on the y -axis, as a function of the glucose supplied to the media,
on the x-axis. We modified Monod’s growth model (in black, see p. 97) to include, explicitly, the glucose-dependence
property of the yield. We observed an absolute, overall optimum per capita growth rate at ≈0.5 mg/mL of glucose.
B) Upon variation in environmental conditions, here in glucose supplied, the relative maximum per capita growth rate
(green, strains in black) is achieved by strains with different number of rrn operons. Per-strain hyperbola, as formalised
in p. 97, shown in grey. C) Landscape of possible per capita growth rates achieved as a function of the glucose supplied
and the number of rrn operons. Contour lines show the combination of glucose and number of rrn operons with identical
yield.
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FIGURE 5.6. Representation of the change in per capita growth rate, shown on the y -axis, as a function of the number
of rrn operons. Each subplot shows this relationship when different concentrations of glucose is supplied of the media.
We compared whether the change in per capita growth rate is linear (light grey) or non-linear (black). We tested the
non-linearity of the data by fitting the quadratic model r (G) = a + b ·G + b ·G2 to the data. Here r denotes per capita
growth rate, G the concentration of glucose, a per capita growth rate when G = 0, and b and c phenomenological
coefficients.
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FIGURE 5.7. Left) Relationship between the per capita growth rate, measured as doublings per hour on the y-axis, and
yield, defined as cell density in OD units generated per mg of glucose after 24h of growth, on the x-axis. The black
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ribosomes as it follows:
Growth rate(S) =

φmaxR − φminR
1/γ + 1/ν
 SKm + S
Where the growth rate is a parabolic function of the ribosomal fraction (φR), controlled
by us through the rrn operons, provided the translation efficiency (γ) and yield (ν) are
constant. The differences between FIG. 5.6 and this theory may lie in the fact that
yield can be a function of the abundance of resources, as we will demonstrate in this
chapter (FIG. 5.3).
Following this analysis we were able to compare changes in per capita growth rate
as a function of the yield (FIG. 5.7). Overall, the data described a parabolic profile
which resembled the expectations from the theories introduced at the beginning of
this chapter (FIG. 5.1A). Including the information about glucose supply in each case,
we distinguished three phases in our RYTO dataset also predicted by the models.
First there was a rate-yield trade-off (RYTO) with very low concentrations of glucose,
whereby increases in yield necessarily involved a decrease in per capita growth rate,
and vice versa. On the other hand, a decline in per capita growth rate was coupled
with a decrease in yield with high glucose supply. This therefore described a rate-
yield trade-down (RYTD). Growth rate and yield could also be uncoupled when the
concentration of glucose was in between the previous extreme cases.
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FIGURE 5.8. Relationship between the per capita growth rate, measured as doublings per hour on the y -axis, and
yield, defined as cell density in OD units generated per mg of glucose after 24h of growth, on the x-axis. Each subplot
represents this relationship for every strain, and hereby demonstrates the robustness of this RYTO.
The shape of the general RYTO profile was maintained in all the strains used except
for the one with the fewest ribosomal RNA operons, ∆5, this showed the remarkable
robustness of the relationship between growth rate and yield (FIG. 5.8). We later
asked whether or not the differences in yield and per capita growth rate due to loss
of rrn operons could lead to between-strains RYTOs. FIG. 5.9 highlights the difficulty
of studying between-strain trade-offs. Whilst we have a good understanding of the
within-strain RYTO/RYTD, it was difficult to discern the existence of a self-consistent
set of trade-offs, or trade-downs, from the data presented in FIG. 5.9. The statements
that can be made from linear regression analyses, as to the presence or absence of a
between-strain trade-off, were sensitive to the algorithms used due to the presence of
potential outliers.
Moreover, there is no theory of how a rate-yield trade-off would be mediated by
the number of ribosomal RNA operons. As a consequence, as of yet we have no
understanding of what mechanisms support the data presented in FIG. 5.9.
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FIGURE 5.9. Relationship between the per capita growth rate, measured as doublings per hour on the y -axis, and
yield, defined as cell density in OD units generated per mg of glucose after 24h of growth, on the x-axis. Each subplot
represents this relationship as a function of the number of rrn operons and glucose supply.
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5.3 ROBUSTNESS OF THE RYTO TO DIFFERENT MEASUREMENTS OF GROWTH RATE
Whilst the definition of cell yield is straightforward, the definition for growth rate can
be subject to some interpretation. The above analysis is based on per capita growth
rates, defined as the number of estimated cell divisions per unit of time per capita.
This estimation assumes a density-dependent growth rate, but we could also have
quantified the growth rate in ecological terms using finite difference approximations
applied directly to OD data. These approximations quantify differences in optical density
as a function of time, using a mathematical model-free estimate of the culture growth
rate. We therefore note the rate of change in OD as a function of time, written OD′(t ),
as being
OD′(t ) =
ODt+∆t −ODt
∆t
where ∆t is the read frequency in hours. The maximum growth rate of the culture, rmax ,
is defined as
rmax = max
0≤t≤24h
OD′(t ).
The parameter rmax is expressed as the maximum increase in OD600 units per hour.
In FIG. 5.5 we quantified how the per capita growth rate parameter, taken from the
logistic model in EQUATION 5.1c, has an absolute maximum at a specific concentration
of glucose and, if the glucose was further increased, the growth rate declined. We
demonstrated that this observation is consistent with a non-constant yield. However, if
we quantify the growth rate differently (rmax ) the resulting dataset is no longer consistent
with a non-constant yield. In fact, it is consistent with Monod’s original growth model,
which assumes a constant yield (FIG. 5.10). The relationship of other parameters with
the abundance of rrn operons also applies here and fewer operons lead to higher rmax .
Consequently, the relationship between rmax and yield did not resemble a parabola,
as shown in FIG. 5.7. We did observe a trade-off between rmax and yield, but the profile
generated had different properties, the most significant being the lack of trade-down
between rate and yield when the glucose supplied was high. Thus, this profile is not
compatible with the theories introduced in this chapter (FIG. 5.1). It is, nevertheless,
compatible with the analogue from physics known as ‘maximum power transfer theo-
rem’. The use of this theorem in biology defined the ‘maximum power principle’,116,117
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which proposes that open, self-organised systems tend to operate with an efficiency
that maximises the useful power or biomass production.37,117
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FIGURE 5.10. A) Culture growth rate, rmax , shown on the y -axis as a function of glucose supply, shown on the x-axis.
The black line represents the overall growth rate as predicted by Monod’s growth, as opposed to that predicted per strain,
represented in B).
If we consider the yield (y) to be a proxy for growth efficiency, the production of
biomass (P) in our cultures can be estimated as P = rmax · y .37,117 Thus the production
of biomass reflects the number of cells produced by each cell per hour, per unit of
glucose. The resulting dataset reflects the existence of a production-efficiency trade-off
(PETO, FIG. 5.11). The profile described by the PETO contained all the properties
that we previously described for a RYTO (FIG. 5.7): three different phases leading to a
trade-off, trade-down, independence of power and yield as a function of the glucose
supplied. Also, we observed the effect of the abundance of ribosomal RNA whereby
fewer rrn operons led to higher production of biomass, likely due to a reduction of
the metabolic burden caused by the synthesis of ribosomal proteins in conditions of
low nutrients.112,113 We do not have a theory to explain the existence of a PETO, so
we used a non-mechanistic quadratic model to detect whether or not the relationship
between biomass production and yield conforms a parabola.
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FIGURE 5.11. A) Relationship between the population growth rate, rmax , shown on the y -axis, and yield on the x-axis.
The size of the data points is indicative of the number of rrn operons, from seven copies in the wild-type strain MG1655
(labelled WT) to just two copies in the strain with five deletions, ∆5.Relationship between power output,37 shown on
the y -axis, and yield, on the x-axis. The black line represents the quadratic model P (Y ) = a+ b · Y + b · Y 2, P denoting
the power output, Y the yield, a the growth rate when y = 0, and b and c phenomenological coefficients. The 95%
confidence for a is (-0.003, 0.0004), for b (0.042, 0.086), and for c (-0.220, -0.110). The trend is analogous to that
observed in FIG. 5.7.
5.4 CONTRIBUTION OF EACH rrn OPERON TO THE YIELD
The wild-type strain of E. coli used in this chapter, MG1655, contained seven rrn
operons.101,102 Until now the yield has been defined in absolute terms as OD600 units
produced per mg of glucose. However, this definition does not account for differences
in the abundance of ribosomal RNA operons. Now, we defined the yield per operon, or
relative yield, as the ratio between the yield and the number of rrn operons present in
each strain.
If FIG. 5.3 showed the existence of a negative correlation between ribosomal RNA
abundance and absolute yield, this correlation was maintained when yield per operon
was used (FIG. 5.12). Also, the use of relative yield to quantify RYTOs resulted in the
aggregation of the data in two separate clusters which are characterised by the number
of rrn operons (FIG. 5.13). Strains with three to seven operons were contained within
one cluster, whereas the strain with two operons was contained in the other. These
clusters are also characterised by different combinations of per capita growth rate and
relative yield. The first cluster contained strains with lower relative yields than those
in the second cluster, which contained strains with lower per capita growth rates. We
observed no change in the existence, or lack of thereof, between-strains RYTOs (FIG.
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FIGURE 5.12. Relative yield, defined as OD units generated per mg of glucose per rrn operon, is shown on the y -axis
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5.14).
For completeness we repeated the analysis of the RYTOs using rmax to estimate
the growth rate and relative yield (FIG. 5.15). The use of relative yield did not produce
qualitative changes in the profiles observed previously.
0 0.05 0.1 0.15
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
G
ro
wt
h 
ra
te
 (D
ou
bli
ng
s ⋅
 
h−
1 )
OD per mg of glucose per rrn operon
 
 
WT
∆5
WT (7 x rrn)
∆1 (6 x rrn)
∆2 (5 x rrn)
∆3 (4 x rrn)
∆4 (3 x rrn)
∆5 (2 x rrn)
Quadratic fit
Glucose (mg/mL)
0 0.125 0.25 0.5 0.75 1 2 3
FIGURE 5.13. Shape of the RYTO profile when relative yields are taken into account. The strains containing seven to
three rrn are clustered within a group with high per capita growth rate but low relative yield, whereas the strain with
two rrn operons, ∆5, forms a second cluster characterised by lower per capita growth rates and higher yields. Black
lines correspond to the estimation from a quadratic model. Regression for the wild-type (WT): R2 = 0.56, F-statistic
versus constant model: 11.7, p = 0.000562. Regression for ∆5: R2 = 0.27 , F-statistic versus constant model: 3.44,
p = 0.0541.
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FIGURE 5.16
1 1 0 C H A P T E R V
5.5 CONCLUSIONS
During this chapter we analysed the relationship existing between growth rate and
biomass yield. We observed that these traits can be positively or negatively correlated
depending on the abundance of a carbon source, like glucose, generating a parabolic
profile. The phenomenon is due to the existence of branched metabolic pathways
whereby a carbon source, glucose, is processed with different efficiencies that we
quantified as culture OD per mg of glucose supplied (yield).
When the efficient branch of the pathway is being used we found that growth
rate and yield are negatively correlated, whereas if the inefficient pathway is being
used these traits are positively correlated. This means that if one of the traits is
manipulated, say by the addition of an growth-inhibitor antibiotic, the yield could
change accordingly depending on whether the cells are using the efficient or inefficient
pathway. In CHAPTER 2, for example, we observed how the rate of production of AcrB,
component of the multi-drug efflux pump AcrAB-TolC, is reduced by a protein synthesis
inhibitor antibiotic (FIG. 2.15). However, the total amount of protein produced per cell
(therefore total efflux pumps per cell) was higher until the concentration of the antibiotic
was too high.
Finally we found this phenomenon to be robust not only to artificial changes in
growth rate and yield, through the manipulation of the ribosomal RNA rrn copy number,
but also to how growth is measured. Whether is per capita growth rate or biomass
production, the parabola is maintained.
VI C O N C L U D I N G R E M A R K S
6.1 EVOLUTIONARY LANDSCAPES
One of the central themes in evolutionary biology has been the notion of an evolutionary
landscape118. Such landscapes are based on the idea that absolute fitness can be
represented, typically on a Cartesian z-axis, as a function of two constraining traits
on the x- and y-axes. In this thesis we provide data for two types of evolutionary
landscapes.
In CHAPTER 2 we provided datasets that showed the adaptive strength of the
bacterium Escherichia coli growing in the presence of the antibiotic erythromycin
(FIGURES 2.21 to 2.19). Motivated by a theoretical model, the sensitivity to erythromycin
was quantified over a 24h incubation period and we demonstrated that such sensitivities
can change through time. This change can have different causes but in our case this
is determined by the efflux pump AcrAB-TolC. Originally used for the evacuation of
metabolic byproducts, this pump is recycled by the cell very rapidly to remove molecules
of antibiotic.
The representation of the rate of adaptation (α) in FIGURES 2.24 to 2.26 highlighted
an evolutionary landscape in which very specific concentrations of erythromycin were
able to maximise selection on this efflux pump (evolutionary ‘hotspot’) but other concen-
trations were able to diminish the cell’s capacity to adapt (evolutionary ‘coldspot’). None
of these spots were related to the minimum inhibitory concentration (MIC) as previously
suggested elsewhere,17,18. Moreover, we also saw that the strength of selection on
resistance can be a non-linear and non-monotone function of the dose.
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We also presented another type of landscape. In CHAPTER 5 we showed a fitness
landscape in which we could read the dependence of fitness, as per capita growth
rate, not only on a mutable genetic element but also on the environment (FIG. 5.5C).
The data indicated that different environments had different fitness landscapes associ-
ated with them. It also indicated that a different genotype could be optimal for each
environment regardless of how optimality is interpreted, whether with respect to yield
(FIG. 5.3B) or growth rate (FIG. 5.5B). If we imagine selection, or indeed some form of
historical selection, acting upon copy number variants of the rrn operon, we can use
this representation of our data to tentatively hypothesise a reason why bacteria might
have different numbers of these operons.
According to our data, this number would depend on the glucose concentration of
the environment. For example, FIG. 5.3B predicted that strains ∆1 and ∆4 had the
optimal number of operons in environments where yield is a good predictor of fitness,
depending on the availability of carbon in the environment. On the other hand, FIG.
5.5B showed that ∆3,∆4 and ∆ had the optimal number of operons for growth rate
depending on the availability of carbon in the environment.
We further hypothesised that in environments whereby extracellular resources like
glucose fluctuate in a seasonal manner, the resulting fluctuating selection might act
to support a polymorphism on the number of operons which may allow, for example,
∆3,∆4 and ∆5 to be stably maintained in the same polymorphic community. We have
not, however, tested this prediction.
6.2 ROBUSTNESS OF ANTIBIOTIC SENSITIVITY TESTS
Considering the capacity of bacterial cells to adapt, it seems hard to believe that the
optimal control of such a dynamic system can be achieved by constant, non-responsive
control strategies such as those suggested by ASTs.11 For example, the optimal
inhibiting concentration of erythromycin for the wild-type strain AG100 was ∼37µg/mL,
as we described in CHAPTER 2. This concentration, optimal for a 24h incubation
period, became sub-optimal after three days of treatment due to the duplication and
selection of the multi-drug efflux pump AcrAB-TolC. Although ours was a laboratory
setup, similar changes in sensitivity during antibiotic therapies has also been reported
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in the clinic.119–121
But time was not the only factor altering the outcome of ASTs. We also demonstrated
the role of competitors for resources and how these may sensitise, or otherwise,
bacterial cells. The result of this ‘sensitising’ process would depend on the competitor’s
own sensitivity to the antibiotic. When two competing bacteria were equally sensitive to
an antibiotic they could appear more resistant to the drug when they are grown together
(FIG. 3.2). However, if each of them are differentially drug-sensitive competitors, the
most sensitive competitor appears to be additionally sensitised (FIGURES 3.1, 3.9, and
3.10). For this latter case, the effect is maintained through time (FIGURES 3.15 and
3.12).
We therefore hypothesise, tentatively, that appropriately engineered non-pathogenic
cells, merely acting as resource thieves, or ‘niche occupiers’, might be used to sensitise
pathogenic cells in combination with antibiotics in vivo.
6.3 IN SPATIALLY DISTRIBUTED CULTURES, THE NON-LINEAR SELECTION ON ACRAB-TOLC
IS MANIFESTED AS BULLSEYE PATTERNS
We have used a prediction from the results of several theoretical models to show that
bacterial growth in an antibiotic gradient can result in a visible spatial pattern, moreover
this pattern can be used to reject the hypothesis that more antibiotic necessarily
equates to less bacterial population growth also in a spatial context.
The laboratory model system we have used is not based on the occurrence of single
nucleotide polymorphisms (SNPs) as the drivers of the evolutionary processes that
produce this spatial pattern, but rather a drug efflux operon that is rapidly duplicated by
recombination in the face of antibiotic stresses is the mechanism of resistance selected
for by evolution. It is selection on this operon that creates the requisite spatial pattern.
Moreover, we have introduced a series of quantitative measures of monotonicity to
help discern in quantitative terms what is apparent to the human eye in images of
bacterial growth on agar plates in antibiotic gradients.
Our results are not directly relevant to the interpretation of antibiograms in a clinical
context, although we have shown that an increase in drug dosage increases the size
of the zone of bacterial growth inhibition according to a square root law, consistent
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with diffusion theoretic models of bacterial killing. However, our observations are
key to understanding conditions for which an increase in drug concentration will not
necessarily reduce bacterial densities. After all, all practical uses of antibiotics create
decaying dose profiles as one moves further way from the point source of an antibiotic
drug. So, while it may be thought that one can mitigate, or even obviate, the process
of selection for drug resistance by always passing to ever greater dosages,1,122 those
dosages must eventually decay to zero in regions of treatment located not too far from
the source whereby one might be able to observe the effects we allude to in our study.
S U P P L E M E N TA RY D ATA
I SUPPLEMENTARY CHAPTER 2
I.1 Model fit. This chapter includes the plots that we used to visually validate the
fitting process described in SECTION 2.7. We denoted the readings as a function of
time as R(t ), and fitted the following models to our data using a routine coded using
Matlab (see below)
R(t ) = R0 + bt , with r = b/R0, (S.1a)
R(t ) = R0 + brt , (S.1b)
R(t ) = R0 +
K
1 + b · e−rt . (S.1c)
Here R0 denotes the readings at the beginning of the experiment, r per capita growth
rate, K the carrying capacity, and b a phenomenological coefficient. We considered
the best model to be that with the lowest corrected Akaike Information Criterion (AICc).
FIGURES S.1 to S.8 show a comparison between raw data, and prediction from the
best model.
I.2 Routine code and raw data.
I.2.1 Calculate growth rates.
1 function [AUC, Beta, YPred] = FitData(Data, B)
2 % Beta(Blank, coeff, r, r_diff, G, Data(24h));
3 warning(’off’);
4 i = length(Data);
5 x = 24*(i:(n-1))/(n-1); % This transform time to h.
6 y = Data;
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7
8 %% Fit models!
9 try
10 % Constant model
11 mdl_C = fitlm(x,y); % y = blank + r*t (r DEPENDS ON UNITS OF Y-AXIS!)
12 param_C = abs(mdl_C.Coefficients.Estimate);
13 AIC_C = mdl_C.ModelCriterion.AICc;
14 Rsq_C = mdl_C.Rsquared.Adjusted;
15 YPred_C = mdl_C.Fitted;
16 % Compute duplication time as r/blank = 1/t
17 param_C(3) = str2num(sprintf(’%.3f’, param_C(2))) / str2num(sprintf(’%.3f’, param_C(1))); % r =
divisions per timeunit (1/h)
18 catch
19 AIC_C = NaN;
20 Rsq_C = NaN;
21 disp(’NaNs found in Linear Model.’);
22 end
23
24 try
25 % Exponential model (nested constant model)
26 B_e = B(1:3)/1;
27 modelfun_E = @(b,X)(abs(b(1)) + abs(b(2)) * exp(X*abs(b(3))));
28 mdl_E = fitnlm(x,y,modelfun_E, B_e);
29 param_E = abs(mdl_E.Coefficients.Estimate);
30 AIC_E = mdl_E.ModelCriterion.AICc;
31 Rsq_E = mdl_E.Rsquared.Adjusted;
32 YPred_E = mdl_E.Fitted;
33 catch
34 AIC_E = NaN;
35 Rsq_E = NaN;
36 disp(’NaNs found in Exponential Model.’);
37 end
38
39 try
40 % Logistic model (nested constant model)
41 modelfun_L = @(b,X)(abs(b(1)) + abs(b(4)) ./ (1 + abs(b(2))*exp(-X*abs(b(3)))));
42 mdl_L = fitnlm(x,y,modelfun_L, B);
43 param_L = abs(mdl_L.Coefficients.Estimate);
44 AIC_L = mdl_L.ModelCriterion.AICc;
45 Rsq_L = mdl_L.Rsquared.Adjusted;
46 YPred_L = mdl_L.Fitted;
47 catch
48 AIC_L = NaN;
49 Rsq_L = NaN;
50 disp(’NaNs found in Logistic Model.’);
51 end
52
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53 % Which is more accurate?
54 [AIC_Crit, ~] = min([AIC_C, AIC_E, AIC_L]);
55
56 % Select the appropriate model:
57 if AIC_Crit == AIC_C
58 Param = param_C; % Param(Blank, r)
59 YPred = YPred_C;
60 FitName = ’Linear Fit’;
61 elseif AIC_Crit == AIC_E
62 Param = param_E; % Param(Blank, Lambda, r)
63 YPred = YPred_E;
64 FitName = ’Exponential Fit’;
65 elseif AIC_Crit == AIC_L
66 Param = param_L; % Param(Blank, C, r, K)
67 YPred = YPred_L;
68 FitName = ’Logistic Fit’;
69 end
70
71 % Sort out parameters.
72 Timestep = 1/3; % h;
73 Param(1) = YPred(1);
74 Param(5) = max(diff(YPred(15:end)) ./ Timestep); % Growth rate (/h): Euler Method
75 AUC = YPred(end) ./ trapz(x, YPred); % Growth rate (1/h): AUC Method.
76 Param(6) = YPred(end); % Yield after 24h.
77
78 warning(’on’);
79 end
I.2.2 Calculate AcrB-sfGFP up-regulation rate.
1 function [AUC, Param, YPred] = PumpRegulation(Data, B)
2 % B(K, c, r, B0, r_diff, G, Data(24h));
3 warning(’off’);
4
5 n = length(Data);
6 x = 24*(0:(n-1))/(n-1);
7 y = Data;
8
9 %% Fit models!
10 try
11 % Constant model
12 mdl_C = fitlm(x,y); % y = blank + r*x
13 param_C = abs(mdl_C.Coefficients.Estimate); % Growth rate: estimated from data.
14 AIC_C = mdl_C.ModelCriterion.AIC;
15 YPred_C = mdl_C.Fitted;
16 % Compute duplication time as r/blank = 1/t
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17 param_C(3) = str2num(sprintf(’%.3f’, param_C(2))) / str2num(sprintf(’%.3f’, param_C(1))); % r =
divisions per timeunit (1/h)
18 catch
19 AIC_C = NaN;
20 disp(’NaNs found in Linear Model.’);
21 end
22
23 try
24 % DownUp model
25 modelfun_L = @(b,X)(abs(b(4)) + abs(b(5))*exp(-X*abs(b(6))) + abs(b(1)) ./ [1 + abs(b(2))*exp(-X*abs(b
(3)))]) ;
26 mdl_L = fitnlm(x,y,modelfun_L, B);
27 param_L = abs(mdl_L.Coefficients.Estimate);
28 AIC_L = mdl_L.ModelCriterion.AIC;
29 YPred_L = mdl_L.Fitted;
30 catch
31 AIC_L = NaN;
32 disp(’NaNs found in Logistic Model.’);
33 end
34
35 % Which is more accurate?
36 [AIC_Crit, AIC_idx] = min([AIC_C, AIC_L]);
37
38 % Select the appropriate model:
39 if AIC_Crit == AIC_C
40 Param = param_C; % Param(Blank, r)
41 YPred = YPred_C;
42 Param(3) = Param(2); % For convenience: r always 3rd item.
43 FitName = ’Linear Fit’;
44 elseif AIC_Crit == AIC_L
45 Param = param_L; % Param(Blank, C, r, K)
46 YPred = YPred_L;
47 FitName = ’DownUp Fit’;
48 end
49
50 % Sort out parameters.
51 Timestep = 1/3; % h;
52 Param(4) = YPred(1);
53 Param(7) = max(diff(YPred) ./ Timestep); % Growth rate (OD/h): Euler Method
54 AUC = YPred(end) ./ trapz(x, YPred); % Growth rate (1/h): AUC Method
55
56 warning(’on’);
57 end
I.2.3 Implementation of mathematical model.
1 % Main function
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2 function [timeOut,stateOut] = NonMonotoneDR(parameters,IC)
3 if nargin == 1
4 IC = parameters.initialCondition;
5 end
6
7 timeOut = [];
8 stateOut = [];
9
10 for days = 1:parameters.days
11 [times,states] = SolveMdl(parameters, IC);
12
13 IC = states(end,:);
14
15 IC(1) = parameters.SZero;
16 IC(2) = parameters.AInitial;
17 IC(3) = parameters.BInitial;
18
19 dilution = parameters.dilution*parameters.dilRatios(days);
20
21 IC(parameters.cells) = IC(parameters.cells)*dilution;
22 IC(parameters.internalA) = IC(parameters.internalA)*dilution;
23 IC(parameters.internalB) = IC(parameters.internalB)*dilution;
24
25 timeOut = [timeOut ; parameters.Time*(days-1) + times];
26 stateOut = [stateOut ; states];
27 end
28
29 end
30
31
32 % Call ode15s solver
33 function [t,state] = SolveMdl(parameters,IC)
34 %Solve Model
35 if nargin == 1
36 IC = parameters.initialCondition;
37 end
38 refine = 4;
39 options = odeset(’NonNegative’,ones(size(IC)),’RelTol’,1e-10,’Refine’,refine);
40 [t,state] = ode15s(@(t,y)Mdl(parameters, y),[0 parameters.Time],IC, options);
41 end
42
43
44 % Inhibition function (Gamma(A))
45 function gamma = gamma(parameters,A)
46 gamma = 1./(1 + parameters.ka*A);
47 end
48 % Transported sugar uptake function
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49 function uptakeRate = uptakeRate(parameters,S)
50 uptakeRate = S.*parameters.Vmax./(S+parameters.K);
51 end
52 % Growth function
53 function Gvector = Growth(parameters,S,A)
54 Gvector = parameters.conversion*uptakeRate(parameters,S).*gamma(parameters,A);
55 end
56 % Protein production function
57 function p = P(parameters,j)
58 p = j./(1+parameters.g * j);
59 %one gene means one protein, with diminishing returns:
60 p = p/p(1);
61 p = p - 1;
62 end
63 % Efflux function
64 function eff = Efflux(parameters,i,v,k)
65 Q = P(parameters,i);
66 eff = v*Q./(k+Q);
67 end
68
69
70 % Model
71 function newState = Mdl(parameters, state)
72
73 Phi = parameters.Phi;
74 Delta = parameters.Delta;
75 delta = parameters.delta;
76 decayA = parameters.decayA;
77
78 Nd = parameters.Ndims;
79
80 S = state(1);
81 a = state(2);
82
83 Aj = state(4:Nd+3);
84 ej = state((2*Nd+4):(3*Nd+3));
85
86 I = 1:Nd;
87 EffluxPump = Efflux(parameters,I’, parameters.Va, parameters.Ka) ;
88 Gvector = G(parameters, S, Aj(2:end-1));
89
90 dSdt = -uptakeRate(parameters,S)*sum(ej);
91 dadt = -a*decayA + Phi*(sum(ej.*(Aj - a))) + sum(EffluxPump.*Aj.*ej);
92
93 dAjdt = -Aj*decayA + Phi*ej.*(a - Aj) - EffluxPump.*Aj.*ej;
94
95 de1dt = G(parameters, S, Aj(1))*ej(1) - Delta*ej(1) + Delta*(1+delta)*ej(2);
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96 deNdt = G(parameters, S, Aj(end))*ej(end) - Delta*(1+delta)*ej(end) + Delta*ej(end-1);
97
98 dejdt = Gvector.*ej(2:end-1) - Delta*((2+delta)*ej(2:end-1) - ej(1:end-2) - (1+delta)*ej(3:end));
99
100 newState = [dSdt ; dadt ; dbdt ; dAjdt ; dBjdt ; de1dt ; dejdt ; deNdt];
101
102 end
I.2.4 Raw data.
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FIGURE S.1. Growth profiles for E. coli AG100 based on OD600 measured every 20min (1/3h), for 24h, during 7 days.
Each subplot contains the growth profile of eight replicates as a function of time, and as a function of the dose of
erythromycin (columns). The different rows show the fit, and the data for different days ranging from days 1 to 7. We
used the degree of overlap of the data (grey) and the model (blue) to validate the appropriateness of the models that we
used to calculate the growth rate in each case.
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FIGURE S.2. Growth profiles for E. coli AG100-A based on OD600 measured every 20min (1/3h), for 24h, during 7
days. Each subplot contains the growth profile of eight replicates as a function of time, and as a function of the dose
of erythromycin (columns). The different rows show the fit, and the data for different days ranging from days 1 to 7. We
used the degree of overlap of the data (grey) and the model (blue) to validate the appropriateness of the models that we
used to calculate the growth rate in each case.
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FIGURE S.3. Growth profiles for E. coli TB108 based on OD600 measured every 20min (1/3h), for 24h, during 7 days.
Each subplot contains the growth profile of eight replicates as a function of time, and as a function of the dose of
erythromycin (columns). The different rows show the fit, and the data for different days ranging from days 1 to 7. We
used the degree of overlap of the data (grey) and the model (blue) to validate the appropriateness of the models that we
used to calculate the growth rate in each case.
C O N C L U D I N G R E M A R K S 1 2 5
0
0.
2
0.
4
0.
6
nGFP (RFU)
Day 1
0µ
/m
L 
Er
y
 
 
TB
10
8
M
od
el
 F
it
5µ
/m
L 
Er
y
10
µ/
m
L 
Er
y
15
µ/
m
L 
Er
y
20
µ/
m
L 
Er
y
25
µ/
m
L 
Er
y
30
µ/
m
L 
Er
y
35
µ/
m
L 
Er
y
40
µ/
m
L 
Er
y
45
µ/
m
L 
Er
y
50
µ/
m
L 
Er
y
0
0.
2
0.
4
0.
6
nGFP (RFU)
Day 2
0
0.
2
0.
4
0.
6
nGFP (RFU)
Day 3
0
0.
2
0.
4
0.
6
nGFP (RFU)
Day 4
0
0.
2
0.
4
0.
6
nGFP (RFU)
Day 5
0
0.
2
0.
4
0.
6
nGFP (RFU)
Day 6
5
10
15
20
0
0.
2
0.
4
0.
6
nGFP (RFU)
Day 7
Ti
m
e 
(h)
5
10
15
20
Ti
m
e 
(h)
5
10
15
20
Ti
m
e 
(h)
5
10
15
20
Ti
m
e 
(h)
5
10
15
20
Ti
m
e 
(h)
5
10
15
20
Ti
m
e 
(h)
5
10
15
20
Ti
m
e 
(h)
5
10
15
20
Ti
m
e 
(h)
5
10
15
20
Ti
m
e 
(h)
5
10
15
20
Ti
m
e 
(h)
5
10
15
20
Ti
m
e 
(h)
FIGURE S.4. Growth profiles for E. coli TB108 based on normalised fluorescence (nGFP) measured every 20min (1/3h),
for 24h, during 7 days. Each subplot contains the growth profile of eight replicates as a function of time, and as a function
of the dose of erythromycin (columns). The different rows show the fit, and the data for different days ranging from days
1 to 7. We used the degree of overlap of the data (grey) and the model (blue) to validate the appropriateness of the
models that we used to calculate the growth rate in each case.
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FIGURE S.5. Growth profiles for E. coli TB108 based on relative fluorescence per OD600 unit (nGFP · OD−1) measured
every 20min (1/3h), for 24h, during 7 days. Each subplot contains the growth profile of eight replicates as a function of
time, and as a function of the dose of erythromycin (columns). The different rows show the fit, and the data for different
days ranging from days 1 to 7. We used the degree of overlap of the data (grey) and the model (blue) to validate the
appropriateness of the models that we used to calculate the growth rate in each case.
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FIGURE S.6. Growth profiles for E. coli eTB108 based on OD600 measured every 20min (1/3h), for 24h, during 7 days.
Each subplot contains the growth profile of eight replicates as a function of time, and as a function of the dose of
erythromycin (columns). The different rows show the fit, and the data for different days ranging from days 1 to 7. We
used the degree of overlap of the data (grey) and the model (blue) to validate the appropriateness of the models that we
used to calculate the growth rate in each case.
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FIGURE S.7. Growth profiles for E. coli eTB108 based on normalised fluorescence (nGFP) measured every 20min
(1/3h), for 24h, during 7 days. Each subplot contains the growth profile of eight replicates as a function of time, and as
a function of the dose of erythromycin (columns). The different rows show the fit, and the data for different days ranging
from days 1 to 7. We used the degree of overlap of the data (grey) and the model (blue) to validate the appropriateness
of the models that we used to calculate the growth rate in each case.
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FIGURE S.8. Growth profiles for E. coli eTB108 based on relative fluorescence per OD600 unit (nGFP · OD−1) measured
every 20min (1/3h), for 24h, during 7 days. Each subplot contains the growth profile of eight replicates as a function of
time, and as a function of the dose of erythromycin (columns). The different rows show the fit, and the data for different
days ranging from days 1 to 7. We used the degree of overlap of the data (grey) and the model (blue) to validate the
appropriateness of the models that we used to calculate the growth rate in each case.
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I.3 Rate of adaptation (α): robustness. The following plots show the rate of
adaptation (α, see SECTION 2.3), per replicate, measured using per capita growth rate
(here labelled as ‘fit’), finite difference approximation (labelled as ‘re’), and area under
the curve (labelled AUC).
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FIGURE S.9. Adaptive landscapes for E. coli AG100 according to the best model fit (left), finite difference approximation
(centre), and area under the curve (right). The analysis reflects the robustness of the existence, and location of the
evolutionary ‘coldspots’ and ‘hotspots’ as a function of the dose of erythromycin. The colorbar indicates the rate of
adaptation, black being the lowest rate of adaptation and white being the highest.
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FIGURE S.10. Adaptive landscapes for E. coli AG100-A according to the best model fit (left), finite difference approxi-
mation (centre), and area under the curve (right). The analysis reflects the robustness of the existence, and location of
the evolutionary ‘coldspots’ and ‘hotspots’ as a function of the dose of erythromycin. The colorbar indicates the rate of
adaptation, black being the lowest rate of adaptation and white being the highest.
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FIGURE S.11. Adaptive landscapes for E. coli TB108 according to the best model fit (left), finite difference approximation
(centre), and area under the curve (right) based on readings for OD600 (A), normalised fluorescence (B), and relative
fluorescence per OD600 unit (C). The analysis reflects the robustness of the existence, and location of the evolutionary
‘coldspots’ and ‘hotspots’ as a function of the dose of erythromycin. The colorbar indicates the rate of adaptation, black
being the lowest rate of adaptation and white being the highest.
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FIGURE S.12. Adaptive landscapes for E. coli eTB108 according to the best model fit (left), finite difference approx-
imation (centre), and area under the curve (right) based on readings for OD600 (A), normalised fluorescence (nGFP,
B), and relative fluorescence per OD600 unit (C). The analysis reflects the robustness of the existence, and location of
the evolutionary ‘coldspots’ and ‘hotspots’ as a function of the dose of erythromycin. The colorbar indicates the rate of
adaptation, black being the lowest rate of adaptation and white being the highest.
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I.4 Oscillations in fluorescence readings: Discrete Fourier Transform. We a
Fourier analysis on the data shown in FIGURES 2.15 and S.8 to answer whether, or not,
the oscillations observed have a biological origin. We computed the discrete Fourier
transform of our dataset using the fft function as implemented in Matlab 2014a.
Represented in FIG. S.13 we show the existence of two main oscillations taking
place, at different frequencies, during our experiment. The first has the highest intensity
and occurs at a frequency of ∼10h (∼0.1 peaks per hour). This corresponds with the
up-regulation of the AcrAB-TolC efflux pump. The second has a lower intensity, and
occurs at a frequency of ∼3/4 of an hour.
We compared the spectra so-represented with that of the inocula-free culture condi-
tion (negative control, FIG. S.14). Here we do not observe the first, intense oscillation
but we do observe the second. Given the absence of cells in this condition, we must
conclude that these small oscillations are mechanically produced by our microplate
reader and not by the subtle regulation of the AcrAB-TolC efflux pump.
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FIGURE S.13. Fast Fourier transform (FFT) spectra for E. coli eTB108. The frequency of the oscillations is shown on
the x-axis and the energy of such oscillations on the y-axis. Each column represents the FFT for the data measured in
different days, in different concentrations of erythromycin (here shown in rows). A feature is shared overall: a peak every
∼3/4 of an hour. This feature corresponds to the small oscillations observed in FIGURES 2.15 and S.8. Mean signal in
black, per replicate signal in light grey.
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FIGURE S.14. Fast Fourier transform (FFT) spectrum for the inocula-free, negative control. The frequency of the oscil-
lations is shown on the x-axis and the energy of such oscillations on the y -axis. The presence of the same signature, a
peak every 3/4 of an hour, suggests a mechanical cause for these oscillations. Mean signal in black, per replicate signal
in light grey.
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II SUPPLEMENTARY CHAPTER 3
II.1 Implementation of mathematical model.
1 % Defining Markov process
2 function p = setMarkov(N,p)
3
4 if nargin < 1
5 N = 11;
6 end
7
8 p.sigma = 0.01;%rate of plasmid loss/gain through segregation
9 p.N = N;%max number of plasmids
10
11 if N == 1
12 p.M = 1;
13 p.Markov = 1;
14 else
15 p.M = (diag(-2*ones(N,1)) + diag(ones(N-1,1),1) + diag(ones(N-1,1),-1))/2;
16 p.M(1,1) = 0;
17 p.M(2,1) = 0;
18 p.M(end,end) = -1;
19 p.M(end-1,end) = 1;
20
21 p.Markov = eye(N) + p.sigma*p.M;
22 end
23
24 end
25
26 % Model for plasmid distribution
27 function f = PlasmidDistribution(u,p)
28
29 e = p.e;
30 V = p.V;
31 K = p.K;
32 gamma = p.gamma;
33 phi = p.phi;
34 kappa = p.kappa;
35 d = p.d;
36 Markov = p.Markov;
37
38 N = p.N;
39 sigma = p.sigma;
40
41 c = u(1:N);
42 Aint = u(N+1);
43 Aext = u(N+2);
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44 S = u(N+3);
45
46 U = V*S/(K+S);
47 G = e*U;
48
49 % Maximal cost of resistance gamma value (relative to 1)
50 % cost of carrying _maximal number_ of available plasmids
51 if N > 1
52 s = (0:(N-1))/(N-1);
53 else
54 s = 1;
55 end
56
57 s = s’;
58 GRy = G/(1+kappa*Aint^(2));
59 GRc = s.*gamma*G + (1-s).*GRy;
60
61 dc = Markov*(c.*GRc);
62
63 dAint = -d*Aint + phi*sum(c)*(Aext-Aint);
64 dAext = -d*Aext - phi*sum(c)*(Aext-Aint);
65 dS = -U*sum(c);
66
67 f = [dc;dAint;dAext;dS];
68
69 end
70
71 % Model (plasmids not included)
72 function f = RHS(u,p)
73
74 e = p.e;
75 V = p.V;
76 K = p.K;
77 gamma = p.gamma;
78 phi = p.phi;
79 kappa = p.kappa;
80 d = p.d;
81
82 c = u(1);
83 y = u(2);
84 Aint = u(3);
85 Aext = u(4);
86 S = u(5);
87
88 U = V*S/(K+S);
89 G = e*U;
90
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91 dc = gamma*c*G;
92 dy = y*G/(1+kappa*Aint^(2));
93 dAint = -d*Aint + phi*(c+y)*(Aext-Aint);
94 dAext = -d*Aext - phi*(c+y)*(Aext-Aint);
95 dS = -U*(c+y);
96
97 f = [dc;dy;dAint;dAext;dS];
98
99 end
II.2 Raw data.
C O N C L U D I N G R E M A R K S 1 3 9
A)
0
0.
5
OD
600
 
 
0µ
g/
m
L
Te
t ms
M
od
el
 F
it
0.
05
µg
/m
L
0.
1µ
g/
m
L
0.
15
µg
/m
L
0.
2µ
g/
m
L
0.
25
µg
/m
L
0.
3µ
g/
m
L
0.
35
µg
/m
L
0.
4µ
g/
m
L
0.
45
µg
/m
L
0.
5µ
g/
m
L
01
OD
600
e
 
 
Te
t ms
M
od
el
 F
it
01
OD
600
 
 
0µ
g/
m
L
Te
t mr
M
od
el
 F
it
1.
5µ
g/
m
L
3µ
g/
m
L
4.
5µ
g/
m
L
6µ
g/
m
L
7.
5µ
g/
m
L
9µ
g/
m
L
10
.5
µg
/m
L
12
µg
/m
L
13
.5
µg
/m
L
15
µg
/m
L
0
10
20
0
0.
51
OD
600
e
Ti
m
e 
(h)
 
 
Te
t mr
M
od
el
 F
it
0
10
20
Ti
m
e 
(h)
0
10
20
Ti
m
e 
(h)
0
10
20
Ti
m
e 
(h)
0
10
20
Ti
m
e 
(h)
0
10
20
Ti
m
e 
(h)
0
10
20
Ti
m
e 
(h)
0
10
20
Ti
m
e 
(h)
0
10
20
Ti
m
e 
(h)
0
10
20
Ti
m
e 
(h)
0
10
20
Ti
m
e 
(h)
−
0.
501234
RFU
n
 ⋅ OD
−1
600
 
 
0µ
g/
m
L
Te
t ms
0.
05
µg
/m
L
0.
1µ
g/
m
L
0.
15
µg
/m
L
0.
2µ
g/
m
L
0.
25
µg
/m
L
0.
3µ
g/
m
L
0.
35
µg
/m
L
0.
4µ
g/
m
L
0.
45
µg
/m
L
0.
5µ
g/
m
L
0
0.
2
0.
4
0.
6
−
0.
501234
RFU
n
 ⋅ OD
−1
600
O
D 6
00
 
 
0µ
g/
m
L
Te
t mr
0
0.
2
0.
4
0.
6
1.
5µ
g/
m
L
O
D 6
00
0
0.
2
0.
4
0.
6
3µ
g/
m
L
O
D 6
00
0
0.
2
0.
4
0.
6
4.
5µ
g/
m
L
O
D 6
00
0
0.
2
0.
4
0.
6
6µ
g/
m
L
O
D 6
00
0
0.
2
0.
4
0.
6
7.
5µ
g/
m
L
O
D 6
00
0
0.
2
0.
4
0.
6
9µ
g/
m
L
O
D 6
00
0
0.
2
0.
4
0.
6
10
.5
µg
/m
L
O
D 6
00
0
0.
2
0.
4
0.
6
12
µg
/m
L
O
D 6
00
0
0.
2
0.
4
0.
6
13
.5
µg
/m
L
O
D 6
00
0
0.
2
0.
4
0.
6
15
µg
/m
L
O
D 6
00
B)
FIGURE S.15. A) Model fit for the tetracycline sensitive (Tetsm, green), and the tetracycline resistant (Tet
r
m, red) strains
grown in monoculture. Model fitted to optical density at 600nm (OD600) and optical density estimated from fluorescence
(ODe600). B) Ratio of normalised fluorescence units (RFUn) per optical density unit. This ratio is robust to changes in
optical density.
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III SUPPLEMENTARY CHAPTER 4
III.1 Image processing routine.
1 function [mData, ci95Data] = Radial_Profile_Plot (ImageBW, ImageRef)
2 % This function finds the origin of the inner circle, and integrates
3 % a n radians wide arc, with origin (X0, Y0), to generate a
4 % profile plot from the origin and a radius iR.
5
6 % Required variables.
7 [Height, Width] = size(ImageBW);
8 % Find inhibition origin.
9 [Origin, Radius, ~ ] = imfindcircles(ImageRef, [100 200],...
10 ’Sensitivity’, 0.985);
11 % Make sure I process one circle ONLY.
12 Origin = Origin(1, :);
13 Radius = Radius(1);
14 % Defining X0 and Y0 based on the existence of ‘Origin’
15 X0 = floor(Origin(1));
16 Y0 = floor(Origin(2));
17 Step = 1;
18 iR = floor(Radius * 1.15); % Inner Radius (>1 to avoid circle boundary)
19 oR = floor(Radius * 2.25); % Outter Radius
20
21 mData = zeros(oR, 1); % Preallocation
22 seData = zeros(oR, 1); % Preallocation
23
24 % For Normalisation
25 Arc = round(2*pi*oR); % 2pir = circumference.
26 Theta = linspace(5/3*pi, 11/6*pi, Arc); % Pi = 180 degrees
27 Rho = ones(1, Arc) * round(oR);
28 [ X Y ] = pol2cart(Theta, Rho);
29 X = round(X) + X0;
30 Y = round(Y) + Y0;
31 oX = X;
32 oY = Y;
33
34 % Acr integration and creation of profile
35 for r = oR:-Step:iR
36 Arc = round(2*pi*r); % 2pir = circumference.
37 Theta = linspace(5/3*pi, 11/6*pi, Arc); % Pi = 180 degrees
38 Rho = ones(1, Arc) * round(r);
39 [ X Y ] = pol2cart(Theta, Rho);
40 X = round(X) + X0;
41 Y = round(Y) + Y0;
42 OD = im2double(improfile(Image_OD_Blurred, X, Y));
43 GFP = im2double(improfile(Image_GFP_Blurred, X, Y));
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44 Data = GFP ./ OD;
45
46 mData(r) = mean(Data);
47 seData(r) = std(Data) ./ sqrt(Arc - 1) .* 1.96;
48 end
49
50 % Computing cell density:
51 mData(r) = mean(Data);
52 seData(r) = std(Data) ./ sqrt(Arc - 1) .* 1.96;
53
54 iN = round(2*pi*iR);
55 oN = round(2*pi*oR);
56
57 mData = mData(iR:end);
58 ci95Data = seData(iR:end);
59
60 end
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FIGURE S.16. Pilot experiment for the development of the image analysis pipeline. A) Binary mask created to detect
circular shapes from B) grey scaled photographs. C) The image is corrected by subtracting the photo taken at t = 0h and
read. D) Profile plot, showing mean growth ± standard error on the y−axis as a function of the distance to the centre of
the inhibition zone, on the x−axis.
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FIGURE S.17. Raw Data. MG1655, ∆1, ∆2.
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FIGURE S.18. Raw Data. ∆3, ∆4, ∆5.

M E T H O D S
V MEDIA
V.1 Rich media. We used Lysoneny Broth (LB), LB Agar, and LB Soft Agar as rich
media following the recipes described in the table below. In every case, we prepared
the media using deionised water for a total volume of 1 litre, pH adjusted using NaOH,
and autoclaved at 121oC for 20 min prior to use.
TABLE S.1. Recipe for rich media
LB LB Agar LB Soft Agar
25g LB Powder as for LB as for LB
- 12g Agar Powder 6g Agar Powder
V.2 Minimal media. As a minimal media we used M9, M9 Agar, and M9 Soft
Agar supplemented with casamino acids (CA) as a source of nitrogen and sulphur,
and glucose (Glc) as the main source of carbon (see SUBSECTION V.3 for further
information about the stocks of glucose and casamino acids).
Non-supplemented M9 (M9 salts) was prepared by mixing two components, A and
B. I prepared each of these components as described in TABLE S.2, using deionised
water for a total volume of 1 litre. For convenience, we prepared a stock of M9 salts
fifty times concentrated (50X), and autoclaved at 121oC for 20min. When required,
we diluted accordingly in deionised water a mixture containing equal volumes of each
component to prepare M9 salts (1X). This new solution was also autoclaved at 121oC
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for 20min prior to use.
To prepare M9 Agar and M9 Soft Agar, we added the same quantity of Agar powder
as described in TABLE S.1 to 1 litre of M9 salts (1X), and autoclaved at 121oC for
20min prior to use.
TABLE S.2. Recipe for M9 minimal media 50X
Component A Amount Supplier Component B Amount Supplier
K2HPO4 350g Sigma (P3786) Trisodium Citrate 29.4g Sigma (S1804)
KH2HPO4 100g Sigma (P9791) (NH4)2SO4 50g Sigma (A4418)
– – – MgSO4 10.45g Fisher Scientific (M/1050/53)
V.3 Stock solutions for glucose and casamino acids. We supplemented M9
salts (1X), M9 salts (1X) Agar, and M9 salts (1X) Soft Agar with two specific nu-
trients: glucose and casamino acids. I diluted different proportions of glucose and
casamino acids in 1 litre of M9 salts (1X) to prepare two different stocks of 20%
glucose (200mg/mL) as described below.
TABLE S.3. Recipe for stocks of 20% glucose
Component 10% CA 5% CA Supplier
Glucose 200g 200g Fisher Scientific (G/0500/53)
Casamino acids 100g 50g Duchefa (C1301.0250)
Both glucose and casamino acids are thermolabile substances. Consequently, we
filter sterilised these stock solutions, and not autoclaved, to prevent degradation. When
required, we added aseptically the appropriate volume of stock to either M9 salts (1X),
M9 salts (1X) Agar, or M9 salts (1X) Soft Agar.
Typically, the media used in the experiments was M9 salts (1X) supplemented with
0.2% (2mg/mL) of glucose, and 0.1% (1mg/mL) of casamino acids.
VI ANTIBIOTICS
During the experiments presented in this thesis, we used a number of different clin-
ically relevant antibiotics. Erythromycin (Ery), doxycycline (Dox), and tetracycline
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(Tet) are used to treat infectious diseases produced by pathogens such as Neisse-
ria gonorrhoeae, Vibrio cholera, meticillin-resistant Staphylococcus aureus (MRSA),
multidrug-resistant Acinetobacter baumannii, among others.123–129
TABLE S.4. Antibiotic stock solutions, and typical working dilutions.
Drug Solvent Stock solution Working dilution Supplier
Erythromycin Pure Ethanol 10mg · mL−1 1 / 0.5 / 0.03mg · mL−1 Duchefa (E0122.0010)
Doxycycline Water 5mg · mL−1 8 × 10−3 / 8 × 10−4mg · mL−1 Sigma (D9891-5G)
Tetracycline Water 5mg · mL−1 8 × 10−3 / 8 × 10−4mg · mL−1 Duchefa (T0150.0025)
We prepared stock solutions for Ery, Dox and Tet as described in TABLE S.4 (above),
using pure ethanol or deionised water for a volume of 10mL. The stock solutions were
stored at -20oC as recommended by the manufacturer, the solutions for Dox and Tet
being filter sterilised and aliquoted. To prepare the working dilutions, samples from
these stock solutions were diluted accordingly using the same media that would later
be used for the experiment. The working dilution was further diluted in media to prepare
the final concentrations of the antibiotic.
VI.1 Dilution of antibiotic stock solutions. We typically used ten different con-
centrations of antibiotic. To avoid over- or mis-representation of a concentration (i.e. too
many low concentrations or too few high concentrations), we prepared the antibiotic
as it follows: we defined ten concentrations, c = (1, ... , 10), the highest concentration
being denoted by h, and the lowest concentration being denoted by l = h · 10−1. The
final concentration is calculated as l × c. We defined this range after several iterations
in which the stock solution of antibiotic was diluted 10, 100 and 1000 times. The density
of the cultures was measured using the filter-based microplate reader ELX808 from
BioTek for CHAPTER 2 and the monochromator-based microplate reader Tecan Infinite
200 PRO for CHAPTERS 2, 3 and 5. The cultures were read in 96-wells microplates by
Greiner bio-one (655101).
The working dilution was diluted accordingly using the same media used in the
experiment for a volume of 10mL.
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VII PLATE READERS PROTOCOLS
The plate readers were programmed to perform the following steps.
VII.1 BioTek ELX808.
• Set temperature at 30oC.
• Kinetic Window (length of experiment): 24h, with readings every 20min.
- Shaking time: 300s (5min). Shaking strength: medium (strength options are
low, medium and high). With high culture droplets can be found on the lids.
- Read using the 600nm filter.
The plate reader iterates the steps within the kinetic loop (shaking and reading),
shaking for 5min to homogenise the culture, reading, and then leaving the cultures at
30oC for ≈15min (20min total).
VII.2 Tecan Infinite 200 PRO.
• Set temperature at 30oC.
• Kinetic Window (length of experiment): 24h, with readings every 20min.
- Shaking time: 300s (5min). Shaking: linear at 680rpm.
- Read each well once at 600nm in a 2x2 matrix, 1450µm from the border.
The plate reader iterates the steps within the kinetic loop (shaking and reading),
shaking for 5min to homogenise the culture, reading, and then leaving the cultures at
30oC for ≈15min (20min total). Reading each well in four different points (2x2 matrix)
reduced the noise of the data.
VIII STRAINS
On reception, all the strains used for this thesis were grown overnight (>16h) in 10mL
of M9 salts (1X) supplemented with 0.2% Glc and 0.1% CA, at 30oC and 180rpm. We
froze three samples at −80oC after adding 500µL of 80% glycerol for a total volume of
1.5mL.
IX MICROBIOLOGICAL TECHNIQUES
IX.1 Cell culture.
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TABLE S.5. Strains of Escherichia coli. The strain TB108 was kindly provided by Dr. Tobias Bergmiller. The strain
eTB108 is an evolved sample of TB108 after six transfers in media containing 10µg/mL of erythromycin.
Strain Genotype Reference
E. coli AG100 K–12 argE3 thi–1 rpsL xyl mtl ∆(gal-uvrB)
supE44
68
E. coli MG1655 K–12 F- λ- ilvG0 rfb–50 rph–1 130
E. coli MC4100 F- [araD139]B/r ∆(argF–lac)169 λ- e14-
flhD5301 ∆(fruK–yeiR)725(fruA25) relA1
rpsL150(strR) rbsR22 ∆(fimb–fimE)632(::IS1)
deoC1
131
E. coli AG100–A AG100 ∆acrAB::Tn903 68
E. coli Wyl MC4100 galK::YFP, ampR , pCS-λ 84
E. coli GB(c) MC4100 galK::CFP, ampR , pGW155B 85
E. coli TB108 MG1655 acrB–sfGFP–FRT Unpublished
E. coli eTB108 MG1655 acrB–sfGFP–FRT ± ? This thesis
IX.1.1 Solid media. A frozen sample was taken using a flamesterilised loop, and
spread over a Petri dish containing 25mL of sterile, antibioticfree LB Agar. This Petri
dish was incubated overnight at 30oC, and the resulting colonies were picked to perform
tests and calibrations described in the following sections.
IX.1.2 Liquid media. A frozen sample, or a colony in solid LB Agar, was taken using
a flamesterilised loop and spread in the corresponding liquid media. This media was
typically M9 supplemented with different concentrations of Glc, CA, and the appropriate
antibiotic if required. 10mL of this media was inoculated in a universal tube (30mL),
incubated in aerated conditions overnight at 30oC.
IX.2 Colony counting. To quantify the number of colony forming units (CFUs)
0.1mL from a liquid culture was diluted in 100-fold or 10-fold dilutions, depending on
the culture’s optical density measured at 600nm. In triplicate, a 0.1mL droplet from the
final dilution, ranging typically from 10−5 to 10−9, was mixed in a Petri dish with 25mL
of sterile LB Soft Agar. The cultures were incubated overnight at 37 oC.
Photos of these Petri dishes were taken and processed computationally with a
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Noise
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Thresholding
Background
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FIGURE S.19. Algorithm designed to count CFUs from photographs using ImageJ.
routine created in ImageJ132 (FIG. S.19). The cell density in the original culture was
calculated using the following formula, assuming that each colony is developed from a
single bacterial cell:
Density (Cells · mL−1) = Colonies
Dilution Factor
× 10 (S.2)
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X CALIBRATIONS
X.1 Fluorescence. Upon reception of a fluorescent strain we reviewed the litera-
ture, including original publication, to find the appropriate wavelenghts (λ) for excitation
(λex ) and emission (λem) of the corresponding fluorochrome. When the appropriates
wavelengths were not provided, an overnight culture of the fluorescent strain was
screened in the monochromator-based reader by Tecan.
Once λex and λem were known, we compared the fluorescence from overnight
cultures of the corresponding fluorescence strains with that coming from a parental,
non-fluorescent strain. Three replicates of 150µL each were read in a 96-well microplate
and read at 505nm/540nm to measure the fluorescence produced by the yellow
fluorescence protein (emission/excitation wavelengths), and at 430nm/480nm for the
cyan fluorescent protein. No fluorescence was detected in the non-fluorescent parental
strain. Therefore the fluorescence detected comes from the corresponding fluorescent
protein and not by another protein or by metabolic byproduct.
X.2 Dose-response curve. In SUBSECTION VI.1, we introduced how we defined
the range of concentrations of the antibiotic to be used. To define the highest concen-
tration, h, we prepared the concentrations in c from increasing 10-fold dilutions of the
stock solution of antibiotic. If ch is the highest concentration at which we observed
growth during this process, we interpolated the concentrations of antibiotic between 0
and the concentration ch+1 until we could observe the transition from maximum growth
to lack thereof.
Once we identified the range of concentrations, c, we prepared the corresponding
number of 96-well microplates depending on the length of the experiment. If several
days were required, we used a 96-pin replicator to transfer the culture from a previous
96-well microplate.
X.3 Quantitative PCR (qPCR).
X.3.1 DNA extraction. The DNA from 10 mL of culture was processed with the DNA
extraction kit ‘GeneJET’ (ThermoScientific #K0729), and quantified using the ‘Qubit’
system. The DNA extracts were later diluted accordingly to normalise the concentration
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TABLE S.6. Primers and probes designed using ‘Primer3’. Amplicon ranging from 100 to 141bp. Tm indicates the
estimated melting temperature.
Target gen Sequence (5′ → 3′) Tm (oC) Feature
tatB CGATGAAGCGTTCCTACGTT 60.27 Forward
TCATGCGCAGCTTCATTATC 59.94 Reverse
AAGGCGAGCGATGAAGCGCA 70.70 Probe
tet(36) ATTGGGCATCTATTGGCTTG 59.22 Forward
CCGATTCACAGGCTTTCTTG 60.76 Reverse
AGCCTTTGCCAATTGGGGCG 70.37 Probe
of DNA across the samples, so we have the same concentration of DNA in every
sample.
X.3.2 Primers and probes. Upon reception, primers and probes were diluted in
sterile, DNAse-free deionised water pH 8.0, to prepare 25pmol/µL stocks. We later
aliquoted, and stored at −20oC these stocks. Probes are molecular beacons, tagged
with the fluorochrome HEX in 5′, and the quencher BHQ1 in 3′.
The Primers and probes were designed using PRIMER3 as implemented in UGENE.133
We targeted tatB as a chromosomal reference using the reference genome se-
quence for the bacterium Escherichia coli strain MG1655 (NCBI reference sequence:
NC_000913.2). For the plasmid pGW155B, we targeted the locus tet(36) using a
reference sequence published elsewere.134 The sequences in TABLE S.6 where tested
by PCR and qPCR against so-called no template controls (NTC), containing no DNA,
and strains of E. coli lacking the aforementioned plasmid. The efficiency of the reaction
is close to 100% (FIG. S.20) and therefore the material for these loci is considered to
double per cycle.135
X.3.3 Reaction mix. The qPCR reaction mix was prepared as detailed by the
manufacturer for the ‘Luminaris Color Probe Low ROX’ kit (ThermoScientific #K0342,
see TABLE S.7), and we calculated the volume required for the primers following the
EQUATION S.3.
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FIGURE S.20. Baseline corrected, normalised amplification curves (dRn) for the chromosomal locus tatB (A), followed
by that for the plasmid-borne locus tet(36) (C). The efficiency of the qPCR for each loci, in subplots B and D, shows the
efficiency of the reaction (Ef ) calculated as Ef = 10−1/Slope − 1.
M =
mol
vol (L)
→ mol = 10−7M︸ ︷︷ ︸
0.1µM
·(2 · 10−5L︸    ︷︷    ︸
20µL
) = 2 · 10−12mol︸         ︷︷         ︸
2pmol
(S.3)
Therefore, the concentrations for the primers specified in TABLE S.7 correspond
to 6pmol or 0.24µL from the 25pmol stock solutions; whereas for the probe 4pmol
or 0.16µL from such stocks. The qPCR was set up using the conditions described in
TABLE S.8.
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TABLE S.7. Recommended recipe for Luminaris Color Probe Low ROX (ThermoScientific).
Component Volume (µL)
PCR Master Mix 10
Primer F Final Concentration = 0.3µM
Primer R Final Concentration = 0.3µM
Probe Final Concentration = 0.2µM
Template DNA 6 200ng per reaction
Nuclease-free Water to 20
TABLE S.8. qPCR thermal cycling conditions.
Step Temperature (oC) Time (min) N. of cycles
UDG pre-treatment 50 2 1
Enzyme activation 95 10 1
Denaturation 94 0.5 }
40Annealing 60 0.5
Extension 72 1
Final Extension 72 10 1
X.4 Spatial plates. We performed the spatial plates on Petri dishes containing M9
(1X) soft agar supplemented with 0.2% glucose (w/v) and 0.1% casamino acids (w/v),
inoculated with of an overnight culture (0.1mL per litre). The centre of the Petri dish
was surgically removed with a sterile universal tube, and refilled with non-inoculated
media containing 64µg/mL of the antibiotic doxycycline. This plate was incubated at
30oC in a device developed as part of this PhD project, and photos were taken during
5 days at 2h intervals. These photos were later analysed with a routine coded using
Matlab.
A D D E N D A
1 5 6 C H A P T E R V I
XI ADDITIONAL ANALYSIS FOR CHAPTER 2
A) B) C)
0
0.
5
1
1.
5
2
0
0.
51
1.
52
nGFP ⋅ OD
−1
a
cr
 
co
py
 n
um
be
r
 
 
0 
µg
/m
L 
Er
yt
hr
om
yc
in
Fi
tte
d 
Li
ne
ar
 M
od
el
Fi
tte
d 
Sq
ua
re
 R
oo
t M
od
el
0
0.
5
1
1.
5
2
LM
 R
2 :
 0
.6
58
SQ
RT
M
 R
2 :
 0
.7
37
10
 µ
g/
m
L 
Er
yt
hr
om
yc
in
a
cr
 
co
py
 n
um
be
r
0
0.
5
1
1.
5
2
LM
 R
2 :
 0
.7
30
SQ
RT
M
 R
2 :
 0
.8
28
15
 µ
g/
m
L 
Er
yt
hr
om
yc
in
a
cr
 
co
py
 n
um
be
r
0
0.
5
1
1.
5
2
LM
 R
2 :
 0
.9
67
SQ
RT
M
 R
2 :
 0
.9
69
20
 µ
g/
m
L 
Er
yt
hr
om
yc
in
a
cr
 
co
py
 n
um
be
r
0
0.
5
1
1.
5
2
LM
 R
2 :
 0
.9
76
SQ
RT
M
 R
2 :
 0
.9
74
25
 µ
g/
m
L 
Er
yt
hr
om
yc
in
a
cr
 
co
py
 n
um
be
r
0
0.
5
1
1.
5
2
LM
 R
2 :
 0
.7
28
SQ
RT
M
 R
2 :
 0
.8
01
30
 µ
g/
m
L 
Er
yt
hr
om
yc
in
a
cr
 
co
py
 n
um
be
r
0
0.
5
1
1.
5
2
LM
 R
2 :
 0
.4
15
SQ
RT
M
 R
2 :
 −
0.
04
8
40
 µ
g/
m
L 
Er
yt
hr
om
yc
in
a
cr
 
co
py
 n
um
be
r
1
1.
5
2
0
0.
51
1.
52
nGFP ⋅ OD
−1
0 
µg
/m
L 
Er
yt
hr
om
yc
in
a
cr
 
co
py
 n
um
be
r
1
1.
5
2
10
 µ
g/
m
L 
Er
yt
hr
om
yc
in
a
cr
 
co
py
 n
um
be
r
1
1.
5
2
15
 µ
g/
m
L 
Er
yt
hr
om
yc
in
a
cr
 
co
py
 n
um
be
r
1
1.
5
2
20
 µ
g/
m
L 
Er
yt
hr
om
yc
in
a
cr
 
co
py
 n
um
be
r
1
1.
5
2
25
 µ
g/
m
L 
Er
yt
hr
om
yc
in
a
cr
 
co
py
 n
um
be
r
1
1.
5
2
30
 µ
g/
m
L 
Er
yt
hr
om
yc
in
a
cr
 
co
py
 n
um
be
r
1
1.
5
2
40
 µ
g/
m
L 
Er
yt
hr
om
yc
in
a
cr
 
co
py
 n
um
be
r
1
1.
5
2
0.
51
1.
5
nGFP ⋅ OD
−1
 ⋅ acr
−1
a
cr
 
co
py
 n
um
be
r
 
 
0 
µg
/m
L 
Er
yt
hr
om
yc
in
Co
ns
ta
nt
 M
od
el
1
1.
5
2
10
 µ
g/
m
L 
Er
yt
hr
om
yc
in
a
cr
 
co
py
 n
um
be
r
1
1.
5
2
15
 µ
g/
m
L 
Er
yt
hr
om
yc
in
a
cr
 
co
py
 n
um
be
r
1
1.
5
2
20
 µ
g/
m
L 
Er
yt
hr
om
yc
in
a
cr
 
co
py
 n
um
be
r
1
1.
5
2
25
 µ
g/
m
L 
Er
yt
hr
om
yc
in
a
cr
 
co
py
 n
um
be
r
1
1.
5
2
30
 µ
g/
m
L 
Er
yt
hr
om
yc
in
a
cr
 
co
py
 n
um
be
r
1
1.
5
2
40
 µ
g/
m
L 
Er
yt
hr
om
yc
in
a
cr
 
co
py
 n
um
be
r
FIGURE S.21. A) Representation of the relative abundance of efflux pumps (nGFP−1 ·OD−1), on the y−axis, as a function
of acr operon copy number on the x−axis during the first five days of the experiment. The raw data is represented as
grey dots and their size indicates if the culture was sampled after one, five or seven days of growth. Mean ± standard
error of the mean shown in green and grey, respectively. The dataset is compared to the predictions from a linear (light
grey) and square root (dark grey, model in p. 72) models. The goodness of fit was quantified using R2. B) Concavity
analysis (orange) using the convhull function in matlab. The hull highlights a transition, from a concave to convex, in the
relationship between the relative abundance of efflux pumps per operon copy number. This transition is also captured
when the relative expression of efflux pumps per acr operon is considered (C). Further genomic analysis will reveal the
specific mutations responsible for the transition.
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FIGURE S.22. Relative copies of the plasmid pGW155B per cell of Tetr after 120h of coculture with Tetr . We robustly
fitted the linear model y = a + bx where the 95% confidence interval for a is (8.68, 153.07) and for b is (143.33,
1762.40), with R2adj = 0.307. The number of plasmids per cell has increased through time and the increase was stronger
with higher dosages of tetracycline. This observation is compatible with the model in EQUATION 3.2.
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FIGURE S.23. Left) Relationship between carrying capacity (K), on the y−axis and cell yield, on the x−axis. Overall,
there is a negative correlation between K and yield that is approximately linear as shown by the model in EQUATION
5.2 (black). In Right) we show the prediction per strain. We observed that higher population densities were achieved in
conditions that led to low cell yield, such as a high concentration of glucose. However, the model does not capture the
role of the rrn operons: the highest population size were achieved with 7-6 copies of this operon with low concentrations
of glucose, but with more glucose the highest population sizes were achieved with fewer of these operons.
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